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Chapter I 
INTRODUCTION AND LITERATURE REVIEW 
1.1     The AMPA Subtype of Ionotropic Glutamate Receptors 
The amino acid neurotransmitter glutamate mediates most fast excitatory synaptic 
transmission in the mammalian central nervous system (CNS).  Glutamate gates three 
subtypes of ionotropic receptors named for their selective agonists: N-methyl-D-aspartate 
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), and 
kainate.  Kainate receptors are primarily presynaptic and modulate neurotransmitter 
release in the CNS (Huettner, 2003) while NMDA and AMPA receptors co-localize 
postsynaptically.  The AMPA receptor is the primary mediator of fast synaptic 
transmission in the mammalian CNS while NMDA receptors play a predominantly 
modulatory role (McBain and Mayer, 1994; Dingledine et al., 1999).    
AMPA receptors are tetrameric assemblies (Rosenmund et al., 1998) composed of 
various homomeric and heteromeric combinations of the subunits GluR1, 2, 3, and 4 
(Boulter et al., 1990), also termed GluR-A, B, C, and D (Keinanen et al., 1990).  Mature 
subunit proteins are approximately 900 amino acids in length, with a molecular weight of 
98-100 kD (Hollmann and Heinemann, 1994).  All four subunits share the same 
membrane topology (Diagram 1), namely a large amino-terminal extracellular domain, an 
intracellular carboxyl-terminus, three full membrane spanning domains (TM1, 3 and 4) 
with the second hydrophobic sequence forming a re-entrant loop lining the channel pore 
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(TM2) and an extracellular loop between TM3 and TM4 (Hollmann et al., 1994).  Stern-
Bach et al. (1994) demonstrated that the membrane proximal region of the first 
extracellular domain (termed S1) and the initial portion of the extracellular loop (S2) 
form the agonist binding domain, also referred to as the ligand binding core.   
All four subunits naturally occur as one of two alternative splice variants, flip or flop 
(Sommer et al., 1990), that exhibit characteristic responses to agonist binding.  The 
flip/flop splice cassette is located in the latter portion of the extracellular loop between 
TM3 and TM4 (Diagram 1).  The subunits also vary in length of the C-terminal tail, with 
GluR2 and 3 occurring primarily in short form, and GluR1 and 4 in long forms (Diagram 
7, Dingledine et al., 1999).  The short form of GluR4 is expressed primarily in 
cerebellum and referred to as GluR4c (Gallo et al., 1992).   
 
1.1.1     AMPA Receptor Functional Properties Depend Upon Receptor Composition 
While most neuronal AMPA receptors are Ca2+ impermeable, homomeric channels 
composed of GluR1, 3 and 4 are highly Ca2+ permeable.  Homomeric GluR2 channels, 
Diagram 1: Membrane topology of AMPA receptor subunits (from 
Dingledine et al., 1999) 
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however, are impermeable to Ca2+ ions (Hollmann et al., 1991; Sommer et al., 1991).  
Interestingly, while the genetic sequence of the channel-lining TM2 region is identical 
between the four subunits, nearly 100% of GluR2 mRNA undergoes editing by dsRNA 
adenosine deaminase, converting a glutamine (CAG  Q) to an arginine ( CIG  R; 
Sommer et al., 1991).  Inclusion of a single edited GluR2/GluR-B subunit in a tetramer 
dramatically decreases calcium permeability of the channel (Hume et al., 1991; 
Burnashev et al., 1992).  This was one of the first demonstrations that mRNA editing, in 
addition to alternative splicing, is a mechanism by which the cell can generate a diverse 
protein population from a single gene.  The presence of an arginine residue in the pore 
also prevents channel block by endogenous polyamines and polyamine spider toxins, 
creating a non-rectifying channel that equally passes inward and outward current 
composed primarily of Na+ ions.  Homomeric receptors composed of GluR1, 3 or 4, on 
the other hand, are Ca2+ permeable, strongly inwardly rectifying and blocked by 
polyamines (Verdoorn et al., 1991).  mRNA editing of an R/G site found in the second 
extracellular domain before the flip/flop cassette in GluR2, 3, and 4 speeds recovery from 
and reduces the amount of steady-state desensitization (Lomeli et al., 1994; Mosbacher et 
al., 1994).   
An important characteristic of AMPA receptors is the profound desensitization that 
occurs in the continued presence of agonist.  Desensitization of G-protein coupled 
receptors has a time course of seconds to minutes and involves phosphorylation and 
subsequent uncoupling of the activated receptor from second messengers; however, 
desensitization of AMPA receptors occurs in milliseconds and involves a conformational 
change in tertiary and quaternary structure that restricts current flow through the channel.  
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The rate of onset of desensitization and degree of steady-state desensitization vary with 
subunit and flip/flop composition (Lomeli et al., 1994; Mosbacher et al., 1994).  For 
example, although flip subunits in general desensitize to a lesser degree than do flop 
subunits (Diagram 2A), the flip splice variants of GluR1 and GluR3 desensitize more 
strongly than do flip splice variants of GluR2 and GluR4 (Diagram 2B).  At certain 
synapses, the rapidity of AMPA receptor desensitization may affect the time course and 
amplitude of synaptic responses, especially under conditions of high frequency synaptic 
activity (Trussell et al., 1993; Otis et al., 1996; Arai and Lynch, 1998).  In addition, 
desensitization may serve to limit nerve cell death induced by pathologically elevated 
levels of glutamate release during ischemic events (Brorson et al., 1995).  
 
1.1.2    AMPA Receptor Pharmacology  
Various agonists elicit different degrees of desensitization at the AMPA receptor 
(Diagram 3).  Binding of the endogenous agonist glutamate or the selective agonist 
AMPA initiates a brief high conductance opening of the channel followed by rapid 
desensitization (τ 1-10 ms), resulting in a steady-state current that is typically < 2% of the 
peak response (Tang et al., 1989; Patneau and Mayer, 1991).   Quisqualate is a non-
selective full agonist that activates both ionotropic and metabotropic glutamate receptors, 
and produces strongly desensitizing responses at AMPA receptors.  The willardiines and 
the partial agonist kainate evoke more weakly desensitizing responses at the AMPA 
receptor, paradoxically producing greater steady-state currents than those seen in the 
presence of the full agonists glutamate, AMPA or quisqualate (Boulter et al., 1990; 
Patneau and Mayer, 1990; Patneau et al., 1992). 
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Diagram 2: Unique desensitization profiles of various heteromeric and 
homomeric AMPA receptor subunit combinations.  A.  Heteromers composed 
of pure flop isoforms exhibit more strongly desensitizing responses resulting in 
smaller steady-state currents than receptors composed purely of flip isoforms.  
B. Subunit specific desensitization profiles.  Note that the flip isoforms of 
GluR-A and C are more strongly desensitizing than the flip isoforms of GluR-
B and D.  Traces were obtained by rapid application of 3 mM glutamate for 
500-600 ms to HEK293 cells transiently transfected with GFP and the 
indicated AMPA receptor subunit combination.  Note that GluR-A is also 
referred to as GluR1, GluR-B as GluR2, GluR-C as GluR3, and GluR-D as 
GluR4. 
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There are a variety of antagonists of the AMPA receptor.  CNQX (6-cyano-7-
nitroquinoxaline-2, 3-dione) and NBQX (2, 3-dihydroxy-6-nitro-7-sulfamoyl-
benzo(f)qunoxaline) are potent competitive antagonists (Honore et al., 1988; Watkins et 
al., 1990; Gill et al., 1992; Zeman and Lodge, 1992), while argiotoxin and Joro spider 
toxin are channel blockers (Kawai et al., 1982; Budd et al., 1988). Interestingly, block by 
Diagram 3: Representative traces of full and partial agonists at the AMPA 
receptor.  Responses obtained by 500 ms applications of agonists 
producing varying degrees of desensitization to hippocampal neurons.  
Glutamate and AMPA are strongly desensitizing full agonists of the 
AMPA receptor while kainate is a weakly desensitizing partial agonist. At 
neuronal AMPA receptors, iodowillardiine produces peak responses 
comparable to glutamate, but with much less steady-state desensitization 
(from Patneau et al., 1992). 
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the spider toxins is dependent upon Q/R editing: channels lacking edited GluR2 are 
susceptible to block, while the presence of an edited GluR2 confers insensitivity to toxin 
binding, just as it eliminates block by internal polyamines (Blaschke et al., 1993; Herlitze 
et al., 1993).  Unlike the 1,4-benzodiazepines, which potentiate responses of GABAA 
receptors, the 2,3-benzodiazepines are noncompetitive antagonists of the AMPA receptor 
(Donevan and Rogawski, 1993) that appear to selectively bind and hold the receptor in 
the desensitized state (Turetsky et al., 2004).  The derivative GYKI 52466 has both 
anticonvulsant properties in animal models of epilepsy and neuroprotective properties in 
focal and global ischemia (Chapman et al., 1991; Smith et al., 1991; Smith and Meldrum, 
1992; May and Robison, 1993; Yamaguchi et al., 1993; Gill, 1994). 
Positive allosteric modulators of the AMPA receptor bind at a site distinct from the 
agonist binding site and enhance current flow through the ion channel.  Positive allosteric 
modulators of the AMPA receptor exert their effects through a variety of mechanisms.  
Aniracetam GYKI 52466 Cyclothiazide 
 
H
5
2
4 
1
6 3
H
O O 
N
N HS2NSO2
Cl CH2
Diagram 4:  Chemical structures of various allosteric modulators of the 
AMPA receptor.  GYKI 52466 inhibits agonist-evoked responses at AMPA 
receptors while aniracetam and cyclothiazide are positive allosteric 
modulators. 
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The classic benzoylpiperidine aniracetam increases single channel open time (Tang et al., 
1991; Vyklicky et al., 1991; Partin et al., 1996; Lawrence et al., 2003) and possibly single 
channel conductance (Staubli et al., 1992) by slowing the rate of receptor deactivation.  
Aniracetam is more efficacious at flop splice isoforms (Johansen et al., 1995).  CX516 
(BDP-12) and CX546, also benzoylpiperidines, were developed as memory-enhancing 
drugs and are known as Ampakines (Staubli et al., 1994b; Staubli et al., 1994a; Lynch et 
al., 1996; Ingvar et al., 1997; Hampson et al., 1998).  CX516 and CX546 modulate 
AMPA receptor mediated currents by accelerating channel opening and slowing channel 
closing, respectively (Arai et al., 2002).   
The classic benzothiadiazine cyclothiazide acts at a site distinct from that of the 2,3-
benzodiazepines (Kessler et al., 1996; Donevan and Rogawski, 1998) and significantly 
inhibits AMPA receptor desensitization (Patneau et al., 1993; Yamada and Tang, 1993).  
Unlike aniracetam, the benzothiadiazines act preferentially at receptors composed of flip 
subunits (Partin et al., 1994), with the selectivity determined by a single amino acid 
residue in the flip/flop domain (Table 2; Partin et al., 1995; Partin et al., 1996).   Residues 
outside of the flip/flop region have also been shown to influence cyclothiazide 
modulation (Partin, 2001).  The mechanism of action of cyclothiazide is frequently 
described as reduction or attenuation of desensitization (Nagarajan et al., 2001; Horning 
and Mayer, 2004).   
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1.2     Synaptic Physiology 
1.2.1    Varying AMPA Receptor Subunit Composition Produces Functional 
Heterogeneity 
AMPA receptors mediate the majority of fast synaptic transmission in the mammalian 
nervous system; however, the specific subunit composition of the receptor varies between 
neurons, and even between different synapses on a single neuron (Zhao et al., 1997), 
resulting in unique postsynaptic responses.  For example, cerebellar Purkinje and granule 
cells express GluR2 and GluR4, while GluR1 is relatively absent in cerebellar neurons 
(Hack et al., 1995; Zhao et al., 1997; Brorson et al., 1999; Huh and Wenthold, 1999).  
Inclusion of GluR2 in a tetramer determines the physiological properties of the receptor 
channel: lower channel conductance, minimal Ca2+ permeability, and slower deactivation 
and desensitization kinetics.  Certain mature auditory, visual and cerebellar neurons 
primarily express the flop isoform of GluR4, resulting in Ca2+ permeable channels with 
extremely fast deactivation and desensitization kinetics (Geiger et al., 1995; Rubio and 
Wenthold, 1997; Gardner et al., 1999; Lawrence and Trussell, 2000; Gardner et al., 2001; 
Wall et al., 2002; Veruki et al., 2003; Joshi et al., 2004).  
Excitatory pyramidal neurons in the CA1, CA2 and dentate gyrus regions of the 
hippocampus primarily express heteromeric combinations of GluR1/GluR2 and 
GluR2/GluR3 as well as a small population of homomeric GluR1 receptors (Geiger et al., 
1995; Wenthold et al., 1996).  Assembly of GluR1/2 heteromers preferentially includes 
two GluR1 and two GluR2 subunits assembled so each GluR1 subunit is flanked by 
GluR2 and vice versa (Mansour et al., 2001).  GluR1 and GluR2 in hippocampus and 
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neocortex are found as both flip and flop splice variants (Hestrin, 1993; Geiger et al., 
1995; Fleck et al., 1996).  Heteromeric receptors preferentially include both flip and flop 
isoforms in a single tetramer (Brorson et al., 2004), suggesting native hippocampal 
AMPA receptors are composed of GluR1flop/GluR2flip and/or GluR1flip/GluR2flop.  
More mature synapses in cultured hippocampal neurons have a relatively greater 
proportion of GluR2 than do immature synapses (Pickard et al., 2000), suggesting AMPA 
receptors with higher Ca2+ permeability may be important during neuronal and synaptic 
development in the hippocampus.  Additionally, the AMPA receptor subunit content of 
inhibitory GABAergic interneurons is unique from that in excitatory neurons.  
Hippocampal and neocortical interneurons desensitize faster and have greater Ca2+ 
permeability than pyramidal neurons in the corresponding area due to elevated expression 
of GluR4flop and reduced expression of GluR2 (Hestrin, 1993).     
Regional differences and developmentally regulated changes in AMPA receptor 
subunit composition have been studied extensively in brainstem nuclei involved in 
auditory processing.  Before synapse formation occurs, AMPA receptors in neurons from 
avian nucleus magnocellularis (nMAG) desensitize relatively slowly, are Ca2+ 
impermeable and are not sensitive to polyamine channel block, indicating incorporation 
of GluR2.  After synapse formation, AMPA receptors in these cells desensitize rapidly, 
have increased Ca2+ permeability and sensitivity to polyamine block as a consequence of 
GluR2 downregulation and GluR4 upregulation (Lawrence and Trussell, 2000).  Neurons 
in the cochlear nuclei, the mammalian homologue of nMAG, receive input from both 
auditory nerves and axons of local granule cells. Neurons directly involved in auditory 
processing exhibit fast, Ca2+ permeable synaptic responses mediated primarily by 
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GluR4flop, while those synapsing with local fibers exhibit slower, Ca2+ impermeable 
responses due to the presence of GluR2 (Gardner et al., 1999, 2001; Joshi et al., 2004). 
 
1.2.2    Desensitization During Normal Synaptic Transmission 
The duration of excitatory postsynaptic currents (EPSCs) varies between 100 µs and 2 
ms (Raman and Trussell, 1995; Kinney et al., 1997), while the time constants for AMPA 
receptor desensitization range from 2-12 ms in various brain regions (summary in Raman 
et al., 1994).  Desensitization plays a role in auditory and cerebellar synaptic transmission 
(Trussell and Fischbach, 1989; Trussell et al., 1993; Kinney et al., 1997; Wall et al., 
2002).  For example, in the cerebellum the rapidity of desensitization of GluR4flop 
receptors may shape EPSCs at mature mossy fiber/granule cell synapses and mossy 
fiber/unipolar brush cell synapses in rat cerebellum (Kinney et al., 1997; Wall et al., 
2002).  However, the time course of normal synaptic transmission in most brain regions 
is believed to be determined primarily by deactivation rather than desensitization kinetics 
of the AMPA receptor (Jonas and Spruston, 1994; Conti and Weinberg, 1999). 
AMPA receptor desensitization affects postsynaptic responses during the prolonged 
presence of glutamate in the cleft and/or high frequency stimulation.  A common feature 
of high frequency stimulation is a decrement in the “second response”, which can be 
abolished by cyclothiazide (Otis et al., 1996), a positive modulator that inhibits AMPA 
receptor desensitization (Patneau et al., 1993; Yamada and Tang, 1993).  Thirty-five to 
forty percent of AMPA receptors in avian neurons are desensitized after a single synaptic 
event (Otis et al., 1996).  The relatively high affinity of glutamate for the desensitized 
state slows dissociation of neurotransmitter, suggesting the extent of desensitization of a 
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synaptic population of AMPA receptors can define synaptic responses during high 
frequency stimulation.  Desensitization therefore limits the frequency at which full 
amplitude responses can be elicited at a particular synapse (Trussell and Fischbach, 1989; 
Jones and Westbrook, 1996). 
 
1.3    Conformational Changes Involved in Agonist Binding, Channel Gating        
and Desensitization 
Crystallization of the extracellular domains of the GluR2 subunit of the AMPA 
receptor in complex with various ligands (Armstrong et al., 1998; Armstrong and 
Gouaux, 2000; Hogner et al., 2002; Sun et al., 2002) has significantly enhanced our 
understanding of the mechanism of AMPA receptor gating and desensitization.  The 
propensity of the extracellular domains to form dimers in solution suggests native 
tetramers are assembled as a pair of dimmers (Diagram 5).  Interestingly, dimerization is 
enhanced by mutations that disrupt desensitization (Stern-Bach et al., 1998), as well as by 
binding of the positive allosteric modulator cyclothiazide (Sun et al., 2002).  The 
extracellular portion of each AMPA receptor subunit has two distinct regions, termed 
domain 1 (D1) and domain 2 (D2) that are assembled into a “clamshell” conformation  
(Stern-Bach et al., 1994; Armstrong et al., 1998; Armstrong and Gouaux, 2000; Mayer et 
al., 2001; Hogner et al., 2002; Sun et al., 2002).  As pictured in Diagram 5, D2 consists 
primarily of the extracellular domain between TM3 and TM4 while D1 is made up of 
both the first ~150 amino acids of the extracellular domain preceding TM1 and of the 
alternatively spliced flip/flop domain found in S2 (Armstrong et al., 1998).  The agonist 
binding site is formed at the junction of D1 and D2. 
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Each tetrameric AMPA receptor has two dimer interfaces, resulting in two-fold 
rotational symmetry of the extracellular domains.  This symmetry has been shown to 
extend to the outermost portion of the channel (Sobolevsky et al., 2004), while the 
interior and cytosolic portion of the channel is still assumed to have four-fold symmetry 
(Stern-Bach, 2004).  Helix D of S1, helix J of S2 and an interdomain β strand of S1 from 
one subunit interact in a complementary fashion with the same structures in an adjacent 
subunit to form the dimer interface (Diagram 5, Table 1).  A considerable hydrogen bond 
network, two salt bridges and hydrophobic van der Waals interactions maintain the 
interface (Armstrong et al., 1998; Armstrong and Gouaux, 2000; Partin, 2001; Hogner et 
al., 2002).  Table 1 identifies interactions between specific residues in these domains.  Of 
note, helix J consists of amino acids 741-756 of the ~38 amino acid flip/flop region in 
GluR2 (Armstrong et al., 1998; Partin, 2001), a pivotal region in defining the 
desensitization profile of the receptor (Sommer et al., 1990).   
Crystallization of the soluble extracellular domains of GluR2 shows that two 
molecules of the positive allosteric modulator cyclothiazide bind at the dimer interface 
through interactions with residues near the agonist binding site and in the flip/flop region 
(Partin et al., 1996; Partin, 2001; Sun et al., 2002; Leever et al., 2003).  This significantly 
increases the stability of the dimer interface, suggesting that stabilization of inter-subunit 
interactions determines the degree of receptor desensitization.  Stern-Bach and colleagues 
(1998) have identified a point mutation in GluR3 (L507Y) that abolishes desensitization.  
Examination of the crystallized extracellular domains reveals that the homologous amino 
acid (L483) in GluR2 is a primary participant in dimer interface stabilization.  
Substitution of a tyrosine for a leucine at position 483 in GluR2 facilitates hydrophobic 
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interactions between this residue and L748 and K752 on the adjacent helix J (See Table 
2).  The ring structures of the tyrosine side chain also allows favorable cation-π 
interactions (Sun et al., 2002), further strengthening the dimer interface and significantly 
shifting the KD of dimerization to the left.   
 
TABLE I 
N-terminal 
Domain
1 2 3 4
A B
Domain 1
Domain 2
Domain 1
Domain 2
S1
S2
Flip/Flop 
Region (S2)
Agonist Binding 
Site
Diagram 5:  Models of the extracellular domains of the AMPA receptor subunit.  
A.  Crystallized structure of the extracellular domains of two AMPA receptor 
subunits bound by the benzothiadiazine cyclothiazide (CTZ) and the agonist 
glutamate (Glu).  Domain 1 (D1) and domain 2 (D2) from a single subunit are 
outlined, with D1 in light blue and D2 in dark blue (from Sun et al., 2002).  D1 
and D2 of the adjacent subunit are shown in pink and purple, respectively.  Note 
the location of helix J and helix D at the dimer interface.  For reference, the 
channel-forming transmembrane domains, which have not been crystallized, are 
also depicted.  B.  Schematic of the location of the S1 and S2 regions relative to 
domain 1 and domain 2.  Also shown are the channel-forming transmembrane 
portions of the receptor and the N-terminal domain (~400 amino acids).  The N-
terminal domain, which is not necessary for agonist binding or desensitization, 
plays a role in tetramer assembly (Leuschner and Hoch, 1999; Pasternack et al., 
2002).  
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Amino Acid Interactions at the GluR2 (GluR-B) Dimer Interface 
Domain 1  Adjacent Domain 1 
L483 (helix D) ♦ ↔ L748, L751, K752 (helix J) 
E486 (helix D) ↔ K493 * (interdomain β strand) 
N754 (helix J) ♦ ↔ S729 (near interdomain hinge) 
    All amino acid numbers refer to the mature GluR2/GluR-B protein 
*  Conserved in all AMPA and kainate receptor subunits (Armstrong and Gouaux, 2000) 
♦  Residues found at the dimer interface that strongly influence desensitization 
 
 
TABLE II 
Summary of Residues Affecting Agonist Binding and Desensitization 
Agonist Binding  Site 
(GluR2) 
Flip/Flop residue 
determining cyclothiazide 
sensitivity 
Non-Desensitizing   
Mutants 
S1 
      Y405 
      Y450 
      P478 • 
      T480 • 
      R485 • * 
GluR1
GluR2
S/N750 
S/N754 ♦ 
GluR1 
GluR2 
GluR3 
GluR4 
L497Y 
L483Y ♦ 
L507Y 
L484Y 
S2 
      L650 ° 
      S654 • 
      T655 
      L703 
      E705 • 
NOTE: Kainate receptors 
have a Q at this site and are 
insensitive to modulation by 
cyclothiazide 
  
•  Glutamate, AMPA and kainate interact similarly with the α-carboxyl and -amino 
groups of these residues (Armstrong et al., 1998; Armstrong and Gouaux, 2000) 
* Conserved in all ionotropic glutamate receptors (Armstrong and Gouaux, 2000) 
°  Mutation to threonine left-shifts the EC50 of kainate and increases domain closure 
(Armstrong et al., 2003) 
♦ Residues found at the dimer interface that strongly influence desensitization.  The 
comparable amino acids in GluR1, 3, and 4 are predicted to have similar importance in 
desensitization of these subunits. 
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The current working model of AMPA receptor desensitization centers around the 
stability of the dimer interface.  In the resting state, two adjacent subunits are associated 
via interactions between the D1 domains, forming a dimer (Diagram 6).  Agonist binding 
at the ligand binding core near the hinge region of the clamshell produces movement of 
the D2 domain, which is communicated to the transmembrane domains to open the 
channel.  Further closure of the "clamshell" destabilizes the dimer interface, facilitating 
transition into the lower energy desensitized state and closing the channel (Armstrong et 
al., 1998; Sun et al., 2002; Horning and Mayer, 2004).  In verification of this model, 
studies have demonstrated that mutations affecting interactions at the dimer interface 
Diagram 6:  Model of agonist binding and desensitization.  First, agonist 
binds in the ligand binding cleft (1), inducing movement in the D2 domain 
that decreases the angle between D1 and D2 (2), which is coupled to 
channel opening.  Further domain closure places strain on the dimer 
interface (3), initiating a conformational change into the lower energy 
desensitized state and closing the channel (4). 
CLOSED OPEN DESENSITIZED
agonist               Na+
1.
2.
3.
4.
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predictably alter the kinetics and magnitude of receptor desensitization during agonist-
evoked responses (Sun et al., 2002; Horning and Mayer, 2004). 
A major mechanistic question is how agonist-induced conformational changes in the 
extracellular domains are coupled to various open states of the AMPA receptor.  
Interestingly, binding of the full agonists glutamate and AMPA appear to induce 20° 
closure between D1 and D2, while the partial agonist kainate causes only a 12° domain 
closure (Armstrong and Gouaux, 2000).  Binding of the willardiines, a family of 
compounds that acts as partial agonists at GluR2 homomers, also induce lesser domain 
closure than the full agonists glutamate and AMPA (Jin et al., 2003).  The extent of 
domain closure between D1 and D2 directly correlates with the degree of channel 
opening (Armstrong et al., 2003; Jin et al., 2003).  Glutamate and AMPA elicit large peak 
but strongly desensitized steady-state responses, while kainate responses are only weakly 
desensitizing with a minimal peak (see Diagram 3).  It is likely that a greater degree of 
domain closure is initially translated into higher conductance open states but causes 
greater strain on the dimer interface.  This accelerates the transition into the desensitized 
state, resulting in smaller steady-state currents than those produced by agonists that 
induce a lesser degree of domain closure.  This model suggests that agonist-specific 
conformations of the extracellular domains translate into a characteristic profile of 
subconductance states. 
 
1.4    Glutamate Receptors and Models of Learning and Memory 
The synapse is the functional unit of the nervous system.  The basic process of 
neurotransmitter release, binding and activation of postsynaptic receptor with subsequent 
 18
synaptic clearance is repeated innumerable times in the mammalian brain; however, the 
identity of the neurotransmitter, the nature, number and coupling of the postsynaptic 
receptor and the rate of neurotransmitter clearance makes each synapse a unique and 
dynamic entity.  One of the fundamental goals of neuroscience is to determine how 
tuning of these parameters allows individual synaptic events to encode the alterations in 
cognition defined as learning and memory.   
 
1.4.1    A Historical Perspective of Learning and Memory 
In the late nineteenth and early twentieth century Ivan Pavlov defined criteria for a 
type of vertebrate learning known as the conditioned response.  In this paradigm a 
conditioned stimulus (such as a bell tone) is temporally linked to an unconditioned 
stimulus (food presentation) that produces a conditioned physiological response 
(salivation) in such a way that the animal “learns” to respond physiologically to the 
conditioned stimulus alone.  Pavlov firmly established that successsful associative 
learning is critically dependent upon the order of stimulus presentation (conditioned 
stimulus preceding unconditioned stimulus) and the latency between stimuli (Pavlov, 
1940); thus, learning is an orderly, time-dependent process.  Pavlov’s behavioral studies 
begged the question: What physiological changes in the CNS accompany and maintain 
associative learning? 
Early in the 20th century, the famous neurohistologist Santiago Ramon y Cahal 
proposed the Neuron Doctrine, which identifies the neuron as the fundamental 
physiological and anatomic unit of the nervous system.  He hypothesized that neurons 
store information through changes in synaptic strength (Ramon y Cajal, 1913).  Less than 
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a decade after the publication of Pavlov’s codification of associative learning, the 
psychologist Donald Hebb elaborated upon Cajal’s theory and Pavlov’s results, 
postulating that:  
When an axon of cell A is near enough to excite a cell B and repeatedly or 
persistently takes part in firing it, some growth process or metabolic 
change takes place in one or both cells such that A’s efficiency, as one of 
the cells firing B, is increased (Hebb, 1949).   
Hebb proposed that elevated activity at a particular synapse increases the strength 
of the synapse.  In other words, learning and memory cause or are a consequence 
of a persistent, activity-dependent molecular change in the synapse.   
 
1.4.2    NMDA Receptors as Coincidence Detectors 
Glutamate receptors play a central role in the activity-dependent molecular events 
believed to underlie learning and memory.  As previously mentioned, AMPA receptors 
synaptically colocalize with NMDA receptors, which, unlike most AMPA receptors, are 
permeable to Ca2+ ions.  NMDA receptors are unique in that they are both ligand- and 
voltage-gated.  Glutamate released into the synapse binds and activates NMDA receptors; 
however, the channel is blocked by a Mg2+ ion until the membrane is sufficiently 
depolarized (-45 to -35 mV).  This singular arrangement ensures that only strong 
postsynaptic depolarization activates the NMDA receptor, allowing it to detect the 
coincidence of pre- and postsynaptic activity that occurs during high frequency 
neurotransmission.  Influx of Ca2+ ions through the receptor activates a variety of 
enzymes, including calcium-calmodulin dependent kinase II (CaMKII) and protein kinase 
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A (PKA), that activate downstream cascades that alter synaptic strength in an activity-
dependent manner (Malinow and Malenka, 2002; Bredt and Nicoll, 2003; Lynch, 2004).   
 
1.4.3   Long Term Potentiation (LTP) and Long Term Depression (LTD) 
An initial question that sparked great debate in the neuroscience community was 
whether the modifications effecting synaptic plasticity were found pre- or 
postsynaptically.  At the center of the dispute were “silent synapses” (Nicoll and 
Malenka, 1999), which are synapses that appear functionally mature upon visual 
examination but do not participate in normal synaptic transmission.  During neuronal 
development, AMPA receptor expression lags behind that of NMDA receptors, resulting 
in a significant number of “silent” synapses containing only NMDA receptors, which are 
unable to mediate basal neurotransmission.  Conversion of silent synapses to active 
synapses after appropriate stimulation was initially interpreted as evidence of alterations 
in neurotransmitter release; however, during development these synapses become 
functional due to AMPA receptor incorporation (Rao et al., 1998; Petralia et al., 1999).  
Trafficking of AMPA receptors into the synapse allows the released neurotransmitter to 
effect postsynaptic depolarization, creating an active contact from a “silent synapse”.  
The overwhelming majority of research in the past ten years indicates that postsynaptic 
events, specifically increased trafficking of AMPA receptors into the synapse, are the 
primary mediators of synaptic plasticity (reviewed in Malinow and Malenka, 2002).   
Research focusing on the molecular events underlying synaptic plasticity has 
primarily drawn inferences about intact brain function from studies examining long term 
potentiation (LTP) in hippocampal slice preparations, which preserve hippocampal 
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circuitry.  Induction of LTP in hippocampal slices involves brief (1 s to 1.5 min), high 
frequency (2-100 Hz) stimulation of a presynaptic neuron often paired with 
depolarization of the postsynaptic neuron (-5 to 5 mV).  This protocol produces 
prolonged increases in postsynaptic responses that can persist hours beyond the initial 
stimulus.  LTP-like alterations in vivo have been shown to persist for days after induction 
(Bliss and Lomo, 1970).   
The primary mechanism of elevated postsynaptic responses is rapid incorporation of 
AMPA receptors into the postsynaptic density (Shi et al., 1999).  LTP induction in the 
hippocampus, for example, initiates an interaction between PDZ domain-containing 
proteins and the long C-terminal tail of GluR1 that drives synaptic insertion of 
GluR1/GluR2 heteromers (Shi et al., 1999; Hayashi et al., 2000).  The associativity, input 
specificity, and persistence over time of LTP (Bliss and Collingridge, 1993) make this 
process an excellent model for the processes underlying learning and memory.  Several 
studies have found evidence of LTP-like synaptic plasticity resulting from experience-
related changes in vertebrate cortex (reviewed by Lynch, 2004).  Also, certain drugs that 
facilitate LTP also enhance learning (Staubli et al., 1994b; Staubli et al., 1994a; Lynch et 
al., 1996; Hampson et al., 1998). 
Long term depression (LTD) involves regulated removal of synaptic AMPA receptors 
to reduce synaptic strength (reviewed in Song and Huganir, 2002).  The classic form of 
LTD is observed at parallel fiber/Purkinje cell synapses in the cerebellum and is NMDA 
receptor-independent, relying instead upon activation of metabotropic glutamate 
receptors and Ca2+ influx through voltage-gated calcium channels (reviewed in Daniel et 
al., 1998; Ito, 2001).  Hippocampal neurons exhibit NMDA receptor-dependent LTD 
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after low (1 Hz), rather than high, frequency stimulation that involves activation of 
protein phosphatases such as calcineurin (reviewed in Malenka and Bear, 2004).    
It is clear that the mechanisms implementing long-term alterations of synaptic 
strength differ between brain regions and can be mediated by a myriad of overlapping 
mechanisms; however, rapid insertion and removal of AMPA receptors appears to be a 
fundamental mechanism of synaptic modification  (Martin et al., 2000; Malinow and 
Malenka, 2002; Bredt and Nicoll, 2003; Lynch, 2004). 
 
1.5    Glutamate Receptors and Pathophysiology 
According to the most recent statistics from the American Heart Association, 70.1 
million Americans have cardiovascular disease (2005).  Of these, 7.1 million individuals 
have experienced a heart attack and 5.4 million have suffered from stroke.  
Excitotoxicity, a process in which over-activation of glutamate receptors leads to 
neuronal death, is a major cause of brain damage resulting from these hypoxic-ischemic 
insults.  Focal or global ischemia in the CNS inhibits ATP production, causing a 
breakdown in ionic gradients.  This leads to elevated vesicular release of glutamate and 
impaired uptake of the neurotransmitter.  Synaptic and extra-synaptic AMPA receptors 
mediate an initial Na+ influx that causes osmotic swelling, cytoplasmic dilution, organelle 
disruption, and, if perpetuated, cell lysis.  Prolonged depolarization of the postsynaptic 
membrane activates NMDA receptors, allowing abnormally elevated Ca2+ entry into the 
cell.  Unregulated levels of Ca2+ activate a variety of enzymes, including various 
proteases, kinases, phosphatases, endonucleases and, in particular, nitric oxide synthase, 
resulting in disturbance of the electron transport chain, production of toxic amounts of 
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free radicals, and peroxidation of cell membranes, ultimately causing neuronal death 
(Choi, 1988).   
While Ca2+ flux through NMDA receptors is thought to initiate neuronal death 
during excitotoxic events, NMDA receptor antagonists are less neuroprotective than 
AMPA receptor antagonists in models of ischemia (Buchan et al., 1991).  Additionally, 
the selective vulnerability of cerebellar Purkinje cells, which express AMPA but not 
NMDA receptors (Crepel et al., 1982; Cull-Candy et al., 1998), to ischemia suggests a 
key role for AMPA receptors in excitotoxic events.  The neuroprotective effect if AMPA 
receptor antagonists in in vivo models of ischemia (Sheardown et al., 1990; Gill, 1994) 
suggests that AMPA receptor inhibition is a clinically relevant treatment option for 
ischemic events such as heart attack and stroke.   
Excitotoxic events are also implicated in neurodegenerative diseases, including 
amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease).  ALS is an 
adult onset disease characterized by progressive degeneration of upper (corticospinal) and 
lower (spinomuscular) motor neurons leading to death within two to five years after 
diagnosis, normally from respiratory failure (Doble, 1999).  In the United States, ALS 
incidence is between 1 and 2 per 100,000 individuals and is most commonly diagnosed in 
middle age, affecting men more frequently than women (Walling, 1999).  The glutamate 
release inhibitor riluzole modestly increases ALS patient survival time and slows the rate 
of motor function deterioration (Doble, 1999).  Excitotoxic events, and thus glutamate 
receptor involvement, are also implicated in other neurodegenerative diseases such as 
Alzheimer’s, Parkinson’s and Huntington’s diseases as well as such disorders as epilepsy 
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and schizophrenia (Hollmann and Heinemann, 1994; Yamada, 1998; Johnson et al., 
1999; Lees, 2000; Goff et al., 2001; Danysz, 2002b). 
 
1.6    Modulation of AMPA Receptor Desensitization by Exogenous Drugs 
The initial portion of this thesis project focuses on defining the interaction of the 
benzothiadiazine modulators with AMPA receptor desensitization.  The nootropic effects 
of positive allosteric modulators of the AMPA receptor have been demonstrated in both 
animal and human models of learning and memory  (Johnson et al., 1999; Goff et al., 
2001; Danysz, 2002b) and are being explored as novel therapies for cognitive disorders 
such as schizophrenia (Danysz, 2002a) and Alzheimer’s disease (Derkach et al., 1999).  
Rational drug design to enhance learning or reduce deleterious effects of stroke or other 
excitotoxic events relies upon a clear understanding of the modulator mechanism of 
action.  For example, a modulator with high affinity in the absence but rapid dissociation 
in the continued presence of agonist may act as an ideal nootropic by increasing the 
efficacy of synaptic responses without danger of excitotoxic cell death. 
 
1.7    Intracellular AMPA Receptor Associated Proteins 
In recent years a number of proteins have been identified that associate with AMPA 
receptors (Bredt and Nicoll, 2003).  These proteins are primarily cytosolic and appear to 
be involved either in anchoring the receptor at the synapse and maintaining basal synaptic 
strength, or in trafficking events associated with long-term modifications of synaptic 
strength.  Regulated insertion and removal of AMPA receptors from the synapse is a 
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major mechanism of synaptic plasticity and is likely to be involved in the molecular 
changes intrinsic to learning and memory formation (see Section 1.4.3).   
Glutamate receptor subunits with short C-terminal tails (GluR2, 3 and 4c) have a 
type II PDZ binding domain at the extreme C-terminus that mediates binding to the 
cytosolic proteins GRIP1 (glutamate receptor interacting protein 1), GRIP2/ABP (AMPA 
receptor binding protein), and PICK1 (protein interacting with C kinase) (Dong et al., 
1997; Srivastava et al., 1998; Dev et al., 1999; Dong et al., 1999).  PDZ domains, named 
after three proteins containing the motif (PSD-95, Discs-large/DLG, ZO-1), are ~90 
amino acids long and mediate a vast array of protein-protein interactions, typically by 
recognition of short sequences in the C-terminus of their binding partner.  GluR2 also 
contains a short non-PDZ sequence that binds NSF (N-ethylmaleimide-sensitive factor), a 
membrane fusion ATPase associated with SNARE complex disassembly (Nishimune et 
al., 1998; Osten et al., 1998).  GluR1 and 4 interact via a non-PDZ domain interaction 
with the cytosolic actin-binding band 4.1 proteins (Shen et al., 2000; Coleman et al., 
2003; Diagrams 7 and 8).  AMPA receptor subunits also associate with the 
transmembrane AMPA receptor regulatory proteins, or TARPs, which include 
stargazin/γ2, γ3, γ4, and γ8 (Tomita et al., 2003).  The following sections focus on the 
role of PICK1, GRIP1 and stargazin in AMPA receptor trafficking and long term 
modifications of synaptic strength.  
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Long C-terminal tails:
Short C-terminal tails:
G luR 1
G luR 4
G luR 2L
G luR 2
G luR 3
G luR 4c
Band 4.1N
CaMKII
PKC PKA SAP97
NSF
GRIP1, ABP/GRIP2, PICK1
PKC
out in
out in
EFCYKSRSESKRMKGFCLIPQQSINEAIRTSTLPRNSGAGASGGGGSGENGRVVSQDFPKSMQSIPCMSHSSGMPLGATGL-
EFCYKSRAEAKRMK-------LTFSEAIRN--KARLSITGSV-----GENGRVLTPDCPKAVHTGTAIRQSSGLAVIASDLP
EFCYKSRAEAKRMK-------MTLSDVMRS--KARLSITGST-----GENGRVMTPEFPKAVHAVPYVSPGMGMNVSVTDLS
*******.*.****        ......*.    * *  *.      ******.. * **.... .    *. . .. *
EFCYKSRAEAKRMKVAKNPQNINPSSSQNSQNFATYKEGYNVYGIESVKI
EFCYKSRAESKRMKLTKNTQNFKPAPATNTQNYATYREGYNVYGTESVKI
EFCYKSRAEAKRMKVAKSAQTFNPTSSQNTHNLATYREGYNVYGTESIKI
*********.****. *. *...*  ..*..*.***.******* **.**
Diagram 7: Short and long C-terminal domains of selected AMPA receptor 
subunits.  Single residues highlighted in green are sites of phosphorylation.  
Amino acids highlighted in blue are sites of protein-protein interactions.  The 
black line delimits the C-terminal PDZ binding domain.  Enzymes are shown in 
bold italics, binding proteins in bold.  CaMKII, calcium calmodulin dependent 
kinase II; PKC, protein kinase C; PKA, protein kinase A; SAP97, synapse 
associated protein 97; NSF, N-ethylmaleimide-sensitive factor; GRIP1, glutamate 
receptor interacting protein 1; ABP, AMPA receptor binding protein; PICK1, 
protein interacting with C kinase.  (Modified from Malinow and Malenka, 2002.) 
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Diagram 8:  Association of synaptic AMPA receptors with various 
proteins.  PICK1, GRIP1 and GRIP2 associate with GluR2 via PDZ 
binding domains, while NSF binds to GluR1 via a non-PDZ domain 
mediated interaction.  Stargazin/γ2 also associates with the receptor via a 
non-PDZ domain interaction.  Also shown is association of PSD-95 and 
nPIST with stargazin (γ2).  Proteins depicted: PKC-α, protein kinase C-α; 
PICK1, protein interacting with C kinase 1; PSD-95, postsynaptic density 
protein, 95kD; nPIST, neuronal isoform of protein-interacting specifically 
with TC10; GRIP1 and 2, glutamate receptor interacting proteins 1 and 2; 
GRASP, GRIP associated protein; NSF, N-ethylmaleimide-sensitive factor. 
Other abbreviations: PDZ, PSD-95, Discs large/DLG, ZO-1 domain (~90 
amino acids); SH3, Src homology 3 domain (~60 amino acids); acidic 
amino acid cluster sequence is EESEE.  (Modified from Song and Huganir, 
2002).   
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1.7.1    The Glutamate Receptor Interacting Protein (GRIP) Family 
While GRIP1 has no catalytic activity, it contains 7 PDZ domains, allowing it to 
interact with numerous proteins (Table 3).  GRIP1 interacts with the extreme C-terminus 
of GluR2 and GluR3 via PDZ domains 4 and 5 (Dong et al., 1997) and colocalizes with 
synaptic AMPA receptors (Dong et al., 1997; Wyszynski et al., 1999).  GRIP1 is 
enriched in the postsynaptic density, with a small but significant cytosolic presence 
(Wyszynski et al., 1998; Dong et al., 1999).  Its numerous PDZ domains allow multiple 
and diverse binding partners, suggesting possible functions as an anchoring protein, or as 
a bridge juxtaposing receptors with regulatory enzymes or trafficking complexes.   
A highly homologous protein called ABP or GRIP2 is also synaptically localized and 
binds GluR2 and GluR3 via PDZ domains 3, 5 and 6.  ABP/GRIP2 forms 
homomultimers as well as heteromultimers with GRIP1 (Srivastava et al., 1998; Dong et 
al., 1999; Im et al., 2003), compounding the number and extent of possible protein 
interactions.  In rat cerebrum ABP and GRIP1 infrequently colocalize, with 
complementary expression patterns both neuronally and synaptically (Burette et al., 2001; 
Takamiya et al., 2004).  GRIP1 expression early in embryonic development precedes that 
of AMPA receptors, while GRIP2 is expressed in parallel with the receptor [(Dong et al., 
1999), but see also (Bruckner et al., 1999)].  A shorter splice variant called GRIP1c 4-7 
contains 4 PDZ domains identical to PDZ domains 4-7 of GRIP1 and also colocalizes 
with AMPA receptors at excitatory synapses in the hippocampus (Charych et al., 2004). 
ABP is found in rat as three splice variants: a shorter version with 6 PDZ domains, a 
longer version with 7 PDZ domains called ABP-L or GRIP2 (Srivastava et al., 1998; 
Dong et al., 1999) and an N-terminal palmitoylated variant of ABP-L (deSouza et al., 
 29
2002).  Similar variants have been identified in mouse brain (Yamazaki et al., 2001).  A 
region between PDZ3 and PDZ7 in non-palmitoylated ABP-L/GRIP2 targets and clusters 
GluR2-containing receptors at intracellular membranes, possibly creating and 
maintaining a subsynaptic pool of AMPA receptors available for activity-dependent 
insertion (Fu et al., 2003).  Palmitoylated ABP-L is localized on the surface of dendritic 
spines, implying a synaptic presence (deSouza et al., 2002).  Palmitoylation is a 
reversible modification (Magee et al., 1987; Milligan et al., 1995), similar to 
phosphorylation, and is associated with appropriate membrane localization and 
stabilization of molecules ranging from small G proteins to morphogens involved in 
embryonic development (Dudler and Gelb, 1996; Go and Mitchell, 2003; Chen et al., 
2004); thus, palmitoylation of ABP may constitute a mechanism by which neurons can 
regulate synaptic AMPA receptor content.   
 
1.7.2    GRIP Binding Partners 
GRIP1 is specifically bound by several GRIP-associated proteins (GRASPs).  
GRASP-1 is a neuron-specific guanine nucleotide exchange factor regulated by NMDA 
receptor activation (Ye et al., 2000).  In hippocampal cultures, over-expression of 
GRASP-1 reduces synaptic AMPA receptor clustering.  Signaling through this pathway 
may comprise an unexamined component of synaptic plasticity or a possible protective 
mechanism during excitotoxic events (Ye et al., 2000). 
The association of GRIP1 with the heavy chain of the motor protein kinesin via a 
non-PDZ domain interaction may contribute to trafficking GluR2-containing AMPA 
receptors from the soma to dendritic locations (Setou et al., 2002).  Association with 
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MAP-1B (microtubule associated protein-1B) may allow GRIP1 to anchor synaptic 
AMPA receptors to the cytoskeleton (Seog, 2004).  GRIP1 and ABP/GRIP2 also mediate 
synaptic anchoring of AMPA receptors via a PDZ domain 6 association with liprin-α, a 
protein that interacts with a family of receptor protein tyrosine phosphatases.  Co-
immunoprecipitation of liprin-α, GRIP1 and GluR2/3 from rat cortex shows a strong, 
physiologically relevant association between the three proteins.  Disrupting the GRIP-
liprin-α interaction in cultured hippocampal neurons severely diminishes GluR2 synaptic 
localization, suggesting that association with liprin-α is necessary for GRIP1 to act as a 
membrane anchor (Wyszynski et al., 2002).   
GRIP family members associate with a broad array of neuronal proteins (Table 3).  
While a large percentage of GluR2/3 in adult rat brain is believed to associate with GRIP 
family members (Wyszynski et al., 1999; Burette et al., 2001), only 30-50% of GRIPs are 
associated with AMPA receptor subunits (Wyszynski et al., 1998; Wyszynski et al., 
1999).  It is clear from the multitude of GRIP1 binding partners that this protein family 
has diverse roles in neuronal and non-neuronal cells.  For example, GRIPs clearly 
associate with GABAergic as well as excitatory synapses (Burette et al., 1999; Dong et 
al., 1999; Wyszynski et al., 1999; Charych et al., 2004).  GRIP1 also interacts with the 
intracellular C-terminus of the extracellular matrix protein Fras1 to play a crucial role in 
embryonic epithelial development, digit morphogenesis and kidney formation. 
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TABLE III 
Summary of GRIP1 and PICK1 Binding Partners 
 Binding Partner via PDZ Domain: Comments: Reference/s 
GRIP1 GluR2, 3, 4c 4, 5 Targeting and anchoring 
AMPA receptors in 
synaptic and intracellular 
membranes 
(Dong et al., 1997; 
Dong et al., 1999; 
Osten et al., 2000; 
Braithwaite et al., 
2002) 
 GRIP1/2 4, 5, 6 Create scaffolding for 
protein anchoring 
(Dong et al., 1999; 
Ye et al., 2000) 
 GRASP-1 7  A neuronal ras-GEF 
regulated by NMDA 
receptor activity 
(Ye et al., 2000) 
 Liprin-α 6 AMPA receptor synaptic 
targeting 
(Wyszynski et al., 
2002) 
 EphrinB1 ligand 
Eph Receptors 
6, 7 Scaffolding for 
multiprotein signaling 
complexes 
(Torres et al., 
1998; Bruckner et 
al., 1999) 
 KIF5 Linker between 6 
and 7 
Somatodendritic receptor 
trafficking 
(Setou et al., 2002) 
 MAP-1B LC Region 
containing PDZ2 
Synaptic anchoring of 
AMPA receptors 
(Seog, 2004) 
 NG2 7 Glial-neuronal 
recognition and signaling 
in glial progenitor cells 
(Stegmuller et al., 
2003) 
 Fras1 1, 2, 3 Limb morphogenesis, 
kidney genesis, epithelial 
adhesion (animal model 
of Fraser Syndrome) 
(Takamiya et al., 
2004) 
PICK1 GluR2 1 Clustering and activity-
dependent removal of 
GluR2 subunits 
(Dev et al., 1999; 
Xia et al., 1999; 
Terashima et al., 
2004) 
 PKCα 1 Localization of enzyme 
to synaptic sites 
(Staudinger et al., 
1997; Perez et al., 
2001) 
 mGluR7a 1 Clustering of 
metabotropic GluRs at 
presynaptic sites 
(Boudin et al., 
2000) 
 EphB2, ephrin-
B1, EphA7 
1 Clustering Eph receptors 
and ligands, possibly at 
synapses 
(Torres et al., 
1998) 
 DAT, NET 1 Localization, expression, 
and function of 
monoamine transporters 
(Torres et al., 
2001) 
GEF, guanine nucleotide exchange factor; KIF5, heavy chains of conventional kinesin; MAP-1B 
LC, light chain of microtubule association protein-1B (Setou et al., 2002); NG2, single pass 
transmembrane proteoglycan expressed in oligodendrocyte progenitor cells (Stegmuller et al., 
2003); Fras1, extracellular matrix protein mutated in animal model of Fraser syndrome, which is 
characterized by blistering of embryonic but not adult skin, renal agenesis and cryptophthalamos 
(Takamiya et al., 2004); mGluR7a, metabotropic glutamate receptor 7a; DAT, dopamine 
transporter; NET, norepinephrine transporter 
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1.7.3    Protein Interacting with C Kinase (PICK1)   
PICK1 was originally isolated by its association with the extreme C-terminus of 
PKCα (Staudinger et al., 1995).  Via its single  PDZ domain, PICK1 also binds the 
extreme C-terminus of GluR2 and GluR3 (Dev et al., 1999; Xia et al., 1999).  While 
GRIP1 associates with GluR2 through a type II PDZ domain interaction (Dong et al., 
1997), the PICK1 PDZ domain accommodates both a type II interaction with GluR2 and 
a non-conventional type I interaction with PCKα (Staudinger et al., 1997; Perez et al., 
2001).  Mutation of one amino acid (K27E) in its single PDZ domain disrupts GluR2 but 
not PKCα binding (Dev et al., 2004).  PICK1 is capable of homo-oligomerization via 
interactions distinct from those mediating PCKα association, and can simultaneously 
interact with AMPA receptor subunits and PKCα (Staudinger et al., 1997; Xia et al., 
1999; Perez et al., 2001).  PICK1 is capable of clustering AMPA receptors  in 
heterologous cells (Dev et al., 1999; Xia et al., 1999).  Unlike the GRIPs, PICK1 appears 
to colocalize with AMPA receptors only at excitatory synapses on dendritic spines and 
does not colocalize with markers for inhibitory synapses (Xia et al., 1999).   
 
1.7.4    Differential Interactions of GRIP and PICK1 with GluR2   
Interactions between GRIP1, PICK1 and GluR2 are believed to be important in 
regulating the removal, insertion and stabilization of AMPA receptors at synaptic and 
internal membrane sites during induction of long term depression.  Over-expression of 
the C-terminal GluR2 PDZ domain in cultured rat neurons interferes with binding of 
endogenous GRIP1 and/or PICK1 with AMPA receptors and disrupts AMPA receptor 
clustering (Dong et al., 1997) without affecting extrasynaptic receptor distribution or 
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synaptic density (Dong et al., 1997; Osten et al., 2000; Shi et al., 2001).  While PICK1 
and GRIP1 bind the same C-terminal PDZ domain in GluR2, phosphorylation of serine 
880 (GluR2-S880) in the GluR2 C-terminus dramatically interferes with GRIP1 but not 
PICK1 binding (Dong et al., 1997; Chung et al., 2000; Matsuda et al., 2000).  A construct 
distinguishing between these proteins demonstrates that GRIP1 association is responsible 
for stabilizing GluR2-containing AMPA receptors at the synapse (Osten et al., 2000).  
Mutant GluR2 subunits that interfere with GRIP1 but not PICK1 binding are poorly 
synaptically localized in hippocampal slice cultures (Seidenman et al., 2003), further 
supporting a role for GRIP1 as a synaptic membrane anchor.  Interestingly, association of 
ABP-L/GRIP2, which appears to stabilize AMPA receptors in subsynaptic membranes, 
interferes with phosphorylation of serine 880 (Fu et al., 2003), suggesting a feedback 
mechanism by which of GRIP2 association with GluR2 maintains intracellular 
localization of AMPA receptors and thus down-regulation of synaptic receptors. 
Ligand binding studies of AMPA receptor surface expression after NMDA-induced 
LTD in cultured hippocampal neurons support a role for PICK1 in activity-dependent 
AMPA receptor internalization (Iwakura et al., 2001).  Disruption of GRIP1 and/or 
PICK1 binding in hippocampal slices and cerebellar Purkinje cells using a peptide 
corresponding to the GluR2 PDZ binding domain (pep2-SVKI) blocks induction of LTD 
(Daw et al., 2000; Xia et al., 2000; Kim et al., 2001).  While these studies generated 
conflicting evidence about the exact involvement of GRIP1 and PICK1 in hippocampal 
and cerebellar LTD, both groups propose models in which the phosphorylation-mediated 
differential association of PICK1 and GRIP1 with GluR2 is involved in destabilizing 
(PICK1) and stabilizing (GRIP1) AMPA receptors in preparation for or in maintenance 
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of LTD, respectively.  The GRIPs appear to act as membrane anchors at both surface and 
internal membranes.  Phosphorylation of GluR2-S880 may disrupt GRIP1 association with 
synaptic receptors and facilitate PICK1 binding, leading to internalization of GluR2-
containing receptors.  Subsequent dephosphorylation would promote association of 
GRIP1 with AMPA receptors at subsynaptic membranes to maintain synaptic depression.  
Distinct signaling cascades mediating hippocampal and cerebellar LTD raise the 
possibility that these proteins play slightly different roles in the two brain regions.  
Several studies have shown active involvement of PICK1 in regulation of GluR2 
surface expression.  PICK1 preferentially associates with active PKCα, an enzyme 
associated with cerebellar LTD that can phosphorylate GluR2-S880 in vitro.  
Pharmacological activation of endogenous neuronal PKCα redistributes the diffusely 
localized enzyme so it colocalizes with PICK1 in dendritic spines (Perez et al., 2001).  In 
both hippocampal and cortical neurons, PKCα activation results in AMPA receptor 
internalization, decreased GluR2 surface expression, and serine 880 phosphorylation of 
most internalized GluR2 (Chung et al., 2000; Perez et al., 2001).  PKCα activation does 
not affect GRIP distribution in hippocampal neurons (Chung et al., 2000) or heterologous 
cells (Matsuda et al., 2000).  These studies suggest a model in which PKCα activation 
initiates its association with PICK1.  Close proximity to the C-terminal tail then 
facilitates phosphorylation of serine 880, dissociating GRIP from the receptor, and 
allowing receptor internalization (Perez et al., 2001).  While evidence exists that PKCα  
is not the kinase mediating GluR2-S880 phosphorylation (Daw et al., 2000; Kim et al., 
2001), phosphorylation of this residue is necessary for induction of hippocampal LTD 
(Kim et al., 2001; Chung et al., 2003; Seidenman et al., 2003), suggesting association of 
 35
PICK1 with phosphorylated GluR2 mediates activity-dependent down-regulation of 
synaptic AMPA receptors.  
PICK1 may also be involved in regulating basal GluR2 surface expression.  In an 
attempt to clearly define the interaction of PICK1 with GluR2, Collingridge and 
colleagues (2004) found that, in agreement with Perez et al. (2001) and Chung et al. 
(2000), expression of a PICK1-Sindbis virus construct in rat hippocampal slices 
selectively down-regulates synaptic GluR2.  This occurs without changing GluR2 
internal distribution, total GluR1 and GluR2 levels or, interestingly, GluR1 surface 
expression.  Paradoxically, the reduced presence of GluR2 in the synapse increases the 
magnitude of EPSCs, possibly due to the greater channel conductance of GluR2-lacking 
receptors (Terashima et al., 2004).  It is clear that the availability of PICK1 can affect 
basal synaptic transmission; however, both the physiological significance of this finding 
and confirmation of the more dynamic role of this protein in LTD remains open to further 
experimentation.  
GRIP1 and PICK1 have been implicated in processes beyond cerebellar and 
hippocampal LTD.  There is some evidence that GRIP1 plays a slightly more active role 
in LTP-like events in the spinal cord.  Li and colleagues (1999) found that peptide-
mediated disruption of GRIP1 but not PICK1 binding blocked the serotonin-mediated 
conversion of silent synapses to functional connections between sensory afferents and 
dorsal horn neurons, an effect that appeared to be mediated by PKC.  Elsewhere in the 
nervous system, GRIP1 and PICK1 may be involved in development of schizophrenia.  A 
recent study reported elevated levels of GRIP1 mRNA in the dorsolateral prefrontal 
cortex and occipital lobe of elderly schizophrenics (Dracheva et al., 2005). The PICK1 
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gene has been mapped to an area associated with increased susceptibility to schizophrenia 
and incidence of a single polymorphism of this gene is elevated in schizophrenic 
individuals (Hong et al., 2004). 
 
1.8    Modulation of AMPA Receptor Desensensitization by GRIP1/PICK1 
Reversible modifications such as phosphorylation have been shown to change 
channel properties: phosphorylation of GluR1 at serine 831 by CaMKII increases single 
channel conductance (Derkach et al., 1999) while phosphorylation of the same subunit at 
serine 845 by PKA increases channel open probability (Banke et al., 2000).  Reversible 
protein associations may also alter functional properties.  The burgeoning number of 
proteins involved in AMPA receptor trafficking yield a field of promising candidates.  It 
has been previously shown that the PDZ-domain mediated association of PSD-95/SAP90 
with kainate receptors significantly slows the rate of glutamate-evoked desensitization 
(Garcia et al., 1998; Bowie et al., 2003), raising the possibility that interactions of the 
AMPA receptor with PDZ domain-containing proteins could alter channel properties.  
The differential association of a large protein such as GRIP1, GRIP2 or PICK1 may 
influence parameters such as desensitization or channel conductance.  If cytoplasmic 
proteins can, by physical association, alter AMPA receptor channel function, a new 
parameter must be included in models of receptor kinetics, basal synaptic transmission 
and synaptic plasticity. 
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1.9    The Transmembrane AMPA Receptor Regulatory Protein (TARP) Family 
The stargazer mutant mouse exhibits symptoms of severe cerebellar dysfunction, 
including ataxia as well as impaired eyeblink conditioning, a motor learning paradigm 
dependent on intact cerebellar function (Noebels et al., 1990; Qiao et al., 1998).  The 
spontaneous viral insertion of a 6-kb early transposon into intron 2 of the stargazer gene 
prematurely arrests transcription, causing complete ablation of protein expression (Letts 
et al., 1998).  Stargazin/γ2 was initially grouped by homology in the voltage-gated 
calcium channel γ family (Letts et al., 1998); subsequent experiments demonstrated that 
the mutant phenotype is due primarily to a severe deficit of AMPA receptor surface 
trafficking in cerebellar granule cells (Chen et al., 2000).   
Based on homology and the ability to rescue AMPA receptor-mediated currents in 
stargazer cerebellar granule cells, a family of tetraspanning transmembrane AMPA 
receptor regulatory proteins (TARPs) has been identified that includes stargazin/γ2, γ3, 
γ4, and γ8 (Tomita et al., 2003).  Western blotting and in situ hybridization show high 
levels of expression of stargazin/γ2 in the cerebellum, γ3 in cerebral cortex, γ4 in caudate 
putamen, and γ8 in hippocampus.  γ4 is expressed in both neurons and glia while 
expression of the remaining family members is exclusively neuronal.  While γ2 is the 
only TARP expressed in cerebellar granule cells, there is overlap in TARP distribution in 
other brain regions.  The TARPs appear to be developmentally regulated; γ4 expression 
peaks early in post-natal maturation while γ2, γ3, and γ8 mRNA appears later and 
increases into adulthood until maximum levels are obtained (Tomita et al., 2003).   
Evidence exists that the members of the TARP family function as auxiliary subunits 
of the AMPA receptor.  TARPs co-purify with synaptic AMPA receptors in rat brain 
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(Nakagawa et al., 2005; Vandenberghe et al., 2005b), and single particle electron 
microscopy indicates the transmembrane regions of TARPs are closely associated with 
the transmembrane regions of the native AMPA receptors (Nakagawa et al., 2005).  
TARP family members do not coimmunoprecipitate, which suggests they do not intermix 
at a single AMPA receptor (Tomita et al., 2003); however, the number of TARPs 
associated with an individual AMPA receptor is unknown.   
  
1.9.1    Augmentation of AMPA Receptor Surface Expression by Stargazin/γ2  
Electrophysiological recordings from stargazer (stg, -/-) cerebellar granule cells 
revealed a critical reduction in both synaptic and extrasynaptic AMPA receptor currents 
(Chen et al., 2000).  Transcription and translation of AMPA receptor subunit genes is 
comparable between mutant and wild-type cells; therefore, the profound deficit in AMPA 
receptor mediated currents in stargazin mutant mice is due to defective surface 
trafficking of the ion channel (Hashimoto et al., 1999).  Expression of stargazin enhances 
glutamate-evoked responses between 5- and 10-fold in both neurons and heterologous 
systems (Schnell et al., 2002; Chen et al., 2003) and performs a vital role in AMPA 
receptor surface trafficking.  γ3, γ4 and γ8 are believed to function similarly in other 
brain regions such as cortex and hippocampus.   
AMPA receptors from stargazer cerebellar granule cells exhibit immature 
glycosylation patterns, suggesting stargazin may in part function as an ER chaperone 
(Tomita et al., 2003).  The unfolded protein response (UPR) is a process by which 
accumulation of unfolded proteins in the endoplasmic reticulum (ER) stimulates 
transcription of chaperone proteins like BiP (Ig binding potein).  Stimulation of the UPR 
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increases surface expression of GluR1 in heterologous cells.  In cells cotransfected with 
GluR1 and stargazin there is no further increase in GluR1 surface expression upon 
stimulation of the UPR.  This suggests stargazin and the UPR have similar mechanisms 
of action, namely facilitating proper protein folding and exit from the ER (Vandenberghe 
et al., 2005a).  
 
1.9.2    Stargazin/γ2 and Synaptic Trafficking of AMPA Receptors   
Stargazin mutant mice display severely diminished transmission at cerebellar mossy 
fiber/granule cell synapses (Hashimoto et al., 1999) which can be restored by exogenous 
expression of γ2 (Chen et al., 2000).  Transfection of a truncated stargazin construct 
restores extrasynaptic responses in stg cerebellar granule cells to the same degree as full-
length stargazin; however, this construct slightly decreases synaptic AMPA receptor 
responses in both wild-type cerebellar granule cells and hippocampal neurons (Chen et 
al., 2000).  The truncated four C-terminal amino acids comprise a PDZ domain that binds 
PSD-95 (postsynaptic density protein, 95kD; see Diagram 6), a protein that does not 
directly interact with AMPA receptors but enhances AMPA receptor synaptic 
transmission (Schnell et al., 2002) and limits the incorporation of AMPA recepters into 
the synapse during activity-dependent synaptic plasticity (Ehrlich and Malinow, 2004).   
Over-expression of stargazin in hippocampal neurons increases current density mediated 
by extrasynaptic receptors but does not alter EPSCs (Schnell et al., 2002), suggesting that 
synaptic AMPA receptor trafficking involves both stargazin and PSD-95.  Association of 
stargazin with the receptor is sufficient for surface trafficking, while a subsequent 
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interaction between stargazin and PSD-95 is necessary to move the receptor into the 
synapse (Chen et al., 2000; Schnell et al., 2002). 
Stargazin can associate with various other proteins via regions of its C-terminus 
distinct from the PDZ domain.  Stargazin interacts with nPIST, the neuronal isoform of 
protein-interacting specifically with T10 (Cuadra et al., 2004; Ives et al., 2004).  nPIST 
binds the stargazin C-terminus between amino acids 243-283 and, like PSD-95, appears 
to be necessary for AMPA receptor synaptic targeting (Cuadra et al., 2004; Diagram 8).  
Stargazin also binds LC2 (light chain 2 of microtubule associated protein) via a C-
terminal non-PDZ domain mediated interaction.  The association of LC2 with non-
synaptic stargazin/AMPA receptor complexes in cerebellar neurons suggests LC2 
participates in early stages of AMPA receptor surface trafficking (Ives et al., 2004). 
The C-terminal tail of stargazin has multiple phosphorylation sites.  Phosphorylation 
of threonine 321 in the PDZ binding domain disrupts PSD-95 mediated receptor 
clustering (Chetkovich et al., 2002).  Basal levels of stargazin T321 phosphorylation have 
been demonstrated in vivo and disruption of PSD-95 association by this modification has 
been verified by several biochemical techniques (Choi et al., 2002).  Introduction of a 
T321 phospho-mimic stargazin construct into cultured hippocampal cells reduces the 
amplitude and frequency of AMPA receptor mEPSCs (Chetkovich et al., 2002), 
suggesting disruption of the stargazin/PSD-95 association is a potential mechanism for 
LTD-like processes.    
Phosphorylation of multiple strongly conserved serine residues in the stargazin C-
terminal tail selectively increases synaptic AMPA receptor responses (Tomita et al., 
2005).  Classic LTP involves depolarization of the postsynaptic membrane sufficient to 
 41
remove NMDA receptor channel block, allowing an influx of Ca2+ that subsequently 
activates various kinases, followed by rapid insertion of AMPA receptors into the 
synaptic membrane (Malinow and Malenka, 2002; Bredt and Nicoll, 2003).  The 
downstream molecular events between kinase activation and receptor insertion, however, 
are unclear.  Interestingly, phosphorylation and dephosphorylation of stargazin appear to 
be required for expression of hippocampal LTP and LTD, respectively.  CaMKII activity 
is critical for induction of hippocampal LTP (Malenka et al., 1989; Malinow et al., 1989; 
Hayashi et al., 2000) while PKC activation is crucial in cerebellar LTD (Crepel and 
Krupa, 1988; Linden and Connor, 1991).  Both kinases are capable of phosphorylating 
the nine serine residues in the stargazin C-terminus (Tomita et al., 2005).  In light of the 
critical role stargazin plays in AMPA receptor trafficking, it is not surprising to find that 
this protein is involved in regulated insertion of receptors during activity-dependent 
synaptic plasticity.  The presence of multiple phosphorylatable serines in the C-terminus 
further suggests graded responses to synaptic stimulation, a possibility which remains 
open to investigation. 
 
1.9.3    Molecular Determinants of Stargazin/AMPA Receptor Binding 
Unlike the association of GluR2 with PICK1 and GRIP1, the association of AMPA 
receptor subunits and stargazin is not mediated by PDZ domain interactions.  The 
interaction of stargazin with individual AMPA receptor subunits has been reported to be 
non-specific (Chen et al., 2000; Tomita et al., 2004); however, research from this lab 
indicates this interaction is subunit-specific (Chapter 5).  Co-expression of stargazin and 
kainate receptor subunits in Xenopus oocytes has been reported to have no effect on 
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glutamate-evoked currents (Chen et al., 2003); again, research from this lab has shown 
stargazin to increase surface trafficking of certain kainate receptor subunit combinations 
in heterologous cells.   
Assessment of elevated stargazin-mediated AMPA surface trafficking has primarily 
used current recordings obtained during bath application of agonist.  Interpretation of 
agonist-evoked responses obtained in this fashion is confounded by the profound steady-
state desensitization of AMPA receptors (see Section 1.1.1).  While an increase in current 
may be interpreted as increased surface expression (Schnell et al., 2002; Tomita et al., 
2004), it may in fact represent altered functional properties, such as reduced receptor 
desensitization.  The first extracellular loop and intracellular C-terminus of stargazin 
interact with the AMPA receptor and are important for stargazin-mediated enhancement 
of current responses to bath-applied glutamate (Tomita et al., 2004).  While these regions 
of stargazin were interpreted to mediate AMPA receptor surface trafficking, research 
from this lab suggests the first extracellular loop alters AMPA receptor responses to the 
partial agonist kainate, while the C-terminal tail plays a role both in surface trafficking 
and altering the desensitization profile of the receptor (Chapter 5).    
 
   1.10    Modulation of AMPA Receptor Functional Properties by Stargazin/γ2 
The effect of stargazin (γ2) on AMPA receptor trafficking in cerebellar granule 
cells is undisputed.  The ability of stargazin to enhance currents in hippocampal neurons 
(Chen et al., 2000) suggests TARPS are involved in AMPA receptor membrane 
trafficking in brain regions beyond the cerebellum and are candidates for involvement in 
synaptic plasticity; however, the function of basal TARP association with synaptic 
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AMPA receptors is less clear (Vandenberghe et al., 2005b).  Bredt and colleagues have 
concluded that the association of stargazin does not affect desensitization (Schnell et al., 
2002); however, the resolution of evoked currents in their study was too gross to detect 
subtle changes in channel properties.  Additionally, Bredt and colleagues did not examine 
other properties of the receptor altered by stargazin, such as rectification.  Stargazin’s 
homology to voltage-gated calcium channel subunits and its direct binding to AMPA 
receptors in the postsynaptic density suggests the fascinating possibility that TARPs alter 
synaptic channel function.  The functional properties of voltage-gated sodium (Catterall, 
2000), potassium (Nerbonne, 2000) and calcium channels (Arikkath and Campbell, 2003) 
are known to be modified by the presence of auxiliary subunits not involved in pore 
formation; however, stargazin is the first such auxiliary subunit defined for ionotropic 
glutamate receptors.  Clarification of the role of TARPs at the plasma membrane will 
lead to a better understanding of native AMPA receptor function. 
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Chapter II 
RESEARCH DESIGN AND METHODS 
2.1   Neuronal Tissue Culture 
2.1.1    Rat Hippocampal Neurons 
Hippocampi dissected from the brains of newborn (P0-1) Sprague-Dawley rats 
were incubated with papain for 10 minutes in a 37°C water bath and further dissociated 
by trituration with a glass pipette.  The cells were resuspended in 90% Dulbecco’s 
modified Eagle’s medium/10% FBS supplemented with 2 mM Glutamax (Life 
Technologies, Rockville, MD) and 1% penicillin/streptomycin at a density of 35-75 x104 
per ml, plated on 35mm tissue culture dishes pre-coated with poly-L-lysine and 
maintained in a humidified 10% CO2 incubator.  These conditions inhibit neuronal 
survival and allow glial cell proliferation.  After the glial monolayer became confluent, 
33 µg/ml uridine and 13 µg/ml 5’-fluorodeoxyuridine were added to the culture medium 
to inhibit mitosis.  Neurons from a second dissection were plated at a density of 75-500 
x104 per ml onto the glial monolayer and maintained in 94% Dulbecco’s modified 
Eagle’s medium/5% horse serum/1% FBS, supplemented with 2 mM Glutamax, 5’-
fluorodeoxyuridine, and 1% N3.  Most experiments were performed at room temperature 
(23-25°C) using neurons 4-10 days in culture; recordings for hippocampal developmental 
studies were performed under the same conditions at DIV7, 14, and 21; recordings from 
transfected neurons were performed at DIV7. 
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2.1.2  Mouse Cerebellar Granule Cells 
     Primary cultures of cerebellar granule neurons were prepared as previously described 
(Bito et al., 2000).  Briefly, cerebellae were dissected from P2 Swiss Webster mice, 
incubated in trypsin and dissociated by trituration with a glass pipette.  Cells were 
resuspended in Minimal Essential Medium with Earle’s salts (MEM, supplied without 
glutamine or phenol red), supplemented with 10% fetal bovine serum (FBS), 2 mM 
glutamine, 25 µg/ml insulin, and 2% B27 (Invitrogen, Grand Island, NY), and plated at a 
density of 1.6 cerebellae per 35mm dish.  Dishes were coated with poly-D-lysine (100 
ng/ml) and laminin (4 ng/ml) 24 hrs prior to the dissection.  On the second day in vitro 
cultures were fed with MEM supplemented with 5% FBS, 0.5mM glutamine, 25 µg/ml 
insulin, 2% B27 and 10 µM cytosine arabinoside to inhibit glial division.  Afterwards, 
cells were fed every 3 – 4 days with the 5% FBS medium, lacking Ara C.  Cultures were 
maintained in a humidified 37°C, 5% CO2 incubator.  Note that these cultures are both 
plated and maintained in normionic K+.  All experiments were performed after 7 days in 
vitro. 
 
2.1.3  Neuronal Transfection 
Hippocampal neurons or cerebellar granule neurons were transfected on DIV5 using a 
Lipofectamine2000 (Invitrogen, Grand Island, NY) based protocol.  For each 35mm dish 
to be transfected, 4 µg of DNA and 2 µl of lipid were diluted, separately, into 50 µl of 
DMEM and incubated for 5 min at room temperature.  The diluted DNA and lipid were 
then combined and incubated for an additional 20 min at room temperature.  During this 
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20 min incubation, 1 ml of media was removed from each dish (leaving ~1ml of media in 
the dish), and this conditioned media was reserved for later use.  100 µl of transfection 
solution was then added to each dish, the dishes were tilted to mix, and returned to their 
respective incubators.  ~12 hrs after the initiation of transfection, 1 ml of conditioned 
media was returned to each dish, and the dishes were returned to their incubators.  
Electrophysiology experiments were conducted ~40 hrs after initiation of transfection.  A 
trace amount of pEGFP (Clontech, Palo Alto, CA) was included in all transfections to 
allow identification of transfected cells during subsequent electrophysiology experiments.  
The stargazin (γ2) : green fluorescent protein (GFP) ratio used was 3 : 1 with control 
dishes receiving 4 µg of GFP. 
 
Diagram 9.  Transfection of a hippocampal neuron with 
GFP.  An example of a DIV7 rat hippocampal neuron 
expressing GFP is shown at approximately 40 hours post-
transfection. Magnification is at 40X. 
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2.2  HEK293 Tissue Culture 
For expression of recombinant AMPA receptors, human embryonic kidney (HEK) 
293 cells (American Type Culture Collection, Manassas; VA) were grown at 37°C in a 
humidified 5% CO2 incubator in 90% MEM plus Earle’s salts/10% FBS in 25 cm2 flasks. 
Once cells were 60-70% confluent, they were passaged and/or plated on 35 mm dishes 
for transfection and recording.  Media was removed and cells were washed with MEM 
and then incubated for 2 minutes in trypsin-EDTA (0.02% trypsin, 0.53 mM EDTA).  
Media was added and the cells were centrifuged at 1500 rpm for 5 min, then resuspended 
in media.  Cells were plated at 50-65 x104 per ml in 35 mm dishes for transfection or 1 ml 
of cells was combined with 5 ml media for passaging. 
 
2.2.1    HEK293 Transient Transfection   
HEK293 cells were transfected using a LipofectamineTM Reagent-based protocol 
(Invitrogen Life Technologies, Grand Island, NY).  Briefly, 2 µg of purified DNA and 8 
µl Lipofectamine per 35 mm dish were diluted in OPTIMEM (room temperature, 
Invitrogen, Grand Island, NY), and incubated for 20 min at room temperature.  Culture 
media was replaced with this transfection solution and cells were returned to 37°C 
incubator for 3 h.  Afterwards, the DNA/lipid complexes were washed off the cells, and 
cultures were fed with MEM +10% fetal bovine serum or bovine growth serum 
containing 30 µM 2,3-dihydroxy-6-nitro-7-sulphamoylbenzo[f]quinoxaline (NBQX) to 
block activation of expressed AMPA receptors by trace amounts of glutamate in the 
medium.  Electrophysiology experiments were conducted at room temperature 40 to 48 h 
later.  
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 GFP was included in all conditions to allow visualization of transected cells 
during electrophysiology experiments and excess GFP under a CMV promoter acted as a 
control in all other conditions.  2 µg total DNA per 35 mm dish was transfected for all 
HEK293 experiments.  For experiments examining interactions  of GRIP1, GRIP2 and 
GRASP-1 with AMPA receptors, the ratio of GluR-Ai : GluR-Bi was kept constant at 1 : 
1.5 and the GRIPs were transfected at a 1 : 1 ratio with GluR-Bi.  The transfection ratio 
of GRIP1/2 : GluR-Bi : GluR-Ai : GFP was 1.5 : 1.5 : 1 : 0.5.  For experiments including 
GRASP-1, the ratio of GRIP1 : GluR-Bi : GluR-Ai : GRASP-1 : GFP was 1.5 : 1.5 : 1 : 
1.5 : 0.5.  For experiments examining PICK1 interactions, the ratio of GluR-Ai : GluR-Bi 
: PICK1 : GFP was 1 : 1.5 : 3 : 0.5.  Because the PICK1 construct was driven by an SV40 
promoter, a vector expressing the protein ranilla under an SV40 promoter was used as a 
control in these experiments.   
For experiments examining stargazin (stg) interactions with homomeric AMPA 
receptors the ratio of GluR : stg : PSD-95 : GFP was 1 : 1 : 1 : 0.64, with conditions not 
containing stg and/or PSD-95 having additional GFP added to maintain a constant GluR : 
stg ratio in experiments without PSD-95.  For heteromeric receptors a ratio of GluR-A : 
GluR-B : stg : GFP of 1 : 1.5 : 1.5 : 0.5 was employed.   Kainate receptor subunits were 
transfected at a ratio of GluR-6 : KA2 : stg : GFP of 1 : 1 : 1 : 0.64, with conditions not 
containing stg and/or KA2 having additional GFP added to compensate. 
Plasmids containing cDNA for the GluR subunits GluR-A, B, C, and D in both 
flip (i) and flop (o) isoforms were gifts from Dr. P. Seeburg (Heidelberg, Germany).  
Flag-tagged PICK1 in pFLAG under the control of an SV40 promoter was a gift from Dr. 
E. Olson (Dallas, TX).  Dr. R. Huganir (Baltimore, MD) graciously provided GRIP1, 
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GRIP2, GRASP and PICK1 under the control of a CMV promoter.  The plasmids were 
grown in E. coli and purified by 2X CsCl density centrifugation or using a plasmid kit 
(Qiagen, Inc., Valencia, CA).  Restriction digests and gel electrophoresis were performed 
to verify the identity of the purifed construct.  γ2, γ3, γ5 and various chimeric constructs 
were cloned by Dr. Dorothy Turetsky (Tulsa, OK).  Cacng2 (γ2) was cloned from adult 
rat cerebellum, and Cacng3 (γ3) and Cacng5 (γ5) from adult rat forebrain total RNA 
using the ProSTAR Ultra HF RT-PCR system (Stratagene, La Jolla, CA), and the 
following primers: γ2forward 5’ ATGGGGCTGTTTGATCGAGGTG 3’, γ2reverse 5’ 
TCATACGGGCGTGGTCCGGCG 3’, γ3forward 5’ 
ATGAGGATGTGTGACAGAGGTATCC 5’, γ3reverse 5’ 
TCAGACGGGCGTGGTGCGTCT 3’, γ5forward 5’ 
ATGAGCACCTGTGGGAGGAAGGC3’, γ5reverse 5’ 
TCAGCAGGGAGATGATGACATCTGG 3’. All three PCR products were subsequently 
subcloned into the expression vector pCMV-Script (Stratagene, La Jolla, CA) and 
sequenced for verification.  The γ2/γ5 chimeras γ2(∆26-103)/γ5(ins26-99) and γ2(∆89-
103)/γ5(ins85-99) were generated by taking advantage of unique BsaBI, BbsI and XhoI 
sites in γ2 at nucleotide positions 72, 257 and 308 respectively.  Both constructs were 
originally assembled in pGEM-T Easy (Promega, Madison, WI) and later transferred by 
PCR into pCMV-Script.  The C-terminal truncation γ2(1-212) was generated by PCR 
using the γ2 forward primer (above) and the reverse primer: 5’ 
TCAGGCCGTGGCCCGCAGCTGTTTG 3’, and subcloned into pCMV-Script.  
Construct sequence was verified by sequencing at the Oklahoma State University 
Biochemistry Core Facility (Stillwater, OK). 
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2.3    Electrophysiology 
2.3.1    Recording Solutions   
Extracellular saline for neuronal experiments contained (in mM) 160 NaCl, 2.5 KCl, 
10 HEPES, 10 glucose, 2 CaCl2, 1 MgCl2, and 0.01 mg/ml phenol red; the pH was 
titrated with NaOH to 7.3 and, when necessary, the osmolarity was adjusted to 325 
mOsM with sucrose.  Tetrodotoxin (400 nM; Calbiochem, La Jolla, CA), bicuculline (5 
µM), and (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine 
hydrogen maleate (MK-801; 5 µM) were added to block voltage-gated sodium channels, 
GABAA receptors, and NMDA receptors, respectively.  The standard intracellular 
solution for neurons contained (in mM) 125 CsMeSO3 (Aldrich Chemical Co., 
Milwaukee, WI), 15 CsCl, 10 HEPES, 5 Cs4BAPTA (Molecular Probes, Eugene, OR), 
0.5 CaCl2, 3 MgCl2 and 2 Na2ATP.  The osmolarity was adjusted to 295 mOsm when 
necessary and the pH was titrated to 7.2 using CsOH.  Sucrose was added to standard 
neuronal intracellular solution to create a modified intracellular solution with higher 
osmolarity (345 mOsm) for peptide perfusion experiments.  The pH was adjusted to 7.2 
with CsOH. 
Extracellular saline for HEK 293 cells contained (in mM) 145 NaCl, 5.4 KCl, 1 
MgCl2, 1.8 CaCl2, 5 HEPES, 0.01 mg/ml phenol red. The pH was titrated to 7.3 with 
NaOH and the osmolarity was adjusted to 295 mOsm with sucrose when necessary.  
Patch pipettes were filled with intracellular solution containing (in mM) 135 CsCl, 10 
CsF, 2 MgCl2, 0.5 CaCl2, 5 Cs4BAPTA, 10 HEPES, 2 Na2ATP.  Osmolarity was adjusted 
to 295 mOsm and pH to 7.2 with CsOH. 
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2.3.2 Whole Cell Voltage Clamp Recording Conditions and Drug Perfusion 
The recording chamber was continuously perfused with control extracellular saline 
solution at ~0.4 ml/min.  Bath solution for HEK 293 experiments contained 0.5 mM 
kynurenate, a non-selective antagonist of iontropic glutamate receptors, to protect against 
excitotoxicity and pre-exposure to agonists.  Recording electrodes were pulled from 
borosilicate glass, coated with Sylgard, and fire-polished; typical electrode resistance was 
2-7 MΩ when filled with intracellular solution and was compensated by 60-80% using an 
Axopatch 200A patch-clamp amplifier (Axon Instruments, Foster City, CA).  Recorded 
data was filtered at 1-3 kHz and sampled at 2-10 kHz using pClamp (Axon Instruments, 
Foster City, CA).  See Ihle and Patnea, 2000 for further detail. 
For whole-cell recording, rapid agonist application was achieved using a glass 
flowpipe array (10-12 parallel barrels, each 400 µm in diameter and a stepper-motor 
based system.  The flowpipe array was placed near a voltage-clamped cell.  Solutions 
were driven by a peristaltic pump (Minipuls3; Gilson, Middleton, WI and Dynamax; 
Rainin, Woburn, MA) through three-way Isolatch valves (Parker Hannifin, Fairfield, NJ) 
using a Warner Instrument Corporation SF-77B Perfusion Fast-Step system (Hamden, 
CT) to control the fast perfusion system and flowpipe movement, allowing millisecond 
solution exchange (τ = 6-8 ms) with highly repeatable time courses.   
 
2.3.3  Peptide Perfusion   
The short peptide pep2-SVKI (YNVYGIESVKI) has been used previously to disrupt 
interaction of the GluR-B C-terminal tail with GRIP, ABP, and PICK1.  A more selective 
peptide, pep2-EVKI (YNVYGIRRVKI), blocks intereactions between the GluR-B C-
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terminus and PICK1, exclusively (Li et al., 1999; Daw et al., 2000; Kim et al., 2001). 
pep2-SVKI and pep2-EVKI were obtained from Tocris (Ellisville, MO) and stored as 1 
mM frozen stock (in H2O). Shortly before electrophysiology commenced, the appropriate 
peptide, as well as the peptidase inhibitors leupeptin, bestatin and pepstatin A, were 
thawed and added to the intracellular solution for final concentrations of 100 µM, 100 
µM, 100 µM, and 10 µM, respectively.  Regular intracellular solution containing 
peptidase inhibitors alone was used as a control.  Both solutions were kept on ice for the 
duration of the experiment.  To compensate for the added volume of peptides and 
peptidase inhibitors, the osmolarity of the standard intracellular solution was increased 
from 295 mOsm to 345 mOsm with sucrose, as previously described. 
Recordings from rat hippocampal or mouse cortical neurons voltage clamped at -60 
mV were obtained immediately after whole cell configuration was achieved as intra-cell 
controls.  Agonists and modulators were applied using fast perfusion techniques. After a 
20 min interval allowing the peptide to fully disrupt GluR-B binding, a final set of 
recordings were obtained.  Concentrations and perfusion times were based on the 
methods of Daw et al., 2000.  Neurons were monitored by a brief glutamate pulse every 5 
min.  The recordings were analyzed for current density and kinetic differences. Initial 
recordings were obtained immediately after achievement of whole cell configuration and 
monitored by glutamate pulses every 5 minutes during the 20 min perfusion period. The 
initial protocol was repeated after peptide perfusion and both intra- and inter-cell analysis 
was performed.   
Initial experiments examined the effect of perfusion of pep2-SVKI in DIV7 rat 
hippocampal neurons.  A subsequent developmental study used the same protocol and 
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analysis on DIV4-5, 14-15, and 21-22 neurons.  Recordings at each time point were 
obtained from a single dissection to control for variabilities in dissection and culture 
conditions.  Mouse cortical neurons were also examined.  Initial experiments were 
performed with pep2-SVKI.  Because no significant differences in glutamate 
desensitization rate (Fig. 5B), absolute current density of glutamate- or kainate-evoked 
steady states or interactions the negative modulator GYKI 52466 (Fig. 5C) between 
control cells and those perfused with pep2-SVKI were seen during the 20 min incubation 
period (Fig. 5A), the lack of effect of pep2-EVKI was only confirmed in DIV 7 rat 
hippocampal neurons (data not shown). 
 
2.4  Indirect Immunofluorescence 
HEK293 cells were plated at 60x104 per ml on a 24 well plate and transfected with 
various combinations of GluR-Ai, -Bi, PICK1 and flag-tagged GluR-Di as a positive 
control 24 hr later.  Cells were washed with neuronal extracellular recording solution to 
remove serum and then fixed for 30 min in 4°C 4% paraformaldehyde.  Cells were 
washed with PBS and then either stored at 4°C or immediately processed.  Some wells 
were permeabilized with 0.25% Triton-X 100 in PBS for 7 min at room temperature.  All 
wells were blocked overnight at 4°C in 10% Normal Goat Serum (NGS) in PBS or 10% 
NGS in Flag TBS (to detect the Flag tagged epitope).  Cells were incubated overnight at 
4°C in primary antibody diluted in 2% NGS.  The primary antibodies for each protein 
were diluted as follows: rabbit anti-GluR1 (-A) at 1:100, rabbit anti-GluR2/3 (-C/B) at 
1:100, mouse anti-GluR2/4 (-B/D) at 1:500 and 1:250 (Chemicon International; 
Temecula, CA), and mouse anti-FLAG at 1:1000 (Sigma; St. Louis, MO).  Anti-GluR2/4 
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was better visualized at the 1:250 dilution. Cells were washed in PBS or TBS to remove 
excess primary antibody and incubated in the dark at room temperature 30-60 min in 
secondary antibody diluted in 2% NGS in PBS or in TBS.  Anti-Rabbit CyTM2 or Anti-
Mouse CyTM3 (Jackson ImmunoResearch Laboratories; West Grove, PA) were used as 
appropriate at 1:100 dilution and visualized using a CoolSNAP Monochrome High 
Quality Camera (Photometrics; Tucson, AZ).  Brightfield images were obtained using a 
CoolSNAP Color Camera (Photometrics; Tucson, AZ).  Images were processed using 
Adobe Photoshop 7.0. 
 
2.5    Quantitative Western Blots 
2.5.1    Biotinylation of Surface Proteins   
HEK293 cells were plated and transfected according to previously described protocol.  
AMPA receptor surface expression was measured using the membrane impermeant 
biotinylation reagent NHS-SS-biotin (Pierce Biotechnology, Rockford, IL) (Mammen et 
al., 1997).  Forty-eight hours after transfection, cells were biotinylated using eZ-link-
sulfo-NHS-SS-biotin (Pierce; Rockford, IL).  Briefly, cells were washed once in 37°C 
PBS/Ca2+/Mg2+ (10 mM phosphate buffer, 137 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 
pH 7.4), allowed to cool briefly and then washed twice in 4°C PBS/Ca2+/Mg2+ and placed 
on a cold pack.  Cells were incubated at 4°C on the cold pack in 2 ml of biotinylation 
reagent [1mg/ml EZ-link-NHS-SS-biotin (Pierce; Rockford, IL) in PBS/Ca2+/Mg2+] for 
15 minutes, washed three times with cold PBS/Ca2+/Mg2+ with 1% BSA, and thoroughly 
scraped using a 1 ml syringe plunger in 166 µl of room temperature precipitation buffer 
(PB; 10 mM NaPO4, pH 7.4, 5 mM EDTA, 5 mM EGTA, 100 mM NaCl, 10 mM sodium 
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pyrophosphate, 50 mM NaF, 1mM Na3VO4, 2µl/ml leupeptin, and  2µl/ml aprotinin) with 
1% SDS (PB/SDS).  For some experiments, the 166 µl PB with 1% SDS was used to 
scrape cells from an adjacent well with the same transfection conditions to maximize 
protein yield.  The well was washed with 833 µl PB with 1% Triton X-100 (PB-Triton) 
and the solution was collected in a microfuge tube, sonicated and centrifuged at 1600g 
for 20 min at 4°C.  The top 800 µl of the supernatant was removed to a new microfuge 
tube and 200 µl Ultra Link® Immobilized Streptavidin Plus beads (Pierce; Rockford, IL) 
were added.  The supernatant was rotated at 4°C for 2 hr and then either stored at -80°C 
or immediately separated into membrane fractions. 
For the total protein fraction, 200 µl of bead evenly suspended in the supernatant were 
removed and 100 µl 3X sample buffer containing β-mercaptoethanol (BME) was added.  
For the cytoplasmic fraction, the remaining beads were microfuged for 1 min and the 
supernatant added to 400 µl 3X sample buffer + BME.  The beads were then washed first 
with PB-Triton, then PB-Triton with 600 mM NaCl, and finally PB alone.  For the 
membrane fraction, 1 ml of 1X sample buffer was added to the beads.  All three samples 
were boiled for 3 min, mixed thoroughly, and microfuged. The supernatant was removed 
to microfuge tubes.  The protease inhibitors aprotinin and leupeptin were added at 2 
µg/ml in detergent solutions and 1 µg/ml in wash solutions. 
 
2.5.2  Western Blot and Quantification 
Novex® NuPAGETM 7% Tris-Acetate gels were loaded with 25 µl of total, membrane 
and cytoplasmic fractions of glutamate receptor subunits expressed with and without 
stargazin (γ2).  A dilution series of 50, 20, and 10% of the total protein fraction was also 
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run on the same gel to verify quantification. Proteins were transferred to an Invitrolon 
PVDF membrane (Carlsbad, CA), which was then gently agitated for 2 hr at room 
temperature or overnight at 4°C with either 3% bovine serum albumin or 5% milk in 
TBS-tween to block.  Blots were incubated with primary antibody in the appropriate 
block overnight at 4°C.  The following primary antibodies were used: rabbit anti-GluR1 
at 1:400, rabbit anti-GluR2/3 at 1:200 and mouse tubulin (MAB3804) at 1:1000 
(Chemicon International; Temecula, CA).  After three 5 min washes in TBS/Tween 
(TBS: 20 mM Tris Base, 137 mM NaCl; 1% Tween), blots were incubated for 1 hr at 
room temperature in secondary antibody at 1:10,000.  HRP-conjugated mouse and rabbit 
secondary antibodies from Amersham Biosciences ECLTM Plus Western blotting kit were 
used.  After secondary antibody incubation, blots were washed 3X with TBS/Tween and 
incubated for 5 minutes with LumigenTM PS-3 detection reagent and imaged using a 
Storm PhosphorImager (Molecular Dynamics).  ImageQuant was used to quantify bands.   
Certain gels were stripped and then reprobed for tubulin.  Blots were incubated for 30 
min in a 50°C  water bath with occasional agitation in stripping buffer (100mM BME, 
2% SDS, 62.5 mM Tris-HCL, pH 6.7) and then 3X with TBS Tween for 10 min at room 
temperature.  The blot was blocked at room temperature with gentle agitation for 1 hr and 
then incubated overnight in primary antibody.  Secondary antibody incubation and 
imaging were as previously described. 
 
2.6  Statistical Analysis 
Peak and steady-state amplitude and kinetic measurements were based on single or 
the average of a few (2-5) agonist-evoked responses measured using Clampfit 8.1 or 
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Clampfit 9.2 (Axon Instruments, Foster City, CA).  The kinetics of desensitization and 
onset and offset of modulation were determined using a standard Chebyshev fitting 
algorithm generated by Clampfit 8.1 or Clampfit 9.2.  All statistical analyses were 
performed using GraphPad Prism 4.0 (GraphPad Software, Inc., San Diego, CA) or SPSS 
(SPSS, Inc.; Chicago, IL).  For single comparisons, the data were evaluated using an 
unpaired Student’s t-test.  For multiple comparisons, the data were evaluated using 1-way 
ANOVA followed by Bonferroni’s post hoc test to evalulate specific comparisons.  The 
level of significance is set at P<0.05.  Bar graphs, tables and all data in text are reported 
as mean ± SEM unless reported otherwise. 
For experiments investigating the functional properties of stargazin (γ2) and other 
members of the TARP family, we calculated maximal current density by dividing peak 
current obtained by co-application of 3 mM glutamate and 500 µM trichlormethiazide by 
whole cell capacitance (pA/pF) as a functional assay for AMPA surface expression.  
Trichlormethiazide is a cyclothiazide analog with faster association and dissociation 
kinetics that reduces glutamate-evoked desensitization in hippocampal neurons to a 
similar degree as 100 µM cyclothiazide (Fig. 1).  Time constants for onset of 
desensitization, association and dissociation of kainate, and onset of potentiation by TCM 
were determined by exponential fits using a Chebyshev algorithm.  Time constants for 
TCM dissociation in hippocampal neurons were calculated from 50% decay times 
relative to glutamate steady-state response (τ = 50% decay time/0.69).  The validity of 
this method was verified in selected cells in which longer recovery times were well fit 
with a single exponential function.   
 58
Because glutamate peaks in whole cell recordings can be affected by desensitization, 
both percent desensitization and current density were determined relative to maximum 
glutamate-evoked responses in the presence of the positive allosteric modulator 
trichlormethiazide.  As an assay for inclusion of GluR-B in heteromeric GluR-A/B 
receptors in HEK293 cells +40/-60 rectification ratios for glutamate peak were calculated 
and cells with a rectification ratio of <0.5 were excluded from the data set. 
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Chapter III 
STATE DEPENDENT INTERACTION OF THE BENZOTHIADIAZINE 
POSITIVE ALLOSTERIC MODULATORS WITH THE AMPA RECEPTOR 
3.1   Introduction 
Several drugs have been identified that slow or reduce AMPA receptor 
desensitization, most notably the benzothiadiazine cyclothiazide (Patneau et al., 1993; 
Yamada and Tang, 1993).  Cyclothiazide exhibits marked selectivity for flip over flop 
AMPA receptor isoforms (Partin et al., 1994), with the selectivity being determined by a 
single residue in the flip/flop domain (Partin et al., 1995; Partin et al., 1996).  
Cyclothiazide almost fully blocks desensitization of flip isoforms in all four AMPA 
receptor subunits, but appears to merely slow the rate of onset of desensitization of flop 
isoforms.  Its mechanism of action is frequently described as reduction or attenuation of 
desensitization (Nagarajan et al., 2001; Horning and Mayer, 2004), and the difference in 
its effects on flip versus flop receptors has been attributed to a difference in the affinity of 
cyclothiazide for the isoforms (Partin et al., 1994; Sun et al., 2002). 
Previous work has shown that at saturating concentrations (100 µM) cyclothiazide 
blocks desensitization of AMPA receptor currents in most neurons (Patneau et al., 1993; 
Yamada and Tang, 1993).  At subsaturating concentrations (1 µM, 3 µM), cyclothiazide 
potentiates glutamate steady-state currents but does not completely abolish 
desensitization.  The rate of desensitization remains the same as that seen in the absence 
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of cyclothiazide (Diagram 9).  The most straightforward interpretation of this data is the 
presence of two populations of receptors: one that is bound by agonist and exhibits 
normal desensitization kinetics and a second population of non-desensitizing receptors 
bound by both agonist and modulator.  Similar effects with the AMPAkine CX546 have 
been interpreted as an effect on recovery from desensitization rather than an alteration in 
the kinetics of entry into the desensitizated state (Nagarajan et al., 2001). 
In the dimeric crystal structure, cyclothiazide binds to residues in both subunits, 
suggesting that it acts as a bridge stabilizing the dimer interface (Sun et al., 2002), thus 
favoring the open, non-desensitized state of the receptor.  This crystal structure makes 
several predictions regarding the mechanism of action of cyclothiazide that can be 
directly tested electrophysiologically in intact receptors.  First, if cyclothiazide binds at 
the dimer interface, then the conformational change to the desensitized state disassembles 
the binding site, precluding the binding of cyclothiazide to desensitized receptors.  
Second, the rate at which cyclothiazide can bind in the presence of agonists should reflect 
the agonist-dependent rate at which the receptor recovers from desensitization.  Third, 
receptors with cyclothiazide still bound cannot desensitize.   
The aim of these studies is to verify and extend previous findings regarding the 
benzothiadiazines and their effects on receptor desensitization, specifically focusing on 
their mechanism of action at intact AMPA receptors.  We have therefore examined 
binding of cyclothiazide and related benzothiadiazine modulators in the presence and 
absence of agonists using patch-clamp recording and rapid perfusion techniques, taking 
advantage of the fact that different AMPA receptor agonists have different affinities for  
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1  nA
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Cyclothiazide
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Cyclothiazide
100 µM
Cyclothiazide
τf = 9.4 ms
(89%) τf = 8.2 ms
(94%)
τf = 7.8 ms
(88%)
Diagram 10.  Low concentrations of cyclothiazide reduce steady-state 
desensitization without slowing the rate of onset of desensitization.  
Illustrated are responses of a single hippocampal neuron to 2 mM 
glutamate alone and in combination with 3 concentrations of cyclothiazide. 
The onset of desensitization in the response to glutamate was fit with the 
sum of two exponentials, with the fast time constant and relative amplitude 
given next to each trace.  The kinetics of onset of desensitization in 
response to glutamate are unaffected in the presence of 1 and 3 µM 
cyclothiazide, despite the substantial reduction in the amount of 
desensitization produced by glutamate.  100 µM cyclothiazide fully blocks 
desensitization.  With concentrations of cyclothiazide that are not 
saturating, it appears that there are two populations of receptors present: 
one population of receptors which is unbound by cyclothiazide and 
desensitizing with normal rapid kinetics, and a second population bound by 
cyclothiazide which does not desensitize at all (unpublished data from the 
lab of Doris Patneau). 
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the desensitized state (Patneau and Mayer, 1991).  The results demonstrate that agonist- 
and state-dependent interactions of the benzothiadiazines with their binding site reflect 
the inability of the modulator to bind the desensitized conformation of the receptor.    
 
3.2    Statement of Hypothesis 
Interaction of the benzothiadiazine class of positive allosteric modulators with AMPA 
receptors involves a state-dependent interaction in which the modulator cannot bind to 
the desensitized conformation of the receptor; conversely, the receptor cannot desensitize 
when modulator is bound. 
 
3.3    Results 
3.3.1     Benzothiadiazine Interaction with the AMPA Receptor Is Modulator-
Dependent   
The benzothiadiazines cyclothiazide (CTZ), trichlormethiazide (TCM) and 
hydroflumethiazide (HF) have dramatic effects on AMPA receptor desensitization (Fig. 
1).  Figure 1C compares the potency of block of desensitization by preapplication of HF 
and TCM with the amount of current elicited in the presence of 100 µM CTZ, a 
concentration shown to completely block desensitization (Patneau et al., 1993).  
Application of these modulators to a voltage-clamped hippocampal neuron during 
glutamate-evoked desensitization shows distinctly different rates of onset of modulation 
for each drug (Fig. 1D), which were well fit by the sum of two exponentials (Table 5).  
The rate of onset of modulation appears related to the size and hydrophobicity of the side 
chain at position three (Fig 1A, *), with CTZ exhibiting the slowest onset of modulation 
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and HF exhibiting the fastest.  We chose to perform initial experiments with HF as this 
modulator significantly reduces desensitization, and, importantly, has binding kinetics 
that do not appear to be rate-limiting. 
 
3.3.2   Agonist-Dependent Onset of Modulation by Hydroflumethiazide Suggests a 
State-Dependent Interaction   
AMPA receptor agonists exhibit a distinct pattern of interaction with the three 
functional states of the native receptor: resting, conducting, and desensitized (Diagram 3 
and 6).  Because different AMPA receptor agonists have different affinities for the 
desensitized state (Patneau and Mayer, 1991), we expected to observe agonist-dependent 
differences in modulator binding.  Representative traces of the onset of modulation by HF 
in the presence of three agonists with distinctly different desensitization profiles (Patneau 
and Mayer, 1991) are shown in Figure 2A: kainate, a low affinity, weakly desensitizing 
agonist; glutamate, the strongly desensitizing endogenous ligand; and quisqualate, a high-
affinity, strongly desensitizing agonist.  The onset of the modulation by HF was slowest 
in the presence of quisqualate.  The onset of modulatory effects in the presence of the 
endogenous agonist glutamate and the selective ligand AMPA, which generate similar 
peak and steady-state amplitudes, was significantly faster (p<0.001) than the onset of 
modulation in the presence of quisqualate.  The most rapid onset of modulation was seen 
in the presence of the weakly desensitizing partial agonist kainate (Fig. 2B, Table 1), with 
the rate of onset of modulation by HF more than 20 times faster than in the presence of 
the strongly desensitizing agonist quisqualate (p<0.001).   In fact, binding of HF was 
almost as rapid in the presence as in the absence of kainate (data not shown).    
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Figure 1.  The onset of modulation by the benzothiadiazines is modulator dependent.  
A. Stuctures for the benzothiadiazines used in this study.  The large constituent group 
found at position three (*) in trichlormethiazide (TCM) and cyclothiazide (CTZ) slows 
both association with and dissociation of the modulator from the AMPA receptor.  B.  
Traces illustrating block of 3 mM glutamate-evoked desensitization in cultured 
hippocampal neurons by 1 mM HF, 500 µM TCM, and 100 µM CTZ.  C.  Summary of 
the relative degree of block of desensitization in cultured hippocampal neurons by HF 
and TCM relative to CTZ, which completely blocks AMPA receptor desensitization.  
Peak current measurements were obtained by pre-application of modulator to a 
hippocampal neuron followed by a 1 s co-application with 3 mM glutamate.  All three 
modulators generated significantly larger currents than the peak glutamate response 
(*** p<0.001, 1-way ANOVA, Bonferroni’s multiple comparison).  Also shown 
relative to the CTZ peak response is the glutamate steady-state response, 
demonstrating how rapidly and extensively native receptors desensitize upon agonist 
binding.  D.  Representative traces obtained through whole-cell patch-clamp recording 
of the rate of onset of modulation of 1 mM hydroflumethiazide (HF) and 500 µM 
TCM in the presence of 1 mM glutamate, or 30 µM CTZ in the presence of 200 µM 
glutamate.  Note the time scales for each trace.   
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Figure 2:  The onset of modulation by the benzothiadiazines is agonist-
dependent. A. Representative traces show the agonist dependence of the 
rate of onset of modulation by HF (1 mM) in the presence of a low affinity, 
weakly desensitizing agonist (600 µM kainate), a strongly desensitizing 
endogenous agonist (200 µM glutamate) and a strongly desensitizing, high 
affinity agonist (10 µM quisqualate).  B. The rates of onset of potentiation 
in the presence of quisqualate, AMPA (100 µM) and glutamate were best 
fit by the sum of two exponentials, while that in the presence of kainate 
was best fit by a single exponential. The amplitude of the slow component 
of the rate of onset of modulation is shown above as the percentage of the 
sum of the fast and slow components (n=24-28). The slow component of 
onset of modulation by HF in the presence of quisqualate is significantly 
different from the slow component of onset of modulation in the presence 
of AMPA, glutamate or kainate (+++, p<0.001, 1-way ANOVA, 
Bonferroni’s multiple comparison).  The rate constant describing the rate of 
onset of modulation of HF in the presence of kainate is significantly 
different from the slow component of onset of modulation in the presence 
of the other three agonists (***, p<0.001).  The rate of onset of modulation 
of HF in the presence of AMPA versus glutamate is not significantly 
different (p>0.05).   
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TABLE IV 
Summary of Onset Kinetics of the Benzothiadiazines 
Cyclothiazide Trichlormethiazide Hydroflumethiazide
Agonist 
 
τ (ms) Aslow n τ (ms) Aslow n τ (ms) Aslow n 
τslow 2306±464 457±58 40±1 
Kainate 
τfast 501±53 
68% 13 
93±19 
35% 10 
-- 
-- 24 
τslow 5179±756 1176±113 457±43 
Glutamate 
τfast 751±102 
63% 10 
237±6 
75% 9 
133±16 
52% 26 
τslow -- 1419±90 571±42 AMPA 
τfast -- 
-- -- 
261±20 
71% 23 
153±15 
56% 25 
τslow 6461±978 -- 1361±152 
Quisqualate 
τfast 1711±125 
90% 3 
-- 
-- -- 
316±51 
48% 28 
 
 
 
 
Table 4.  Summary of the rates of onset of modulation by the 
benzothiadiazines in the presence of various agonists.  The rate of onset of 
modulation by the benzothiadiazine modulators was obtained by whole-cell 
voltage clamp recording from cultured hippocampal neurons.  Shown 
above are the rates of onset of modulation by 1 mM HF in the presence of 
100 µM AMPA, 200 µM glutamate and 10 µM quisqualate and 500 µM HF 
in the presence of 600 µM kainate.  Also shown are the rates of onset of 
modulation by 500 µM TCM in the presence of 300 µM AMPA, 600 µM 
kainate, and 1 mM glutamate, as well as the rates of onset of modulation by 
30 µM CTZ in the presence of 1 mM glutamate, 600 µM kainate and 200 
µM quisqualate.  The amplitude of the slow component of the rate of onset 
of modulation is calculated according to the formula [τslow/( τslow + τfast) Χ 
100].  Time constants are shown as milliseconds ± SEM.    
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Figure 3.  A correlation between the kinetics of recovery from 
desensitization and the onset of modulation by hydroflumethiazide.  A. 
Representative traces showing the onset of modulation by HF (1 mM) and 
the on-rate of kainate (3 mM) in the presence of quisqualate (10 µM).  B.  
Summary data for mean rate of onset of modulation of HF, best fit by the 
sum of two exponentials, and the mean on-rate of kainate, best fit by a 
single exponential function, in the presence of quisqualate, AMPA (100 
µM) and glutamate (200 µM; n=9-12).  The amplitude of the slow 
component of the rate of onset of modulation is represented as the 
percentage of the sum of the fast and slow components.  C. A strong 
correlation exists between the slow component of the onset of modulation 
by the benzothiadiazine modulator and recovery from desensitization as 
measured by the on-rate of kainate in the cross-desensitization paradigm 
(r2=0.98, error bars represent mean ± SEM). 
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These results, combined with the data for CTZ and TCM in Table 1, show that the 
binding of the benzothiadiazine modulators is agonist dependent.  The profile of agonist-
dependence is strikingly similar to the relative rates of recovery from desensitization for 
each agonist published by Patneau and Mayer (1991), suggesting a state-dependent 
interaction with the receptor in which the positive modulator is unable to bind the 
desensitized receptor.  Alternatively, the modulator may bind to the desensitized state, 
but the conformation of this state precludes the molecular interactions between receptor 
and modulator necessary for stabilization of the conducting state. 
 
3.3.3   The Rate of Onset of Modulation Examined Within a Cross-Desensitization 
Paradigm 
If the benzothiadiazines can only bind or exert modulatory effects after the receptor 
exits the desensitized state, the rate of onset of modulation should reflect the rate at which 
the receptor recovers from desensitization.  Previous studies have utilized a cross-
desensitization paradigm in which the rate of binding of an agonist with weak affinity for 
the desensitized state (e.g., kainate) in the presence of a strongly desensitizing agonist can 
be used as an independent measure of the rate of AMPA receptor recovery from 
desensitization (Patneau and Mayer, 1991).  We used within cell analysis to compare the 
on-rate of kainate with the onset of modulation by HF in the presence of quisqualate, 
AMPA, and glutamate (Fig. 3A).  Although we could not directly compare the on-rate of 
kainate, which was best fit by a single exponential function, with the onset of modulation 
by HF, which was best fit by the sum of two exponentials, a strong correlation exists 
between the slow component of onset of modulation by HF and the on-rate of kainate 
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(r2=0.98, Fig. 3C).  A strong correlation also exists between the on-rate of kainate and the 
fast component of onset of modulation by HF (r2=0.86, data not shown) 
 
3.5    Discussion 
Our exploration of the agonist-dependence of AMPA receptor modulation by 
cyclothiazide and other benzothiadiazine positive allosteric modulators reveals a state-
dependent interaction that reflects the inability of modulator to bind the receptor in the 
desensitized state.  In keeping with microscopic reversibility, the converse must also be 
true, that AMPA receptors cannot enter the desensitized state when cyclothiazide is 
bound.  Our results confirm and extend molecular and crystallography work on the 
mechanism of AMPA receptor desensitization and its modulation by cyclothiazide  
(Stern-Bach et al., 1998; Partin, 2001; Sun et al., 2002; Horning and Mayer, 2004).  As 
previously discussed (Section 1.3), in the structural model for activation and 
desensitization of AMPA receptors the agonist binding site is formed by two extracellular 
domains within a single subunit, domain 1 (D1) and domain 2 (D2), assembled into a 
“clamshell” conformation  (Stern-Bach et al., 1994; Armstrong et al., 1998; Armstrong 
and Gouaux, 2000; Mayer et al., 2001; Hogner et al., 2002; Sun et al., 2002).  In the 
resting state, two adjacent subunits form a dimer via interactions at the interface between 
the D1 domains (Figure 4A).  Agonist binding at the ligand binding core near the hinge 
region of the clamshell produces movement of the D2 domains, which is communicated 
to the transmembrane domains to open the channel.  Further closure of the "clamshell" 
destabilizes the D1-D1 interactions between adjacent subunits, facilitating transition into  
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Figure 4.  Model of channel activation and desensitization in the presence of agonist 
and modulator.  A. In the absence of modulator, agonist binds the ligand binding core 
(1), interacting with residues from both domain 1 (D1) and domain 2 (D2) and 
inducing domain closure (2), a conformational change linked to channel activation (3). 
This is followed by domain rearrangement into the lower energy desensitized state 
(Armstrong and Gouaux, 2000).  B.  Mutations that stabilize the D1-D1 interface 
inhibit the conformational change into the desensitized state (Stern-Bach et al., 1998; 
Sun et al., 2002).  Likewise, cyclothiazide and its benzothiadiazine family members 
stabilize the D1-D1 interface through interactions with both subunits forming the 
interface and prevent the transition into the desensitized state (1). The 
benzothiadizines clearly binds the receptor in the resting and conducting states; 
however, these compounds cannot bind when the receptor is in the desensitized state 
(2, see Appendix Fig. 2A).  This implies that the benzothiadiazines require interaction 
with both portions of the binding site in order to modulate current at AMPA receptors.
 
CLOSED OPEN DESENSITIZED
CLOSED OPEN NO BINDING
agonist              benzothiadiazine modulator        Na+
1.
2.
3.
4.
A
B
1.
2.
D1
D2
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the lower energy desensitized state and closing the channel (Armstrong et al., 1998; Sun 
et al., 2002; Horning and Mayer, 2004).   
In the crystal structure of the soluble extracellular domains of GluR2flopN754S, two 
cyclothiazide molecules bind at and stabilize the dimer interface through interactions 
with residues near the agonist binding site and in the flip/flop region (Partin et al., 1996; 
Partin, 2001; Sun et al., 2002; Leever et al., 2003), shifting the KD for dimerization to the 
left >1000-fold.  Our data indicate that binding of cyclothiazide at this interface does not 
slow the rate of entry of the receptor into the desensitized state but rather prevents the 
conformational transition into the desensitized state (Fig. 4B).  Because desensitization 
involves loss of interdomain contacts and separation of the dimer interface, the structural 
model predicts that cyclothiazide cannot interact with both sides of its binding site 
simultaneously in the desensitized state.  Other data from our lab does not support the 
idea that cyclothiazide binds to one subunit in the desensitized state, and then, as the 
receptor recovers from desensitization, interacts with the other half of the dimer to hold 
the receptor in the non-desensitized state (Appendix Fig. 2A).  Instead, the state- and 
agonist-dependence of modulation suggests that, without close apposition of adjacent D1 
domains, the binding site for cyclothiazide is essentially abolished in the desensitized 
receptor; therefore, the benzothiadiazines bind only after the receptor recovers from 
desensitization and the interface is restored. 
As predicted by the model, the onset of modulation by the rapidly binding drug 
hydroflumethiazide in the presence of agonist varied directly with the relative rates of 
recovery from desensitization for different agonists (Figure 2; Table 1).  Unlike the on-
rate of kainate, the onset of potentiation by HF in the presence of strongly desensitizing 
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agonists was best fit by the sum of two exponentials; also, the slow component was 
consistently slower than the on-rate of kainate in the cross-desensitization paradigm.  We 
believe this discrepancy is a consequence of comparing two pharmacologically distinct 
mechanisms of action.  HF binds allosterically to the non-desensitized receptor in the 
presence of agonist, while kainate competes with the more strongly desensitizing agonists 
for the binding cleft in both desensitized and non-desensitized states, albeit more 
effectively for the non-desensitized state (Patneau et al., 1993).  In combination with 
evidence from this and other studies, we believe the strong correlation between the on-
rate of kainate and τslow of the onset of modulation by HF supports the model for state-
dependent binding of the benzothiadiazines. 
The differential interaction of the benzothiadiazine modulators with the flip and flop 
isoforms of the AMPA receptor has been explained by weaker binding of CTZ in the 
presence of a bulkier asparagine versus a serine residue (N/S) at a critical position in the 
flip/flop region of the dimer interface (Partin et al., 1995; Sun et al., 2002).  Data 
generated in this lab shows that cyclothiazide binds with similar affinity to both splice 
variants in the resting state (Appendix, Fig. 2), indicating this is an incomplete 
explanation.  Differential modulation of flip and flop isoforms appears to be a 
consequence of allosteric interactions between ligand and modulator binding sites, with 
with negative cooperativity between agonist and benzothiadiazine binding sites 
accounting for the rapid decay of CTZ-mediated currents at flop AMPA receptor 
subunits.  Chimera and crystallography studies indicate close proximity of residues 
involved directly in agonist binding with those involved in desensitization (Table 1) 
(Stern-Bach et al., 1998; Armstrong and Gouaux, 2000; Partin, 2001; Horning and 
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Mayer, 2004).  Binding studies (Kessler et al., 1996) and dose-responses analyses 
(Patneau et al., 1993) show changes in agonist affinity and efficacy in the presence of 
CTZ.  Thus, a functional link between the agonist binding site and the benzothiadiazine 
binding sites at the dimer interface is well supported.   
In the context of previously published work, our data suggest that the nature of the 
allosteric interaction between agonist and modulator binding sites is defined by the 
identity of bound agonist as well as which subunits and splice isoforms comprise the 
dimer interface.  Cyclothiazide slows AMPA receptor deactivation rates two- to three-
fold in the presence of kainate, while increasing the apparent affinity of kainate to a 
similar degree (Patneau et al., 1993), reflecting positive cooperativity between binding of 
cyclothiazide and kainate.  It is interesting to note that the shape of glutamate-evoked 
responses in the presence of another modulator presumed to share the same mechanism 
of action as cyclothiazide indicates positive cooperativity between the binding of 
glutamate and the modulator LY404187 for GluR2flip (steadily increasing currents with 
prolonged application), and negative cooperativity for GluR2flop (Quirk and Nisenbaum, 
2003). 
The time constants for dissociation of cyclothiazide from GluR-AoBo and GluR-AiBo 
receptors in the absence of agonist were almost identical (Appendix, Fig. 2C); however, 
cyclothiazide fully blocks desensitization of AiBo receptors at equilibrium, but has little 
effect on equilibrium responses of AoBo receptors (Partin et al., 1994).  Thus the 
modulator binding sites at the dimer interface formed by these two tetramers have 
equivalent affinity in the resting state but differ in the conformational changes that occur 
upon agonist binding.  Recent data showing that dimers are preferentially assembled from 
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one flip and one flop subunit (Brorson et al., 2004) suggests that each dimer interface in 
receptors comprised of flip and flop subunits will possess one cyclothiazide binding site 
with a serine in the critical position.  It appears that a single cyclothiazide molecule 
bound at the dimer interface can confer complete block of desensitization.  Therefore, 
maintenance of the interface by a single cyclothiazide molecule is sufficient to block the 
agonist-induced conformational change that disrupts the binding of cyclothiazide in pure 
flop receptors.  We would also predict that crystallization of the GluR-Bflop extracellular 
domains in the presence of cyclothiazide, but without glutamate, will show a substantive 
leftward shift in the KD for dimerization, that will be lost in the presence of agonist.   
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Chapter IV 
PERIPHERALLY ASSOCIATED AMPA RECEPTOR BINDING PROTEINS DO 
NOT ALTER AMPA RECEPTOR KINETICS 
 
4.1 Disruption of GRIP and PICK1 Binding in Hippocampal Neurons 
GluR-B (also termed GluR2) contains a type II PDZ domain at its extreme C-
terminus that mediates binding to a variety of PDZ-domain containing proteins including 
GRIP1, GRIP2 and PICK1.  PICK1 and the GRIPs are believed to play a role in 
regulating the removal, insertion and stabilization of AMPA receptors at synaptic and 
internal membrane sites during long term modifications of synaptic strength.  The GRIPs 
appear to function primarily as membrane anchors while PICK1 plays a more dynamic 
role.  Association of the PDZ domain containing protein PSD-95/SAP90 with kainate 
receptor subunits expressed in heterologous cells has been shown to reduce receptor 
desensitization (Garcia et al., 1998).  These findings suggest that intracellular 
associations can modify channel function, prompting experiments to determine the 
effects of disrupting the association of GluR-B with GRIP1 and PICK1 on agonist-
evoked responses in dissociated hippocampal neurons. 
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4.1.1  Statement of Hypothesis 
The association of GRIP1, GRIP2 and PICK1 with the GluR2 subunit of the 
AMPA receptor alters channel properties in a manner that can be detected by whole-cell 
patch-clamp electrophysiology. 
 
4.1.2  Results   
Initial examination of the association of GRIP1 and PICK1 with endogenous 
AMPA receptors was examined using intracellular perfusion of short peptides that 
competitively disrupt GRIP1 and/or PICK1 association with GluR-B (see Section 2.3.3).  
We found no significant differences between control and experimental conditions in any 
of the parameters examined (Figure 5, data not shown).  Studies using these inhibitory 
peptides have primarily focused on their effects on LTP and LTD (Daw et al., 2000; Kim 
et al., 2001).  In our cultures, we examined only possible kinetic differences resulting 
from disruption of peptide binding; thus, in the absence of the synaptic rearrangements of 
LTP and LTD, kinetic differences may not be obvious.  Secondly, our recordings were 
obtained from both synaptic and extrasynaptic receptors.  Because synaptic receptors 
only comprise approximately 4-10% of surface receptors (Shi et al., 1999), extrasynaptic 
receptor currents may have masked changes in synaptic receptor kinetics.   
 
4.2 Association of AMPA Receptor Subunits with GRIP or PICK1 in HEK293 Cells 
Continued examination of the interaction of cytoskeletal proteins with the AMPA 
receptor was performed using transfected HEK 293 cells.  The peripheral association of 
GRASP-1 was also examined.  GRASP-1 is a neuron-specific guanine nucleotide  
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Figure 5: Disruption of interaction of GluR-B with GRIP1 and/or PICK1 
interaction using pep2-SVKI perfusion of cultured hippocampal neurons.  A.  
Responses to 3 mM glutamate were recorded immediately upon achieving whole-
cell configuration and every 5 min during the perfusion period.  Steady-state 
responses were normalized to the initial response.  A slight, but not significant, 
decrease in current in cells perfused with pep2-SVKI versus a slight, non-
significant increase with control intracellular solution is evident.  B.  The rate of 
desensitization of 3 mM glutamate, measured initially upon achieving whole-cell 
configuration and after a 20 min perfusion period, was not significantly different in
cells perfused with pep2-SVKI vs. control intracellular solution.  The relative 
proportion of the fast component of desensitization (τfast) is stated as a percentage 
of the sum of the slow and fast components.  C.  Steady-state currents evoked by 3 
mM glutamate (Glu), 3 mM glutamate + 30 µM GYKI 52466 (GY), or 600 µM 
kainate (KA) were not significantly different between neurons perfused with 
control intracellular solution vs. pep2-SVKI.  Bars represent mean ± SEM; 
Control, n=10; pep2-SVKI, n=10 
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Figure 6: Co-expression of GRIP1, GRIP2, GRIP1 and GRASP-1, or 
PICK1 with GluR-AiBi in HEK293 cells.  A. As a measure of surface 
receptor expression, peak currents elicited by 3 mM glutamate + 500 µM 
trichlormethiazide were normalized to whole cell capacitance (pA/pF).    B. 
The glutamate-evoked (3 mM) desensitization rate was not significantly 
different from control for any of the conditions examined (1-way ANOVA, 
p=0.47).  The rate of desensitization was best fit by a single exponential 
function. Bars represent mean ± SEM, Control, n=12-28; GRIP1, n=7; 
GRIP2, n=9; GRIP1 + GRASP-1, n=6, PICK1, n=17 
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Figure 7: Rectification of GluR-AiBi receptors in the presence and absence 
of PICK1.  A.  Rectification of steady-state current elicited by 3 mM 
glutamate.  Voltage was briefly ramped from -60mV (holding potential) to 
the indicated voltage.  Note the slight outward rectification due to a cesium 
rather than a potassium-based intracellular solution (see Section 2.3.1).  
Near linear rectification indicates GluR-Bi is incorporated into the 
expressed receptor.  Bars represent mean ± SEM; Control, n=11; Pick1, 
n=7 
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TABLE V 
Summary Data for GRIP and PICK1 Experiments 
 Glu SS (pA) 
Glu Pk   
(pA) 
KA SS   
(pA) 
GY SS   
(pA) 
TCM Pk/Wcc 
(pA/pF) 
% 
Desens 
Rate 
Desens 
(ms) 
Control 66±14 28 
1222±225 
28 
110±23 
28 
26±6 
27 
117±35 
10 
94.3±0.4 
28 
11±0.4 
28 
+GRIP1 138±43 7 
1672±491 
7 
189±54 
7 
60±20 
7 
180±46 
6 
92.2±0.6 
7 
11±0.7 
7 
+GRIP2 71±27 9 
1352±575 
9 
100±35 
9 
33±14 
9 
112±42 
8 
93.7±0.6 
 9 
11±0.9 
9 
+GRASP1 87±33 6 
1474±533 
6 
115±43 
6 
39±15 
6 
220±71 
6 
94.2±0.8 
6 
10±0.7 
6 
+PICK1 87±25 17 
1659±567 
17 
154±43 
17 
31±11 
16 -- 
92.6±1.9 
17 
12±0.7 
17 
 
 
 
 
 
Table 5: Summary Data for GRIP and PICK1 Experiments.  HEK293 cells 
were transfected with GluR-AiBi alone (Control) or with GRIP1, GRIP2, 
GRIP1 and GRASP1, or PICK1.  Peak (Glu Pk) and steady-state (Glu SS) 
responses to 3 mM glutamate in the presence and absence of 30 µM GYKI 
52466 (GY SS) as well as steady-state responses to 600 µM kainate (KA 
SS) were assayed.  Surface AMPA receptor expression was assayed by 
normalizing the steady-state current elicited by 3 mM glutamate in the 
presence of 500 µM trichlormethiazide to the whole cell capacitance (TCM 
Pk/Wcc) and is expressed as pA/pF.  % Desensitization is calculated with 
the formula [(1-(Glu steady-state/Glu peak)) x 100].  Values are expressed 
as mean ± SEM; n is given below the corresponding mean.  Analysis was 
performed using a 1-way ANOVA; p>0.05 for all comparisons. 
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exchange factor associated indirectly with AMPA receptors via PDZ-domain interactions 
with GRIP1 in rat brain (Ye et al., 2000).  The constructs were co-expressed with GluR-
AiBi heteromers to most readily detect subtle changes in desensitization properties. 
 
4.2.1  Results and Discussion  
 In various models of GRIP function this protein either stabilizes AMPA receptors 
at a cytoplasmic (Daw et al., 2000) or surface membrane location (Osten et al., 2000; 
Iwakura et al., 2001; Kim et al., 2001; Perez et al., 2001; Seidenman et al., 2003).  
According to these models, cotransfection of GRIP1 with the receptor should result in 
either a decrease or an increase, respectively, in AMPA receptor surface expression.  
There were no significant differences between control and experimental conditions in 
currents elicited by the full agonist glutamate (Fig. 6A), by the partial agonist kainate, or 
in glutamate-evoked responses in the presence of the positive and negative allosteric 
modulators trichlormethiazide and GYKI 52466, respectively (Table 5).  There appeared 
to be a non-significant trend towards greater current density in the presence of GRIP1, 
but not GRIP2 (Fig. 6A, Table 5; 1-way ANOVA, p=0.34).  This is consistent with the 
second model of GRIP function, in which GRIP1 stabilizes AMPA receptors in neuronal 
surface membranes.  Graphical representation of the data additionally suggests that 
GRIP2 may be less able to stabilize AMPA receptors at the membrane surface than 
GRIP1 (Fig.  6A).  Because palmitoylation of GRIP2 modulates its ability to mediate 
surface expression of AMPA receptors (deSouza et al., 2002), it is possible that 
expression of this construct in a non-neuronal cell prevents this posttranslational 
modification and therefore its function as a membrane anchor.  Co-expression of GRIP1 
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with GRASP-1 resulted in a slight, but again not significant, increase in current density 
(Fig. 6A, Table 5).  Ye et al (2000) found that over-expression of GRASP-1 partially 
blocked GRIP-mediated AMPA receptor surface localization; however, this function of 
GRASP-1 is dependent on NMDA receptor activity, suggesting this interaction may not 
be intact in a heterologous system lacking NMDA receptors.  Co-expression of GRIP1, 
GRIP2, or GRIP1 and GRASP-1 with GluR-AiBi did not significantly change either the 
magnitude of steady-state glutamate-evoked desensitization or the rate of desensitization 
(Fig. 6B, Table 5). 
PICK1 appears to play a more dynamic role in AMPA receptor trafficking.  One 
model presents PICK1 as a recruitment protein for activated PCKα, clustering the 
enzyme with the GluR-B C-terminus to facilitate phosphorylation at serine 880 of GluR-
B, which disrupts GRIP binding and allows receptor internalization and long term 
synaptic depression (Iwakura et al., 2001; Kim et al., 2001; Perez et al., 2001; Chung et 
al., 2003).  There was no significant difference in agonist-evoked responses or glutamate 
desensitization rate between control and PICK1 transfected cells (Table 5).  There were 
also no significant differences in rectification properties of GluR-AiBi heteromers in the 
presence of PICK1 (Fig. 7).  
The presence of a FLAG tag in the expression vector allowed us to use 
immunofluoresence to detect PICK1 protein levels. The HEK293 cells in Fig. 8A and B 
are transfected with GluR-B and show detectable levels of receptor expression.  Parts C 
and D verify binding of the FLAG antibody to the FLAG epitope: these cells are 
expressing a FLAG-tagged GluR-D protein.  Parts E and F show an undectable level of  
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Figure 8:  Immunofluorescent detection of GluR-B and PICK1 in 
transfected HEK293 cells.  A. & B. Fluorescent and phase images, 
respectively, of HEK293 cells transfected with GluR-B at 20X 
magnification.  C. & D. Fluorescent and phase images, respectively, of 
HEK293 cells transfected with FLAG-tagged GluR-D at 40X.  E. & F.  
Fluorescent and phase images, respectively, of HEK293 cells transfected 
with GluR-B and FLAG-tagged PICK1 at 40X.  Expression of the PICK1 
protein was undetectable. 
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FLAG-tagged PICK1 expression, explaining our negative results in HEK293 cells and 
indicating the SV40 promoter driving the PICK1 gene is too weak for 
electrophysiological examination of the interaction of PICK1 with the AMPA receptor.  
Our attempts to subclone the PICK1 construct into a pcDNA3.1 vector with a CMV 
promoter were unsuccessful.  A recent study detailed decreased GluR-B surface 
expression during PICK1 over-expression in hippocampal slice cultures (Terashima et al., 
2004; see Section 1.7.4).  Poor expression of the PICK1 construct prevented our ability to 
detect this change, which would have been evident as a decrease in outward current 
(increased inward rectification) in the presence of PICK1 (Fig. 7B).  Because our initial 
examination of the effects of PICK1 and the GRIPs on AMPA receptor functional 
properties suggests that these proteins have no additional effects on channel function, we 
chose to focus our efforts on the substantial changes in receptor function elicited by the 
transmembrane protein stargazin as presented in Chapter V.    
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Chapter V 
STARGAZIN/γ2 REDUCES AMPA RECEPTOR DESENSITIZATION BY 
DESTABILIZING THE DESENSITIZED STATE AND ALSO INCREASES 
KAINATE EFFICACY 
5.1   Introduction 
While several cytosolic AMPA receptor associated proteins have been described that 
are involved in controlling insertion, removal and stabilization of AMPA receptors at the 
synapse (reviewed by Bredt and Nicoll, 2003), none have been demonstrated to directly 
change receptor biophysical properties.  However, evidence that the glutamate receptor 
binding protein PSD-95/SAP90 decreases kainate receptor desensitization (Garcia et al., 
1998) and increases NMDA receptor open channel probability suggests an associated 
protein could alter AMPA receptor function. 
Stargazin, which is disrupted in the stargazer mutant mouse, was initially 
characterized by homology as the second member (γ2) of the voltage-gated calcium 
channel γ subunit family (Letts et al., 1998).  Stargazer mice exhibit seizures 
characterized by upward tilting of the head, thus the term “stargazer”.  Stargazin/γ2 is 
specifically expressed in the brain and, like the skeletal muscle γ1 subunit, produces a 
hyperpolarizing shift in inactivation of the channel-forming VGCC α subunit (Letts et al., 
1998).  This defect in neuronal VGCC inactivation in the absence of stargazin would be 
predicted to increase excitability, providing an appealing explanation for the spike-wave 
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seizures observed in stargazer mice.   Of greater functional significance is the profound 
deficit in AMPA receptor-mediated EPSCs in stargazer cerebellar granule cells 
(Hashimoto et al., 1999), a phenotype that can be rescued by over-expression of γ2 (Chen 
et al., 2000).  γ2 has three apparent functions in AMPA receptor trafficking: facilitating 
surface receptor delivery as a molecular chaperone involved in correct folding and ER 
processing of AMPA receptors (Tomita et al., 2003; Vandenberghe et al., 2005a), 
stabilizing AMPA receptors on the cell surface (Tomita et al., 2004) and, via interactions 
with PSD-95 and n-PIST, targeting AMPA receptors to the synapse (Chen et al., 2000; 
Cuadra et al., 2004).  Three closely related isoforms, γ3, γ4 and γ8, show distinct patterns 
of expression, and have also been identified as transmembrane AMPA receptor 
regulatory proteins (TARPs) based on their ability to restore AMPA receptor-mediated 
currents in stargazer cerebellar granule cells (Tomita et al., 2003).   
TARPs have recently been shown to co-purify with neuronal AMPA receptors 
(Nakagawa et al., 2005; Vandenberghe et al., 2005b), suggesting that they may function 
as auxiliary subunits of the receptor.  Because auxiliary subunits in voltage-gated 
channels can affect channel properties, we examined the effects of stargazin on channel 
function of neuronal and recombinant AMPA receptors.   We find that stargazin reduces 
glutamate-evoked desensitization of native hippocampal AMPA receptors through an 
allosteric interaction that destabilizes the desensitized state, and also substantially 
increases the efficacy of the partial agonist kainate.  Experiments in HEK293 cells 
demonstrate the relative roles of two domains of stargazin in mediating these functional 
effects.  Both trafficking and functional effects of the TARPs γ2 and γ3 vary with 
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receptor composition, suggesting that inclusion of TARPs as auxiliary subunits affects 
AMPA receptor heterogeneity in vivo.  
 
5.2 Statement of Hypothesis 
Enhancement of AMPA receptor currents in the presence of stargazin is a consequence 
not only of enhanced receptor trafficking but also altered receptor properties, including 
destabilization of the desensitized state and increased efficacy of the partial agonist 
kainate. 
 
5.3  Results 
5.3.1  Stargazin/γ2 Decreases Desensitization and  Increases Kainate Efficacy at   
Hippocampal AMPA Receptors 
While stargazin-mediated increases in AMPA receptor currents have traditionally 
been interpreted as increased AMPA receptor surface density, it also seemed possible, 
given the potential role of stargazin/γ2 as an auxiliary subunit, that γ2 could increase 
AMPA receptor currents by altering receptor functional properties.  We therefore 
examined the effects of exogenous γ2 expression on AMPA receptor function in 
hippocampal neurons using fast perfusion techniques during whole-cell voltage-clamp 
recording.  Dissociated cultures were prepared from newborn rat pups, and recordings 
were done at 7 days in vitro to minimize the contribution of endogenous neuronal TARPs 
(γ2, γ3 and γ8), which increase their expression during the 2nd and 3rd postnatal weeks 
(Tomita et al., 2003).  Exogenous γ2 increased normalized steady-state glutamate 
responses more than 6-fold relative to controls (Fig. 9A, B), decreasing desensitization 
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from 98.3 ± 0.2 to 87.8 ± 1.5% (mean ± SEM, n = 21 for each group).   Additionally, 
exogenous γ2 more than doubled the relative size of currents evoked by the weakly 
desensitizing partial agonist kainate.  It is striking that, while kainate currents in 
hippocampal neurons are typically only 40% as large as peak glutamate responses (Fig. 
9A, C), they approached parity in cells over-expressing γ2.   
Glutamate currents evoked in the presence of trichlormethiazide (TCM), a 
cyclothiazide analog that blocks receptor desensitization (Fig. 9A; see Section 2.6), 
provide a functional assay for surface AMPA receptor expression.  Exogenous γ2 had no 
significant effect on AMPA receptor current density in hippocampal neurons (Fig. 9D).  
Thus, in a system where exogenous γ2 did not increase surface expression of native 
AMPA receptors, it nonetheless clearly altered receptor functional properties as 
evidenced by both reduced desensitization of glutamate responses and increased apparent 
efficacy of kainate. 
Co-expression of γ2 significantly decreased steady-state potentiation by TCM ( Fig. 
9D) and significantly increased glutamate-evoked steady-state inhibition by the 2,3-
benzodiazepine GYKI 52466 (GYKI, Fig. 9E).  Both modulators act in a state-dependent 
manner; TCM selectively binds and holds the receptor in the non-desensitized 
conformation (see Chapter 3), while GYKI binds and preferentially holds the receptor in 
the desensitized state (Turetsky et al., 2004).  For both drugs, altered modulation in the 
presence of γ2 is a consequence of a larger proportion of receptors in the non-
desensitized state at equilibrium (Fig. 9F).  The 6-fold reduction of steady-state 
potentiation upon γ2 co-expression (Fig. 9B) reflects a similar degree of reduction in  
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Figure 9. γ2 selectively potentiates steady-state glutamate and 
kainate-evoked currents in hippocampal neurons.  See accompanying 
page for legend.  
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Figure 9.  γ2 selectively potentiates steady-state glutamate and kainate-evoked 
currents in hippocampal neurons.  (A) Responses of representative hippocampal 
neurons transfected with GFP alone (Control) or γ2+GFP to 3 mM glutamate (Glu), 
600 µM kainate (Kain) and glutamate in the presence of 500 µM trichlormethiazide 
(Glu+TCM).  Steady-state currents evoked by glutamate (B) or kainate (C) in 
hippocampal neurons were normalized to the peak glutamate response to assess 
changes in AMPA receptor functional properties.  The ratio of Glu SS/Glu Pk is a 
relative measure of the proportion of receptors in the desensitized state; the inverse of 
this ratio describes the relative occupancy by the receptor of open, non-desensitized 
states.  In control cells, 1.7 ± 0.2% of AMPA receptors occupy the open state at 
equilibrium while 12.2 ± 1.5% of receptors occupy the open state at equilibrium when 
γ2 is present.  (D)  Potentiation of glutamate-evoked steady-state responses by 500 µM 
TCM was calculated by (Glu+TCM SS/Glu SS).  (E)  Inhibition of glutamate-evoked 
steady-state responses by GYKI 52466 was calculated by [1-(Glu+GYKI SS/Glu SS)]. 
(F) Schematic demonstrating the relative decrease in potentiation by TCM and 
increase in inhibition by GYKI in the presence of γ2.  A larger percent of receptors 
associated with γ2 occupy the open, non-desensitized state than receptor alone (γ2 Glu 
SS vs. Con Glu SS).  Simply put, the decreased efficacy of TCM reflects a smaller step
towards full occupancy of the open state of the receptor (Max Current) from a steady-
state current with less desensitization than control currents, while increased efficacy of 
GYKI reflects a larger step towards full occupancy of the desensitized state. (G) 
Current density was determined by normalizing peak glutamate currents in the 
presence of TCM to whole-cell capacitance as a functional measure of AMPA 
receptor surface expression.  For comparison, normalized glutamate peak currents are 
also graphed.  Bars in (B-D) represent mean ± SEM (n = 21 for each group).  Asterisks 
(*) indicate a significant difference from corresponding control (*** P<0.001).   
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glutamate-evoked steady-state desensitization (Fig. 9B, see figure legend).  Because 
GYKI increases the proportion of receptors in the desensitized state, the relative increase 
in GYKI inhibition reflects a larger shift between normal and modulator-induced levels 
of steady-state desensitization (Fig. 9F).       
In contrast to TARP expression in hippocampal neurons, mouse cerebellar granule 
neurons exclusively express γ2, which is crucial for AMPA receptor surface expression in 
these cells (Chen et al., 2000; Tomita et al., 2003).  Cultures were prepared from P2 
mouse pups, and recordings were performed at 7 days in vitro, a time when endogenous 
γ2 is expected to be present but not yet at maximal levels.  Although γ2 over-expression 
significantly increased current density, which reflects increased AMPA receptor surface 
expression (Fig. 10D), it did not significantly increase normalized steady-state glutamate 
currents (Fig. 10A, B) and no significant change in desensitization was observed (control 
97.5 ± 0.4% versus γ2 96.4 ± 0.4%, mean ± SEM, n = 12-14).  There was a small (17%) 
but significant increase in relative kainate responses (Fig. 10A, C).  Interestingly, control 
kainate responses in cerebellar granule cells averaged 50% larger than peak glutamate 
currents (Fig. 10C), a percentage only approached in certain hippocampal neurons with 
exogenous γ2 expression.  Thus, in a system where most surface receptors are associated 
with γ2, over-expression of γ2 increases trafficking of receptors to the membrane but has 
little additional effect on AMPA receptor functional properties.   
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Figure 10.  γ2 increases receptor surface expression in cerebellar granule 
neurons with minimal functional effects. (A) Traces from representative 
cerebellar granule cells transfected with GFP or γ2+GFP illustrate the large 
kainate responses characteristic of these neurons and the relatively smaller 
functional effects of exogenous γ2 expression.  Steady-state currents 
evoked by glutamate (3 mM, B) or kainate (600 µM, C) were normalized 
to the peak glutamate response to assess changes in AMPA receptor 
functional properties.  (D) Current density was determined by normalizing 
peak glutamate currents in the presence of TCM to whole-cell capacitance 
as a functional measure of AMPA receptor surface expression.  Bars in (B-
D) represent mean ± SEM (n = 12–15).  Asterisks (*) signify a difference 
for γ2 relative to the respective control (* P<0.05, ** P<0.01). 
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5.3.2  Stargazin/γ2 Destabilizes the Desensitized State of the AMPA Receptor 
To begin to address the mechanisms underlying γ2’s functional effects on native 
AMPA receptors, we first examined the relative increase in kainate efficacy.  In 
hippocampal neurons, γ2 over-expression shifted the kainate dose-response curve to the 
left ~3 fold (Fig. 11A).  This is similar to the shift produced by the positive modulator 
cyclothiazide (Patneau et al., 1993) and could reflect decreased receptor desensitization.  
However, a mutation that allows kainate to induce greater domain closure, and thus to 
more effectively gate the channel, also shifts the dose-response curve ~3-fold to the left.  
Alternately, γ2 could produce a conformational change in the ligand binding pocket that 
directly affects kainate’s affinity.  In order to distinguish between these possibilities, we 
examined the association and dissociation rates of kainate applied in the presence of 
glutamate.  Because glutamate has a higher affinity for the desensitized state, kainate can 
only compete glutamate from non-desensitized receptors (Patneau and Mayer, 1991).  
Thus, this protocol allowed us to assess both the rate of recovery from glutamate-evoked 
desensitization and the rate of dissociation of kainate.  γ2 over-expression significantly 
increased the rate of recovery from glutamate-evoked desensitization as determined by 
faster kainate association (Fig. 11B, C).  However, there was no change in dissociation 
kinetics (Fig. 11B, C), indicating that γ2 does not alter the affinity of kainate for the 
receptor. 
A faster rate of recovery from desensitization and reduced steady-state desensitization 
in hippocampal neurons suggest γ2 alters the equilibrium between desensitized and non- 
desensitized states of the receptor.  One way to obtain direct information about the 
 94
 
 
 
Figure 11.  γ2 increases kainate efficacy and speeds recovery from 
desensitization in hippocampal neurons.  (A) Dose-response curves for 
kainate-evoked currents in hippocampal neurons transfected with GFP 
(Control) or γ2+GFP.  Currents were normalized relative to 3 mM kainate.  
Points represent mean ± SEM (n = 4 -11, depending on dose).  (B) 
Representative traces from neurons transfected with GFP or γ2+GFP 
illustrate the association and dissociation of kainate (600 µM) in the 
presence of glutamate (200 µM).  (C) Both association (τon) and 
dissociation (τoff) of kainate in the presence of glutamate were well fit by a 
single exponential function.  Bars represent mean ± SEM (control, n = 16; 
γ2, n = 15).  Asterisks (*) signify a difference for γ2 relative to the 
respective control (*** P<0.001).   
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conformational state of the receptor is to examine the association kinetics of the positive 
modulator trichlormethiazide (TCM).  Crystallization of the ligand-binding cores of 
GluR-B has shown that the interface between two adjacent AMPA receptor subunits is 
closely apposed in both the resting and open states but separates during the 
conformational transition to the desensitized state (Sun et al., 2002).  Positive allosteric 
modulators such as cyclothiazide bind at and stabilize this dimer interface, reducing 
desensitization.  Implicit in this model is the loss of the binding site for the positive 
modulators in the desensitized conformation, with substantially slowed modulator 
binding in the presence of strongly desensitizing agonists (unpublished data).  In 
hippocampal neurons over-expressing γ2, the time constants for onset of TCM 
modulation were more than 5 times faster than in control neurons, consistent with a faster 
rate of recovery from desensitization (Fig. 12A, B).  The time constant of dissociation 
was unaffected (Fig. 12C), indicating that the affinity of TCM for the non-desensitized 
state is unchanged, and by implication, that γ2 does not substantially alter the 
conformation of the dimer interface in the open state.  These data therefore suggest that 
γ2 association shifts the equilibrium between desensitized and open conformations of the 
AMPA receptor by destabilizing the desensitized state.   
  
5.3.3  The Functional Effects of Stargazin/γ2 Are Specific for AMPA Receptors 
Because both hippocampal and cerebellar granule neurons express heterogeneous 
receptor populations and have the complication of endogenous TARP expression, we  
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Figure 12.   The onset of modulation by trichlormethiazide is faster in 
neurons transfected with γ2.  (A) Traces from representative hippocampal 
neurons transfected with GFP or γ2+GFP show the association and 
dissociation kinetics of TCM (500 µM) in the presence of glutamate (3 
mM).  Time constants for the onset (B) and offset (C) of TCM modulation 
in hippocampal neurons transfected with GFP or γ2.  Onset kinetics were 
fit with the sum of two exponentials (% contribution of τslow is shown), 
while dissociation kinetics were best described by a single exponential.  
Bars represent mean ± SEM (control, n = 19; γ2, n = 17).  Asterisks (*) 
signify a difference for γ2 relative to the respective control (** P<0.01, *** 
P<0.001).   
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moved to a heterologous expression system to further explore the effects of γ2 on AMPA 
receptor function.  AMPA receptor subunits occur naturally as one of two alternatively 
spliced isoforms, flip (i) or flop (o), which differ in their desensitization properties 
(Sommer et al., 1990).  AMPA receptors are preferentially assembled as heteromers 
containing both flip and flop isoforms (Brorson et al., 2004).  HEK293 cells were 
therefore co-transfected with GluR-Ai and Bo to form heteromeric receptors that 
reproduce some characteristics of native hippocampal AMPA receptors.  γ2 co-
expression had substantially larger effects on kainate efficacy in recombinant AMPA 
receptors than in hippocampal neurons, with both normalized steady-state glutamate and 
kainate currents potentiated approximately 10-fold over control (Fig. 13A, B, C). We also 
observed a pronounced slowing in the rate of glutamate desensitization (control τ = 4.4 ± 
0.2 ms, n = 14; γ2  τ = 7.1 ± 0.5 ms, n = 17, mean ± SEM; P < 0.001, t-test).  Note that 
relative glutamate and kainate steady-state responses in control HEK293 cells expressing 
GluR-AiBo are much smaller (1 and 7% of peak glutamate, respectively) than those of 
native receptors in hippocampal neurons (Fig. 9).  It is intriguing that the characteristics 
of recombinant receptors co-expressed with γ2 more accurately reproduce those observed 
in native receptors.   
In contrast to effects in hippocampal neurons, γ2 co-expression increased current 
density 3.4-fold in HEK293 cells expressing AiBo heteromers (Fig. 13D).  To corroborate 
this functional assay for effects on AMPA receptor trafficking, surface biotinylation 
experiments were performed in sister AiBo cultures.  Quantitative western blots revealed 
an average 3.2-fold increase in GluR-A, and a 2.9-fold increase in GluR-B surface 
protein with γ2 co-expression (Fig. 13E, F).  Thus, the increase in AMPA receptor 
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surface expression can account for the potentiation of glutamate peak responses; 
however, when this increase in surface expression is factored out, a 10-fold increase in 
relative glutamate steady-state responses remains.  To determine whether γ2 differentially 
affected flip and flop splice variants, we also examined AiBi and AoBo heteromers.  We 
observed trafficking and functional effects for all heteromeric combinations; however, 
the magnitude of these effects were dependent on receptor composition (Table 6).   
Three calcium channel γ subunit family members closely related to stargazin, γ3, γ4 
and γ8, have also been identified as TARPs based on their ability to restore AMPA 
receptor-mediated currents in stargazer cerebellar granule cells, while the more distantly 
related family members γ1, γ5, γ6 and γ7 cannot (Tomita et al., 2003).  To determine 
whether other TARPs share the functional effects of γ2, HEK293 cells were co-
transfected with AiBo and γ3 or γ5.  γ3 potentiated both steady-state glutamate and kainate 
currents, while γ5 had no significant effect on receptor function (Fig. 13B, C).  Similar 
results were obtained with γ3 and γ5 in hippocampal neurons (data not shown).  γ3, but 
not γ5, also significantly increased current density in HEK293 cells expressing AiBo 
heteromers (Fig. 13D).  It is particularly interesting that although γ3 significantly 
decreased receptor desensitization, the effect was only half that observed with γ2, 
indicating that various TARPs may differentially associate and/or have different 
functional effects on a given AMPA receptor subtype.   
Chen and colleagues (2003) reported that stargazin could increase AMPA receptor 
surface expression, but had no effect on kainate receptor trafficking.  To determine if γ2’s 
effects on receptor functional properties were also AMPA receptor specific, we co-
expressed γ2 with GluR6 homomers or GluR6/KA2 heteromers in HEK293 cells.   
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Figure 13.  Dissociation of the effects of TARPs on steady-state agonist-
evoked currents and AMPA receptor surface expression in heteromeric 
recombinant receptors.  (A) Responses evoked by glutamate (3mM) and 
kainate (600 µM) for representative HEK293 cells expressing heteromeric 
GluR-AiBo receptors or GluR-AiBo + γ2.  Note the different scale bars for 
control (500 pA) and γ2 cells (2 nA).   Steady-state glutamate (B) or 
kainate currents (C) normalized to peak glutamate responses in HEK293 
cells transfected with GluR-AiBo alone or GluR-AiBo + γ2, γ3 or γ5.  (D) 
Current density was calculated by normalizing peak glutamate + TCM 
responses to whole cell capacitance.  Bars in (B-D) represent mean ± SEM 
(n = 12–17).  Asterisks (*) indicate significant difference relative to 
respective control (* P<0.05, ** P<0.01, *** P<0.001), and pluses (+) 
indicate significant difference from γ2 (+ P<0.05; ++ P<0.01, +++ P<0.001).  
(E) Surface biotinylation experiments were performed in HEK293 cells 
transfected with GluR-AiBo alone or GluR-AiBo + γ2.  Western blots from a 
single experiment probed with antibodies for GluR-A or GluR-B are 
shown.  The GluR-B blot was reprobed with tubulin as a control.   The 
three lanes on the right are 1:2, 1:5, and 1:10 dilutions of the GluR-AiBo 
total protein sample.  (F) Mean data from surface biotinylation of 3 
independent transfections (± SEM). 
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Figure 14.  The functional effects of γ2 are AMPA receptor specific.  (A) 
Representative responses evoked by 3 mM glutamate in HEK293 cells 
expressing homomeric GluR6 (top) or heteromeric GluR6/KA2 receptors 
(bottom) with or without γ2.  Note the different scale bars for control (50 
pA) and γ2 (150 pA) cells expressing GluR6.   (B) Steady-state glutamate 
currents normalized to peak glutamate responses in HEK293 cells 
transfected with GluR6 or GluR6/KA2 ± γ2.  (C) Because the 
benzothiadiazines are inactive at kainate receptors, current density in 
HEK293 cells transfected with GluR6 or GluR6/KA2  ±  γ2 was 
determined by normalizing peak glutamate responses to whole cell 
capacitance.  Bars in (B) and (C) represent mean ± SEM (n = 11–13).  
Asterisks (*) signify a difference for γ2 relative to the respective control (* 
P<0.05).   
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Figure 15.  The functional effects of γ2 are subunit-dependent.  Agonist-
evoked responses of representative HEK293 cells transfected with GluR-Ai
(A) or GluR-Bi (B) alone or with γ2.  Note the different pA scale bars for 
control and γ2 cells.  Normalized glutamate (C) and kainate (D) steady-
state currents in HEK293 cells expressing homomeric Ai or Bi receptors 
alone (control) or with γ2, γ3, or γ5.   (E) Current density was determined 
by normalizing peak glutamate + TCM responses to whole-cell 
capacitance.  Note the different ordinate scales for Ai (left) and Bi (right) 
for each bar graph (C-E).  Values represent mean ± SEM (n = 7-44).  (E) 
Current-voltage relationship for peak glutamate (3 mM) currents in 
HEK293 cells transfected with GluR-Ai alone or GluR-Ai+γ2.  Points 
represent mean ± SEM, (n = 12-41).  Asterisks (*) indicate a significant 
difference relative to the corresponding control (* P<0.05, ** P<0.01, *** 
P<0.001), and pluses (+) indicate significant difference from γ2 condition 
(++ P<0.01; +++ P<0.001).   
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Surprisingly, γ2 did increase current density in cells expressing GluR6 homomers (Fig. 
14C), however, it had no significant effect on normalized steady-state glutamate current 
for either GluR6 homomers or GluR6/KA2 heteromers (Fig. 14A, B). Thus the functional 
effects of γ2 are specific for AMPA receptors.     
 
5.3.4  Stargazin/γ2 Differentially Affects Individual AMPA Receptor Subunits 
To rule out the possibility that γ2 affected AMPA receptor functional properties by 
altering subunit composition in native or heteromeric recombinant receptors, we also 
examined the effects of γ2 expression on homomeric GluR-Ai, Bi, Ci, and Di receptors.  In 
HEK293 cells expressing GluR-Ai homomers, γ2 co-expression potentiated normalized 
steady-state glutamate and kainate currents (3.3- and 37-fold, respectively; Fig. 15A, C, 
D), while increasing current density 3-fold (Fig. 15E).  Although γ2 significantly altered 
functional properties of all four homomers, subunit-specific effects were apparent.   Most 
strikingly, effects of γ2 on kainate and glutamate steady-state were similar for GluR-Bi 
(Fig. 15A-D), while kainate responses were much more strongly affected in the other 
three subunits (Table 7).  The functional effects of γ3 also differed between subunits, 
with effects on GluR-Bi homomers more closely resembling those seen in GluR-AiBo 
heteromers (compare Fig. 13B, C and Fig. 15C, D).  As expected, γ5 had no functional or 
trafficking effects on GluR-Ai or Bi.  Surprisingly, γ2 exhibited subunit-specific 
trafficking effects, producing a 12-fold increase in current density for GluR-B, a 2-4 fold 
increase for GluR-A and D, and no significant change for GluR-C (Table 7).  Taken 
together these results suggest that the functional effects of γ2 are mediated by association 
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at the cell surface rather than by effects on receptor assembly, and that the affinity and/or 
efficacy of the γ2 / AMPA receptor association differs for individual subunits.   
γ2’s effect on peak glutamate-evoked currents in GluR-Ai homomers was voltage-
dependent, with co-expression resulting in significantly less inward current at holding 
potentials ≤ -80 mV and significantly more outward current at potentials ≥ +80 mV 
(normalized relative to -60 mV, Fig.15F).  We also observed a significant increase in 
outward rectification for GluR-Di (data not shown).  Given the voltage-dependence of 
AMPA receptor gating and/or desensitization (Patneau et al., 1993),  it is unclear whether 
this reflects an additional effect of γ2 on channel function or is a consequence of changes 
in other voltage-dependent channel properties. 
Because binding of γ2 to PSD-95 via its C-terminal PDZ-binding motif is important 
for synaptic delivery of AMPA receptors (Chen et al., 2000), we examined co-expression 
of PSD-95 on γ2’s functional effects in homomeric GluR-Ai receptors.  The effects of 
γ2/PSD-95 co-expression were statistically indistinguishable from γ2 alone for 
normalized glutamate (Fig. 16A) and kainate steady-state currents (Fig. 16B) as well as 
whole-cell current density (Fig. 16C).  Although the effects of γ2 relative to control on 
glutamate steady-state were not significant for this subset of experiments (Fig. 16A), we 
nonetheless observed a significant slowing of the onset of desensitization in the presence 
of γ2, which was independent of PSD-95 expression (Fig. 16D).  As expected, PSD-95 
co-expression alone did not alter either the functional properties or levels of surface 
expression for GluR-Ai receptors.  Thus PSD-95 is not necessary for, and does not 
significantly alter, γ2’s functional effects on AMPA receptors.  
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Figure 16.  PSD-95 co-expression does not alter the effects of γ2 on 
AMPA receptor functional properties.  Normalized glutamate (A) and 
kainate (B) steady-state currents in HEK293 cells transfected with GluR-Ai
alone or with γ2, PSD-95, or PSD-95 + γ2.  (C) Current density was 
determined by normalizing peak glutamate + TCM responses to whole cell 
capacitance.  (D) Time constants determined by single exponential fits to 
the onset of desensitization for glutamate-evoked responses in HEK cells 
expressing GluR-Ai alone or with γ2, PSD-95, or PSD-95 + γ2.  Bars in (A-
D) represent mean ± SEM, (n = 11-19).  Asterisks (*) indicate a significant 
difference relative to the corresponding control (** P<0.01, *** P<0.001) 
and pluses (+) indicate significant difference from γ2 condition (+ P<0.05; 
+++ P< 0.001).   
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Figure 17.  Both intracellular and extracellular regions of γ2 mediate 
functional changes in AMPA receptor properties.  (A) Schematic depiction 
of the transmembrane topology of γ2.  Amino acids demarcating 
boundaries for the chimeras and the C-terminal truncation are noted.  
Current density (B), normalized glutamate steady-state currents (C) and 
normalized kainate currents (D) in HEK293 cells transfected with GluR-Ai 
alone or GluR-Ai + γ2, γ2(∆26-103)/γ5(ins26-99), γ2(∆89-103)/γ5(ins85-
99) or γ2(1-212).  Bars in (B-D) represent mean ± SEM (n = 9-46).  
Asterisks (*) indicate a significant difference relative to the corresponding 
control (* P<0.05, ** P<0.01, *** P<0.001) and pluses (+) indicate 
significant difference from γ2 condition (+ P<0.05; +++ P<0.001).   
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5.3.5  Extracellular and Intracellular Domains of Stargazin/γ2 Differentially Mediate 
Trafficking and Functional Effects  
Tomita and colleagues (2004) demonstrated that two regions in γ2, an area in the first 
extracellular loop and a region in the cytoplasmic tail, mediated association with GluR-B 
and were necessary for GluR-A trafficking in Xenopus oocytes.  It was therefore of 
interest whether these same regions mediated the functional effects of γ2.  A γ2 construct 
lacking most of the cytoplasmic tail [γ2(1-212), truncated 10 amino acids after the 4th 
transmembrane domain, see Fig. 17A] produced a significant decrement in current 
density relative to the effects of γ2 on GluR-Ai (Fig. 17B), but not quite to control level.  
This suggests that the γ2 cytoplasmic tail is the major mediator of AMPA receptor 
trafficking.  Removal of the C-terminal tail of γ2 also abolished the effect on glutamate 
steady-state responses for GluR-Ai (Fig. 17C).  Kainate-evoked currents in cells co-
expressing γ2(1-212), although reduced by two-thirds relative to γ2, were significantly 
potentiated over controls (Fig. 17D).  Interestingly, γ3, which shares substantial 
homology (84% amino acid identity) with γ2 through the end of the 4th transmembrane 
region but has greater divergence (56% identity) in the C-terminus, has effects on both 
trafficking and AMPA receptor function that were statistically indistinguishable from 
those of γ2(1-212) (P>0.89).    
Because γ5 had no significant effects on AMPA receptor trafficking or function, we 
constructed a γ2/γ5 chimera, γ2(∆26-103)/γ5(ins26-99), that replaced the first 
extracellular loop of γ2 with the corresponding sequence from γ5 (Fig. 17A).  Co-
expressing γ2(∆26-103)/γ5(ins26-99) with GluR-Ai homomeric receptors produced 
effects that were almost the inverse of those observed with γ2(1-212).  Although current 
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density was unaffected relative to γ2 (Fig. 17B), the shift in kainate efficacy was totally 
eliminated (Fig. 17D).  While normalized steady-state glutamate responses in cells co-
expressing γ2(∆26-103)/γ5(ins26-99) were approximately half of those observed with γ2, 
they were not significantly different from either γ2 or control (Fig. 17C).  A second γ2/γ5 
chimera, γ2(∆89-103)/γ5(ins85-99), which exchanged only 15 aa just prior to TM2, was 
statistically indistinguishable from γ2 on steady-state glutamate-evoked current, but still 
showed a significant decrement in the shift of kainate efficacy (Fig. 17C, D).  Taken 
together these data suggest that functional effects are mediated by multiple regions on γ2.  
While both the intracellular C-terminal domain and first extracellular loop of γ2 appear to 
contribute to each functional effect, the cytoplasmic tail plays a larger role in reducing 
glutamate steady-state desensitization, and the first extracellular loop plays a larger role 
in increasing kainate efficacy.   
 
5.3.6  Subunit-Dependent Differences in Functional Effects Support the Role of 
Extracellular and Intracellular Domains in Altered Kainate Efficacy and 
Desensitization, Respectively 
The trafficking and functional effects of γ2 differed between AMPA receptor 
subunits.  Co-expression of γ2 significantly increased surface trafficking of GluR-Ai, Bi 
and Di but not Ci (Fig. 18B, Table 7).  Cells co-expressing γ2 and GluR-Bi exhibited a 
distribution distinct from that of control responses, while with GluR-Ai and Di the two 
populations prominently overlapped (Fig. 18B).  Co-expression of γ2 with GluR-Ai and 
Di also exhibited considerable overlap in desensitization profiles with control responses, 
while co-expression with GluR-Bi and Ci generated responses distinct from subunit alone 
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(horizontal lines, Fig. 18C).  Note the striking variability in desensitization profiles of 
glutamate-evoked responses of GluR-Ai co-expressed with γ2 (Fig. 17A).   The 
significant increase of the relative kainate response seen upon γ2 co-expression with 
every subunit (vertical lines, Fig. 18C, Table 7) suggests the extracellular portions of the 
AMPA receptor mediating this effect exhibit strong amino acid sequence identity 
between GluR-A, B, C and D.  Interestingly, while γ2 did not effectively traffic GluR-Ci, 
it maintained both functional effects (Table 7, Fig. 18C), suggesting that in the absence of 
trafficking, γ2 maintains a functionally effective association with the AMPA receptor. 
While the first extracellular loop of γ2 is essential for increased kainate efficacy (Fig. 
17D), effects on desensitization, and especially effects on trafficking, are mediated 
through intracellular interactions (Fig. 17B, C).  Comparison of the intracellular 
sequences of the four AMPA receptor subunits suggests three candidate areas as sites of 
γ2 interaction.  The downstream portion of the first intracellular loop of GluR-C contains 
six proline residues, two of which are not present in the other subunits (Fig. 17D).  GluR-
C is unique from GluR-A, B and D in that it is not trafficked by γ2, suggesting the 
possibility that these prolines introduce tertiary changes in the first intracellular loop that 
block the association with γ2 necessary for surface trafficking.  It is interesting that 
GluR-D, which is trafficked less effectively than GluR-A and B (Fig. 17B, Table 7), also 
contains several proline residues in the downstream portion of its first intracellular loop.  
Secondly, GluR-B and C have short C-terminal tails, while GluR-A and D have long C-
termini (Fig. 17D).  The overlap of γ2-mediated GluR-Ai and Di desensitization profiles 
with control responses and the lack of overlap between control and γ2-mediated GluR-Bi 
and Ci responses suggest a long C-terminal tail interferes to varying degrees with 
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destabilization of the desensitized state by γ2.  While the sequence of the second 
intracellular loop is identical between the four subunits (Fig 17D), it is ideally placed to 
influence channel properties due to its proximity to the pore-lining re-entrant loop (M2, 
Diagram 1).  Steric hindrance by long C-terminal tails of the interaction of γ2 with this 
region may underlie the variability in desensitization profiles seen with GluR-A and D. 
 
 
Figure 18 presented on page 109. 
 
 
 
 
Figure 18. Subunit-specific effects of γ2 isolate intracellular regions of 
interaction.  (A)  Representative responses evoked by 3 mM glutamate or 
600 µM kainate in cells transfected with GluR-Ai alone or with γ2.  In 
Example 1, trafficking, altered desensitization and kainate efficacy are 
evident.  In Example 2 trafficking and altered kainate efficacy are apparent 
(see pA scale bar, compare kainate steady-state and glutamate peak) while 
the desensitization profile is similar to that of the control glutamate 
response.  (B)  Scatter plots of the trafficking effects of γ2 on GluR-Ai, Bi, 
Ci and Di homomers.  Means are represented as a horizontal line.  (C)  
Scatter plots comparing the extent of altered desensitization (Glu SS/Glu 
PK) and kainate efficacy (KA SS/Glu Pk)  for each subunit.  Vertical lines 
highlight a clear separation in the magnitude of kainate-evoked currents 
between control and γ2 cells, while horizontal lines separate populations of 
receptor co-expressed with γ2 that have distinct effects on desensitization.  
(D)  Amino acid sequence of the first and second intracellular loops and C-
terminal tail of GluR-A, B, C, and D.  Note the proline residues in the first 
intracellular loop (*) as well as 100% amino acid sequence conservation in 
the second intracellular loop.  GluR-B and C have short C-terminal tails, 
while GluR-A and D have long C-terminal tails.  See also Diagram 7. 
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Figure 18. Subunit-specific effects of γ2 isolate intracellular regions of 
interaction.  See Legend on accompanying page. 
1st IC Loop
GluR-A  RFSPYEWHSEEFEEGRDQTTS--DQSNE   //
GluR-B  RFSPYEWHTEEFEDGRETQSS--ESTNE   //
GluR-C  RFSPYEWHLEDNNEEPRDPQSPPDPPNE   //
GluR-D  RFSPYEWHTEEPEDGKEGPSD--QPPNE   //
*   *  *  ** **
2nd IC Loop
DISPRSLSGR   //
DISPRSLSGR   //
DISPRSLSGR   //
DISPRSLSGR   //
C-Terminal Tail
GluR-A  EFCYKSRSESKRMK  GFCLIPQQSINEAIRTSTLPRNSGAGASGGGGSGENGRVVSQDFPKSMQSIPCMSHSSGMPLGATGL-
GluR-B  EFCYKSRAEAKRMK  VAKNPQNINPSSSQNSQNFATYKEGYNVYGIESVKI
GluR-C  EFCYKSRAESKRMK  LTKNTQNFKPAPATNTQNYATYREGYNVYGTESVKI
GluR-D  EFCYKSRAEAKRMK  -------LTFSEAIRN--KARLSITGSV-----GENGRVLTPDCPKAVHTGTAIRQSSGLAVIASDLP
EC
IC
N
C
1st IC 
loop
2nd IC 
loop
C-terminal 
tail
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TABLE VI 
Effects of γ2 Co-Expression on Heteromeric AMPA Receptors in Heterologous Cells 
  Glu Pk Glu SS KA SS KA/Glu Pk TPk/WCC Desensitization 
   (pA)  (pA)  (pA) (%) (pA/pF) (%)  
                     
AiBo Con 745±168 6±1 55±12 11±2 114±27 99.4 ±0.2 
 γ2 4242±646*** 550±107*** 3625±516*** 92±8*** 350±65* 89.3±1.7*** 
AiBi Con 1349±442 64±19 147±48 12±1 195±48 97.7±0.4 
 γ2 3894±592** 989±174*** 2398±426*** 61±6*** 414±66* 84.0±3.0*** 
AoBo Con 165±48 3±1 56±15 35±5 22±5 99.3±0.1 
 γ2 1843±339*** 205±53** 3079±537*** 170±11*** 214±42** 93.4±1.1*** 
 
Table 6: Effects of γ2 co-expression on heteromeric AMPA receptors in heterologous 
cells.  HEK293 cells were transfected with the AMPA receptor combinations shown with 
or without γ2 co-expression.  Relative kainate efficacy (600 µM) is expressed as a percent 
of the peak response to 3 mM glutamate.  Current density, as an assay for surface 
receptor expression, was determined by normalizing Glu+TCM Peak to whole-cell 
capacitance (Tpk/WCC; 500 µM).  Desensitization was calculated relative to maximal 
currents in the presence of TCM (% desensitization = [1- (GluSS / Glu+TCM 
Peak)]*100).  AiBo n = 15-17, AiBi n = 12-14, AoBo n= 10-14.   Asterisks (*) indicate γ2 
condition is significantly different from receptor alone (* P<0.05; *** P<0.001, t-test).   
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TABLE VII 
Effects of γ2 Co-Expression on Homomeric AMPA Receptors in Heterologous Cells 
 
  Glu Pk Glu SS KA SS KA/Glu Pk KA/Glu SS TPk/WCC Desens 
     (pA)    (pA)  (pA)         (%)      (pA/pF)    (%) 
 
Ai Con 739±124 9±2 9±1 3±1 3±1 173±23 99.6±0.1 
 γ2 5530±421*** 350±52*** 5682±409*** 112±4*** 42±5*** 621±42***  96.3±0.7*** 
Bi Con 78±13 9±2 7±1 8±1 1±0.1 11± 2 96.4±0.4 
 γ2 1841±298*** 1090±220*** 1070±219*** 55±3*** 1±0.1 134±20*** 44.7±4.0*** 
Ci Con 324±57 4±1 19±5 6±1 5±1 80±14 99.7±0.1 
 γ2 726±269 40±21 973±335*  138±7*** 32±3*** 102±24 98.5±0.2*** 
Di Con 1995±347 100±37 48±19 2±0.4 1±0.2 354±51 98.6±0.4 
 γ2 6924±458*** 786±148*** 4926±648*** 70±8*** 9±2*** 728±63*** 92.2±1.8** 
 
Table 7: Effects of γ2 co-expression on homomeric AMPA receptors in heterologous 
cells.  HEK293 cells were transfected with GluR-A, -B, -C or -D flip isoforms with or 
without γ2 co-expression.  Relative kainate efficacy (600 µM) is expressed as a percent of 
the peak response to 3 mM glutamate.  Current density, as an assay for surface receptor 
expression, was determined by normalizing Glu+TCM Peak to whole-cell capacitance 
(TPk/WCC; 500 µM).  Desensitization was calculated relative to maximal currents in the 
presence of TCM (% desensitization = [1- (GluSS / Glu+TCM Peak)]*100).  Ai n = 42-
62, Bi n = 18, Ci n= 12-13, Di n = 17-20.  Asterisks (*) indicate γ2 condition is 
significantly different from receptor alone (* P <0.05; *** P<0.001, t-test). 
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5.4  Discussion 
5.4.1  A Role for TARPs in Functional Heterogeneity of AMPA Receptors 
The data presented here provide evidence that stargazin/γ2 alters the biophysical 
properties of native AMPA receptors in two distinct ways, one causing decreased 
receptor desensitization and the other increased kainate efficacy.  Although reliable 
expression of functional AMPA receptors in heterologous systems demonstrates that 
association with TARPs is not obligatory for AMPA receptor surface expression, the 
more robust surface trafficking upon co-expression with stargazin indicates this protein 
can substantially affect trafficking of native AMPA receptors; however, the extent of 
native receptor TARP association is unclear.  Our data suggest that surface AMPA 
receptors in P7 cerebellar granule cells already contain saturating levels of stargazin, but 
receptors in P7 hippocampal neurons can accommodate additional stargazin association.  
It is not clear whether this is because few AMPA receptors are associated with TARPs in 
immature hippocampus, or because stargazin can displace other TARPs from the receptor 
complex; however, it is clear that TARPs must now be considered a factor in generating 
AMPA receptor functional heterogeneity.  Our observation that individual subunits are 
differentially modulated by stargazin and γ3 further suggests that a given TARP will have 
distinct effects on native receptors with specific subunit compositions.    
During the course of our work two short reports appeared that addressed effects of 
stargazin on recombinant AMPA receptors. Yamazake and colleagues reported that 
stargazin enhanced glutamate-evoked currents in HEK293 cells and Xenopus oocytes 
expressing GluR-A or GluR-B homomeric receptors, and that other TARPs had a similar 
effect.  More recently, Priel et al. showed that stargazin slowed both desensitization and 
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deactivation of glutamate-evoked responses.  Differences in the biophysical 
characteristics of native AMPA receptors, including desensitization and deactivation, 
have primarily been attributed to differences in subunit and isoform composition.  Our 
data and that of Priel et al. (2005) indicate that association with TARPs provides an 
additional mechanism controlling channel properties.  Whether TARPs are present, and 
which TARPs are included in a receptor are both expected to make significant 
contributions to the functional heterogeneity of neuronal AMPA receptors.   
 
5.4.2  Differential Contribution of Intra- and Extracellular Domains to the Functional 
Effects of Stargazin 
Based on recordings from Xenopus oocytes, Tomita and colleagues (2004) found that 
both the first extracellular domain of stargazin and a region in the cytoplasmic tail were 
necessary for increasing AMPA receptor currents, a finding interpreted as being 
exclusively due to trafficking.  However, because this conclusion was based upon whole-
cell currents obtained by bath application of agonists, this study could not discriminate 
between trafficking and potential functional effects of stargazin.  Using whole-cell 
current density as a measure of total cell surface receptors, we found that increased 
receptor surface expression was mediated primarily by the C-terminal intracellular 
domain of stargazin.  In contrast, both the first extracellular domain and the C-terminal 
tail were required for stargazin to exert maximal functional effects on AMPA receptors.  
Interestingly, the functional effects of stargazin can be partially dissociated, with the 
decrease in receptor desensitization being more dependent on an intact cytoplasmic tail, 
and the increase in kainate efficacy being more dependent on the first extracellular loop.  
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Priel and colleagues’ (2005) observations that deletions of the cytoplasmic tail of 
stargazin up to aa 244 did not alter stargazin’s effect on glutamate-evoked 
desensitization, combined with our observation of almost complete loss of effect with a 
truncation at aa 212, suggest that the region between aa 212 and 244 is important for 
modulating steady-state AMPA receptor desensitization.  Conversely, our observation 
that exchange of the entire first loop abolishes the effect of γ2 on kainate efficacy 
indicates that interactions between the extracellular domains of stargazin and AMPA 
receptor subunits mediate the increase in kainate efficacy.  The physical dissociation of 
regions important for the two principal functional effects of stargazin suggests they are 
mediated by distinct local conformational changes in the AMPA receptor protein.    
The decrease in macroscopic glutamate-evoked desensitization observed with 
stargazin co-expression indicates that stargazin shifts the equilibrium between 
desensitized and open conformations of the AMPA receptor toward open states.  This 
could be achieved either by stabilizing the dimer interface, and thus hindering the 
transition into the desensitized state, or by destabilizing the desensitized conformation so 
that the receptor more readily cycles back to an open state.  Based upon reduced 
potentiation of glutamate-evoked currents by cyclothiazide in the presence of stargazin, 
Priel and colleagues (2005) suggest that, similar to cyclothiazide, stargazin affects 
desensitization by stabilizing the dimer interface.  While the observation that stargazin 
slows the onset of desensitization is consistent with stabilization of the dimer interface, it 
can also result from the slowed rate of deactivation documented by Priel and colleagues 
(2005), as well as rapid recovery from the desensitized state.  The speeding of both 
kainate and TCM association rates in the presence of glutamate, without a change in 
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affinity for kainate or TCM, suggests rather that stargazin primarily affects microscopic 
receptor desensitization by destabilizing the desensitized state. While numerous 
manipulations have been described that alter the stability of the dimer interface and thus 
the stability of the open state (Stern-Bach et al., 1998; Sun et al., 2002; Horning and 
Mayer, 2004), our results with stargazin indicate consideration should be given to 
interactions that alter the stability of the desensitized state.   
 
5.4.3  Increased Efficacy of Kainate 
The observed increase in kainate efficacy also suggests specific conformational 
changes in the receptor.  Rosenmund et al. (1998) demonstrated that sequential binding of 
agonist to single AMPA receptor channels elicits three unique subconductance states; 
however, the precise mechanism by which agonist-induced conformational changes in the 
extracellular ligand binding domains are coupled to various conductance states is not 
known.  Partial agonists induce a lesser degree of domain closure between the 
extracellular D1 and D2 domains in the GluR2/GluR-B crystal structure than do full 
agonists, and the amount of domain closure has been correlated with a specific agonist-
dependent, electrophysiological profile of subconductance states (Armstrong et al., 2003; 
Jin et al., 2003).  A binding site mutation that allows kainate to induce greater domain 
closure increases kainate efficacy and shifts the dose-response curve ~3-fold to the left 
(GluR2 L650T, Jin et al., 2003), which is very similar to the effect we see with stargazin.  
It is also possible that rather than affecting the degree of domain closure, stargazin alters 
the efficacy by which the same amount of domain closure is coupled to channel opening.  
Either mechanism would be predicted to result in a change in the distribution of 
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subconductance states, with more frequent and/or longer higher-conductance openings 
with kainate bound.   
Given that the maximal increases in glutamate peak current can be attributed to 
stargazin’s effects on trafficking, stargazin does not appear to alter maximum glutamate-
evoked single-channel conductance.  Normalization of kainate-evoked responses to 
glutamate peak responses (Fig. 18C) suggests that the effect of stargazin on kainate-
evoked currents reaches a relative maximum defined by the highest conducting state 
achievable by the receptor.   
 
5.4.4  Stoichiometry 
Electron microscopy of native receptor complexes indicates TARPs contribute to the 
transmembrane portion of AMPA receptors (Nakagawa et al., 2005); however, the 
number of TARPs associated with a single native AMPA receptor is unknown.  
Stargazin-mediated responses of GluR-Ai (Fig. 18C) appear to partition into three groups, 
each with a similar shift in kainate efficacy, but with varying degrees of altered 
desensitization.  Similar to the model for agonist binding and channel opening proposed 
by Rosenmund et al. (1998), the presence of two stargazin proteins per GluR-Ai tetramer 
may produce the minimum effect of increasing kainate efficacy and slightly altering 
glutamate-evoked desensitization, while association of three and then four stargazin 
proteins with the receptor could alter desensitization in a graded manner to a maximal 
level.  The range of stargazin-mediated desensitization is greater for GluR-Ai and Di than 
for GluR-Bi and Ci, possibly reflecting the distinct effects of stoichiometry on long-tailed 
rather than short-tailed subunits.  Alternatively, assembly of stargazin with short-tailed 
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subunits may result in a less variable stoichiometry.  The ratio of stargazin : GluR-Ai was 
varied in an attempt to manipulate the distribution of glutamate-evoked desensitization 
(1:1, 0.25:1, 2:1, data not shown); however, the results were inconclusive.   
 
5.4.5 Differential Trafficking of AMPA and Kainate Receptor Subunit Combinations 
The recent finding that stargazin acts as an AMPA receptor specific chaperone in the 
endoplasmic reticulum (Vandenberghe et al., 2005a) places it in an ideal location to 
affect AMPA receptor subunit assembly.  The observation of decreased desensitization 
and increased kainate efficacy in homomeric receptors expressed in HEK293 cells 
indicates that, rather than altering subunit composition, stargazin affects AMPA receptor 
functional properties via a direct interaction with the receptor on the cell surface.  
Stargazin most dramatically affects trafficking of GluR-Bi (12-fold increase in surface 
expression) with intermediate effects on GluR-Ai and Di (2-4-fold) and no significant 
alteration of GluR-Ci surface expression (Table 7), suggesting the possibility of a higher 
affinity interaction between stargazin and GluR-Bi.  Stargazin-mediated surface 
trafficking of heteromers composed of GluR-Ai with either flip or flop isoforms of GluR-
B resembles that of GluR-Ai rather than Bi homomers (Table 6).  Interestingly, surface 
expression of GluR-AoBo heteromers is enhanced 10-fold, which may indicate that the 
surface trafficking function of stargazin is more vital for receptors composed 
predominantly of flop isoforms.  Thus, our data suggest that stargazin may preferentially 
traffic native receptors of certain subunit combinations.    
It is unclear why we observed stargazin-mediated trafficking of GluR6 when others 
have not (Chen et al., 2003), but this may reflect differences in expression systems 
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(HEK293 cells vs. Xenopus oocytes).  Chen and colleagues also reported no increase in 
kainate currents in cerebellar granule neurons, and we concur that stargazin does not 
increase trafficking of GluR6/KA2 heteromers, the predominant kainate receptor in 
granule cells.  It is, however, quite interesting that co-expression of KA2 apparently 
breaks the association of stargazin and GluR6.  KA2 is known to contain an ER-retention 
signal in its C-terminal cytoplasmic tail that is masked when KA2 associates with GluR6, 
allowing the GluR6/KA2 receptor to exit the ER (Hayes et al., 2003).  It is tempting to 
speculate that the association of GluR6 and KA2 cytoplasmic tails blocks the cytoplasmic 
interaction of stargazin and GluR6. 
 
5.4.6  Physiological Consequences of AMPA Receptor Association with TARPs 
The contribution of glutamate deactivation versus desensitization to synaptic 
responses varies with receptor type, quantal content, and structure of the synapse 
(Trussell et al., 1993; Kinney et al., 1997; Conti and Weinberg, 1999; Wall et al., 2002; 
Lawrence et al., 2003).  Slowed deactivation, that is, dissociation of ligand from receptor, 
would be expected to prolong the time course of most synaptic responses.  In contrast, 
reduction of and faster recovery from desensitization will have the greatest impact at 
synapses with high-frequency or prolonged activation (Trussell et al., 1993; Otis et al., 
1996; Eliasof and Jahr, 1997).  Certain native receptors exhibit extremely rapid recovery 
from desensitization (16 ms, Raman and Trussell, 1995) that is not observed in 
recombinant receptors.  The demonstration of TARPs as components of native AMPA 
receptor complexes (Nakagawa et al., 2005; Vandenberghe et al., 2005b) and the ability 
of stargazin to destabilize the desensitized state (Fig. 11, 12) suggests that rapid recovery 
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from desensitization in native receptors may be due to the functional effects of TARP 
association.   
Accelerating the rate of recovery from desensitization will affect synaptic responses 
during high frequency stimulation, such as that seen during plasticity-related events.  
Although PSD-95 limits the incorporation of TARP-associated receptors into the synapse 
(Chen et al., 2000; Schnell et al., 2002), our data indicates PSD-95 is not necessary for 
stargazin to alter functional properties of the receptor.  While phosphorylation of 
stargazin plays an important role in AMPA receptor trafficking during bidirectional 
synaptic plasticity (Tomita et al., 2005), the functional effects of association of synaptic 
AMPA receptors with stargazin are also likely to contribute to activity-dependent events.   
The substantial effects of stargazin on steady-state glutamate responses additionally 
suggest that TARP association may influence pathological events.  Principle neurons in 
the hippocampus, striatum and cerebellum are selectively vulnerable to ischemia, while 
interneurons in these same regions may be spared (Cervos-Navarro and Diemer, 1991).  
This selective vulnerability has previously been attributed to the specific subtypes of 
AMPA receptors expressed in particular neurons.  For example, cortical pyramidal cells 
exhibit slower and less extensive desensitization than cortical interneurons (Hestrin, 
1993), which has been correlated with expression of flip AMPA receptor subunit 
isoforms (Lambolez et al., 1996).  Similarly, AMPA receptor-mediated responses of 
Purkinje cells, which are among those cell types most vulnerable to ischemia, exhibit less 
desensitization than those of other cerebellar neurons (Brorson et al., 1995), which has 
also been related to greater expression of flip isoforms (Tomiyama et al., 1999).  
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The assumption that AMPA receptors exhibiting less steady-state desensitization 
(e.g., flip-containing receptors) will disproportionately contribute to the neuronal 
depolarization resulting from tonic glutamate release is well established.  Our data 
indicate that TARP expression may make an equal or larger contribution to glutamate-
evoked steady-state currents than does AMPA receptor subunit composition.  While 
GluR-B mediated calcium-impermeability has been presumed to be neuroprotective, the 
dramatic decrease in desensitization of GluR-Bi homomers co-expressed with stargazin 
suggests that, when associated with stargazin, this subunit may exacerbate postsynaptic 
depolarization during excitotoxic events.  In general, neurons expressing AMPA 
receptors associated with stargazin would be predicted to be more vulnerable to 
glutamate-mediated excitotoxicity during ischemic events.  The lesser effect of γ3 on 
glutamate desensitization (Fig. 13, 15) also suggests that the particular TARP 
complement of the receptor could influence the susceptibility of neuronal subtypes to 
excitotoxicity.   
 
5.4.7  Future Directions 
Guided by the subunit-specific effects of stargazin on AMPA receptor trafficking and 
functional properties, we are generating several AMPA receptor subunit chimeras to 
localize domains in the AMPA receptor influenced by stargazin.  Table 8 lists these 
chimeras and predicts their effects on stargazin-mediated alterations in trafficking and 
glutamate-evoked desensitization.  We predict the first intracellular loop of AMPA 
receptor subunits is important in trafficking and that the presence of multiple proline 
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residues in this region of GluR-C disrupts stargazin association in a manner that 
interferes with its trafficking effects.   
Conservation of the sequence of the second intracellular loop between AMPA 
receptor subunits suggests this is a region of functional importance.  This loop is ideally 
placed near the re-entrant channel-lining membrane domain to influence channel 
properties such as desensitization; therefore, we predict that the second intracellular loop 
mediates effects on glutamate desensitization.  We postulate that the variable effects on 
desensitization are due to interference by a long C-terminal with stargazin’s interaction 
with this region.   
TABLE VIII 
Intracellular Domain AMPA Receptor Subunit Chimeras 
Exchange    From          Into Rational Interpretation 
1st IC  
loop GluR-B  GluR-C 
GluR-C is not 
trafficked by Stg; 
GluR-B exhibits the 
greatest effect on 
trafficking  
If trafficking is mediated 
by this region, this 
exchange should result in 
significant GluR-C 
surface trafficking 
1st IC  
loop GluR-C   GluR-D 
GluR-C is not 
trafficked by Stg; 
GluR-D has greatest 
sequence identity to 
GluR-C 
This exchange should 
diminish surface 
trafficking of the chimera 
2nd IC 
loop  GluR5    GluR-B 
Stg has no functional 
effects on GluR5; Stg 
dramatically reduces 
GluR-B glutamate- 
evoked 
desensitization   
If altered desensitization 
is mediated by this region, 
the chimera should be 
effectively trafficked but 
have no changes in 
desensitization 
C-term 
tail GluR-C   GluR-A 
Stg consistently 
affects GluR-C 
desensitization; Stg 
effects on GluR-A 
overlap with controls  
A short C-terminal tail in 
GluR-A should eliminate 
overlap of Stg-mediated 
glutamate-evoked 
desensitization with 
control responses 
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Increased kainate efficacy is mediated by an extracellular interaction between the 
latter portion of the first extracellular loop of stargazin and the AMPA receptor.  The 
similarity of the shift in kainate efficacy between AMPA receptor homomers, combined 
with the size and complexity of the extracellular domains, makes isolation of AMPA 
receptor residues involved in this effect more complicated than isolation of residues 
involved in intracellularly-mediated effects.  Because the binding site mutant GluR-B 
L650T exhibits a nearly identical shift in kainate efficacy (Armstrong et al., 2003), we 
will examine the effects stargazin co-expression with this mutant.  Occlusion of the shift 
in the dose response curve would suggest a similar mechanism of action, that is, an 
increased degree of kainate-evoked domain closure between D1 and D2 in the presence 
of stargazin.     
The crystal structure of the extracellular portions of the AMPA receptor suggests a 
loop structure in domain 1 (loop 1) may be an extracellular site of interaction between the 
receptor and stargazin.  The effects of stargazin on both kainate efficacy and glutamate-
evoked desensitization are primarily or in part mediated by residues between aa 26 and aa 
89 of stargazin’s first extracellular loop (Fig. 17A, C, D).  The secondary structure of 
stargazin has not yet been resolved; therefore, the distance stargazin’s first extracellular 
domain extends from the membrane is unknown.  It is possible that the extracellular 
residues mediating the effects of stargazin on the AMPA receptor are clustered near the 
apex of the first extracellular loop and interact with loop 1 on the AMPA receptor 
(Diagram 11).  While chimeric AMPA receptor subunits with loop 1 exchanges may have 
significantly altered receptor kinetics in the absence of stargazin, this mutant may disrupt  
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the extracellular interactions between stargazin and the AMPA receptor necessary for 
alterations in kainate efficacy and glutamate-evoked desensitization. 
While all four subunits exhibit a distinct increase in kainate efficacy, this shift is 
relatively smaller for GluR-B and of a similar magnitude as the effect of γ2 on 
desensitization.  Decreased desensitization at AMPA receptors has been shown to left-
shift the kainate dose-response curve (Patneau et al., 1993), suggesting the kainate effect 
Diagram 11.  Loop 1 is a possible extracellular region of interaction 
between stargazin/γ2 and the AMPA receptor.  A.  The crystal structure of 
the extracellular domains is shown with the relative location of the channel 
portions of the receptor and the possible location of stargazin.  The red box 
outlines regions of possible interaction between stargazin and the AMPA 
receptor.  B.  A 90° rotation of stargazin and the crystallized domains of 
the AMPA receptor depicts a bird’s eye view of the possible extracellular 
regions of interaction between stargazin and loop 1 of the AMPA receptor 
(red box; modified from Sun et al., 2002). 
A B
Loop 1
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in GluR-B may reflect reduced desensitization.  mRNA editing of GluR-B at the Q/R site 
in the channel-lining re-entrant loop severely decreases channel conductance (Swanson et 
al., 1997).  While stargazin appears to increase the amount of time the kainate-bound 
receptor resides in higher conductance states, GluR-B may less effectively transduce 
stargazin-mediated allosteric changes to the channel portion of the receptor than GluR-A, 
-C, and -D.  The heteromeric receptors examined in these studies exhibited shifts in 
kainate efficacy resembling that seen with GluR-B rather than GluR-A, suggesting that, 
similar to the dominance of GluR-B in Ca2+ permeability (Hollmann et al., 1991; 
Sommer et al., 1991), the presence of the GluR-B subunit differentially affects the 
responsiveness of the channel to stargazin-mediated conformational changes in the 
extracellular domains of the AMPA receptor.  A shift in kainate efficacy comparable to 
that of GluR-A, -C and -D upon co-expression of stargazin with unedited GluR-B 
homomers would indicate the presence of an arginine in the pore constrains the allosteric 
effects of stargazin on kainate efficacy.   
Co-expression of GluR-A with γ2(∆89-103)/γ5(ins85-99), a chimera with a small 
region in the latter portion of the first extracellular loop of stargazin exchanged with γ5, 
decreases the effect of stargazin on kainate efficacy but not glutamate-evoked 
desensitization (Fig. 17).  If the shift in kainate efficacy in GluR-B is primarily a 
consequence of altered desensitization, expression of GluR-B with this construct should 
result in kainate efficacy indistinguishable from that of wild-type stargazin.  
While stargazin is involved in hippocampal LTP (Tomita et al., 2005), γ8 is the 
primary TARP expressed in hippocampus (Tomita et al., 2003).  γ8 both rescues AMPA 
receptor surface expression in stg/stg cerebellar granule cells (Tomita et al., 2003) and 
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selectively enhances glutamate-evoked currents in heterologous cells (Yamazaki et al., 
2004); however, the specific functional effects identified in this study have not been 
characterized for γ8.  We plan to clone and express this protein in both hippocampal 
neurons and heterologous cells to determine the functional effects of γ8 on native and 
recombinant AMPA receptors. 
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Chapter VI 
SUMMARY AND SIGNIFICANCE 
 
6.1 Disassembly of the Benzothiadiazine Binding Site in the Desensitized State of the 
AMPA Receptor  
Crystallization of the extracellular domains of the GluR-B/GluR2 subunit of the 
AMPA receptor at rest and in complex with various agonists has greatly enhanced our 
understanding of the mechanism of glutamate receptor desensitization.  The strong 
correlation between enhanced dimerization of AMPA receptor extracellular domains with 
certain mutations at the dimer interface and reduced desensitization seen 
electrophysiologically in heterologous systems expressing AMPA receptor subunits with 
the same mutations suggest that the stability of this interaction is crucial in determining 
the extent of desensitization at native receptors.  Binding of the benzothiadiazine positive 
allosteric modulator cyclothiazide at the dimer interface also significantly stabilizes the 
dimer interface (Sun et al., 2002) and greatly decreases desensitization of recombinant 
and native AMPA receptors (Patneau et al., 1993; Yamada and Tang, 1993).   
The initial portion of this dissertation focused on confirmation and extension of the 
model of AMPA receptor desensitization in native hippocampal AMPA receptors.  
Crystallization of the extracellular domains of GluR2 has generated great insight into the 
structure of the non-desensitized state; however, the separation of the dimer interface has 
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thus far prevented crystallization of the extracellular domains in the desensitized 
conformation.  Our results indicate the binding site for the benzothiadiazines is available 
in both the resting and non-desensitized state; however, the conformational change into 
the desensitized state disassembles the binding site for the modulator.  Our findings in 
native hippocampal AMPA receptors reveal that the benzothiadiazines exhibit a state-
dependent interaction with the receptor in which the conformation of residues forming 
the dimer interface is altered in the desensitized state in a manner that precludes 
modulator binding.   
 
6.2  Stargazin/γ2 Decreases Glutamate-Evoked Desensitization and Increases Kainate   
Efficacy at AMPA Receptors 
Unlike the associated proteins GRIP1 and PICK1, stargazin dramatically affects 
AMPA receptor functional properties.  This is the first demonstration of an associated 
protein directly altering AMPA receptor functional properties, adding significant support 
to the argument that TARPs act as the first demonstrated auxiliary subunit of an 
ionotropic glutamate receptor.  While the findings that stargazin selectively enhances 
glutamate-evoked steady-state currents at AMPA receptors (Yamazaki et al., 2004) by 
reducing desensitization (Priel et al., 2005) have recently been published, our lab has 
further identified novel effects of stargazin on kainate efficacy and rectification 
properties of certain AMPA receptor subunits.  We have also presented strong evidence 
that endogenous stargazin contributes to the functional properties of native receptors in 
cerebellar granule cells.  Additionally, we have determined that PSD-95, which is known 
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to be necessary for stargazin-mediated synaptic trafficking of AMPA receptors, is not 
required for stargazin’s effects on AMPA receptor function. 
The identification of domains in stargazin involved in mediating both functional 
effects and AMPA receptor trafficking is a novel finding with the potential of great 
impact in the AMPA receptor field.  Domain swaps between stargazin and the non-TARP 
γ5 revealed that the latter portion of the first extracellular loop of stargazin primarily 
mediates altered kainate efficacy, while truncation of the C-terminal tail suggests that 
trafficking and effects on desensitization are primarily mediated by this portion of 
stargazin.  We have also shown that γ3, another member of the TARP family, affects both 
function and trafficking of the AMPA receptor.  Interestingly, the trafficking and altered 
desensitization seen with γ3 are very similar to that observed with the C-terminal 
truncation mutant.  Stargazin and γ3 have greatest sequence divergence in their C-
terminal tails, further corroborating the importance of the stargazin C-terminus in AMPA 
receptor trafficking and desensitization.  
Because our initial studies identified the state-dependent mechanism of interaction of 
the benzothiadiazine modulators with the AMPA receptor, we were able to use this tool 
to define the mechanism by which stargazin decreases glutamate-evoked desensitization 
at the AMPA receptor.  Unlike mutations and pharmacological compounds that act at the 
dimer interface and stabilize the non-desensitized state, stargazin is unique in that it 
destabilizes the otherwise energetically favorable desensitized state.  Destabilization of, 
and therefore faster recovery from, the desensitized state would decrease the latency at 
which a synapse could produce a full amplitude response during periods of high 
frequency stimulation such as occur during plasticity-related events.  
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While molecular manipulation of various domains of stargazin identified areas of 
functional significance in stargazin, subunit-specific differences in trafficking and 
functional effects suggest areas of interaction within the AMPA receptor.  The variable 
effects of stargazin on desensitization seen in AMPA receptor subunits with long C-
terminal tails versus the more consistent effects with short-tailed subunits further 
supports the idea of an intracellular locus playing a substantial role in altered glutamate-
evoked desensitization. 
 
6.3  Stargazin Differentially Traffics AMPA and Kainate Receptor Subunits 
Although the well-established trafficking function of stargazin was not our primary 
focus, we identified several novel aspects of this interaction.  In contrast to the results of 
Chen et al (2003), we found stargazin traffics certain homomeric kainate receptors, 
indicating the trafficking effects of stargazin are not AMPA receptor-specific.  
Additionally, stargazin differentially traffics both homomeric and heteromeric AMPA 
receptors.  Homomeric GluR-B exhibits the most dramatic increases in surface 
expression, suggesting a higher affinity interaction of stargazin with GluR-B.  
Surprisingly, stargazin does not appear to increase trafficking of GluR-C, although both 
functional effects are evident, indicating that in the absence of trafficking, stargazin 
remains capable of a functionally significant association with AMPA receptors at the cell 
surface.  Interestingly, while GluR-AiBo and GluR-AiBi heteromers are trafficked 
similarly to GluR-Ai, stargazin-mediated surface expression of GluR-AoBo is more like 
that of GluR-Bi, suggesting stargazin preferentially traffics certain heteromeric subunit 
combinations.  
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6.4  TARPs as Auxiliary Subunits of the AMPA Receptor 
Our data add to the argument for designation of TARPs as auxiliary AMPA receptor 
subunits. Three criteria have typically been considered as evidence that a protein acts as 
an ion channel auxiliary subunit: demonstration of a direct and stable interaction with the 
pore-forming subunit, direct modulation of the biophysical properties, and trafficking of 
the pore-forming subunit (Arikkath and Campbell, 2003).  In addition to the considerable 
literature documenting the role of stargazin in AMPA receptor trafficking (Chen et al., 
2000; Schnell et al., 2002; Cuadra et al., 2004; Vandenberghe et al., 2005a), two recent 
papers report the co-purification of TARPs with native AMPA receptors (Nakagawa et 
al., 2005; Vandenberghe et al., 2005b).  The observation that stargazin/γ2 alters AMPA 
receptor channel properties in hippocampal neurons completes these three criteria.  The 
distinct effects of stargazin and the TARP family member γ3 on the function of various 
AMPA receptor subunit combinations suggests that incorporation of TARPs as auxiliary 
subunits increases the functional heterogeneity of native AMPA receptors.  The ability of 
TARPs to alter AMPA receptor functional properties further implies these proteins play 
significant but as yet undefined roles in basal neurotransmission, activity-dependent 
synaptic plasticity and excitotoxic events. 
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Appendix Figure 1.  The Efficacy and Onset Kinetics of Modulation by Cyclothiazide 
(CTZ) Are Dependent on the State of the Receptor.  Responses to 500 ms applications of 
1 mM glutamate (top) correspond to the single data points as indicated on the graph 
below (bottom, a, c-o).  a is the response to glutamate alone before modulator 
application.  b shows the response to a 40 s application of glutamate (filled bar; see 
separate time scale), with CTZ co-applied for 20 s as indicated by the grey bar.  Note the 
very slow onset of potentiation, rapid increase in current immediately after removal of 
CTZ, and the slow kinetics of recovery from potentiation, which was complete in 
approximately 3 minutes (f).  CTZ was then applied in the absence of glutamate, and the 
onset of potentiation developed much more rapidly, with greater potentiation observed 
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after 2 s pretreatment with CTZ (g) than with a 20 s coapplication with glutamate 
(compare to b), and was complete within 17 s (h).  The response in i is 2 s after removal 
of CTZ.  The rate of recovery from potentiation by CTZ is well described by a single 
time constant of approximately 40 s.  Note that the kinetics of desensitization in response 
to glutamate as the block of desensitization by CTZ decreases (e.g., k-n) are similar to 
those for the control response (a) before CTZ treatment.  These results are consistent with 
the interpretation that CTZ either cannot bind to or has very low affinity for the 
desensitized state of the receptor.  Also, the similarity of the rate of dissociation in both 
the presence and absence of agonist indicates CTZ has similar affinity for the receptor in 
the presence and absence of agonist.  
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Appendix Figure 2.  Strong Negative Cooperativity Between Binding of Cyclothiazide 
and Agonist Underlies Differential Modulation of AMPA Receptor Isoforms.  Although 
cyclothiazide dramatically reduces or fully blocks desensitization of most native AMPA 
receptors (Patneau et al., 1993; Fleck et al., 1996), in experiments with recombinant 
receptors cyclothiazide appears to slow, but not block, desensitization of flop splice 
variants (Partin et al., 1994).  Because our data (Appendix Fig. 1, Chapter 3) strongly 
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suggest that cyclothiazide cannot bind to desensitized receptors, and that receptors with 
cyclothiazide bound cannot desensitize, we hypothesized that this "desensitization" of 
responses in the presence of cyclothiazide might instead reflect the dissociation of 
cyclothiazide from the receptor.  To test this hypothesis, we recorded responses to 
glutamate from HEK293 cells transfected with GluR-Ao and -Bo before (A, trace at left), 
during, and after application of 100 µM cyclothiazide. Note that the percent of receptors 
with cyclothiazide still bound following a 1 s wash with control solution was dependent 
on whether cyclothiazide was applied in the presence (middle traces) or absence (trace at 
right) of glutamate. This indicates that the apparent desensitization of agonist responses 
in the presence of cyclothiazide reflects negative cooperativity between the binding of 
agonist and cyclothiazide, which results in the rapid dissociation of cyclothiazide from 
the receptor in the presence of glutamate, rather than receptor desensitization with 
cyclothiazide still bound. (B) When cyclothiazide was removed just prior to the 
glutamate pulse, the response “desensitized” even faster; we interpret this as the time 
constant of  dissociation of cyclothiazide in the presence of glutamate.  (C) In 
comparison, the rate of dissociation of cyclothiazide for AoBo receptors in the absence of 
agonist was 30-fold slower, and was similar to rate of dissociation from AiBo receptors, a 
composition that has a fully non-desensitized response to glutamate in the presence of 
cyclothiazide.  This indicates that the apparent selectivity of cyclothiazide for flip 
isoforms is not due to inherent differences in affinity (Partin et al., 1994), but rather due 
to differences in the allosteric interactions between modulator and glutamate binding 
sites, such that binding of glutamate lowers the affinity for cyclothiazide 30-fold in flop 
receptors.  
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ABSTRACT: 
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(AMPARs) is the rapid and profound desensitization that occurs within milliseconds of 
glutamate binding; however, the mechanisms controlling desensitization of native 
AMPARs are incompletely understood.  We have applied patch-clamp recording 
techniques in cultured neurons and heterologous cells to (1) test a model of AMPAR 
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domains of the receptor is that the benzothiadiazine positive modulator cyclothiazide, 
which blocks AMPAR desensitization, binds at and stabilizes the dimer interface formed 
by adjacent subunits. This and other data suggested a model in which desensitization 
involves a conformational change disrupting the dimer interface.  Our data from intact 
hippocampal AMPAR indicate the benzothiadiazines prevent the conformational change 
to the desensitized state, and, conversely, cannot bind desensitized AMPARs. 
 The transmembrane AMPAR regulatory protein (TARP) stargazin (γ2) serves 
multiple roles in trafficking and stabilizing synaptic AMPARs and may be incorporated 
as an auxiliary subunit.  Transfection of hippocampal neurons with stargazin produced 
two distinct effects on AMPAR functional properties without affecting surface receptor 
density: reduced glutamate-evoked desensitization and increased efficacy of the partial 
agonist kainate.  Kinetic and dose-response analyses suggest that stargazin affects 
glutamate desensitization through an allosteric interaction that destabilizes the 
desensitized state of the receptor, and that potentiation of kainate responses reflects 
increased efficacy rather than altered affinity.  Stargazin’s effects were also observed in 
HEK 293 cells transfected with various heteromeric and homomeric AMPARs, with 
subunit-dependent effects on glutamate desensitization, kainate efficacy, and trafficking.  
We show that two regions of stargazin mediate its functional effects: the C-terminal 
intracellular domain appears more important for effects on glutamate-evoked 
desensitization and receptor trafficking, while the first extracellular domain makes a 
larger contribution to altered kainate efficacy.  These data indicate that TARPs directly 
modulate channel function and, as auxiliary subunits of AMPARs, contribute to 
functional heterogeneity of the desensitization properties of neuronal AMPARs. 
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